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Abstract 
This thesis describes how both LIM Kinase 1 and LIM Kinase 2 are important 
regulators of cell invasion. Chapter 3 presents data that shows that inhibition of 
LIMK function blocks the collective invasion of MDA MB 231 breast carcinoma 
cells in a three-dimensional matrix. Although LIMK was not required for cell 
motility in two dimensions, a novel role for LIMK in both extracellular matrix 
degradation and deformation activities was shown in three dimensions in 
Chapter 4. Consistent with matrix remodeling being a requirement for path 
generation by leading cells in collective invasion, LIMK activity was also shown to 
be required by leading cells in MDA MB 231 collective invasion. However, it was 
also discovered that LIMK activity was not required for path following by MDA MB 
231 cells. The importance of Cofilin activity as a conduit of LIMK activity during 
invasion was investigated in Chapter 5, a well as potential novel protein 
interactions of Cofilin. The identification of novel substrates of LIMK was 
attempted in Chapter 6, leaving prospective routes of investigation to further 
elucidate the roles of LIMK1 and LIMK2 in cells.  
The main findings presented in this thesis reveal a requirement for LIMK activity 
in the path generation function of leading cells in collective invasion. Given that 
individual invading cells must generate their own paths, these results lend 
support to the continued development of LIMK inhibitors to counter tumor cell 
invasion and metastasis. 
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1 Introduction 
Cancer cell metastasis, the process by which cancer cells move away from a 
primary tumour mass, accounts for 90% of human cancer deaths (Hanahan & 
Weinberg, 2000). A multistage process, cancer cell metastasis involves localised 
invasion into surrounding tissue, intravasation from the original tissue, transit in 
either of the circulatory sytems (lymph or blood), extravasation into new tissue, 
and colonisation of a new metastatic site (Olson & Sahai, 2008). The ability of 
metastatic cells to invade is determined by their ability to reorganize the actin-
myosin cytoskeleton and cell morphology, and remodel the extracellular matrix 
(ECM) to facilitate movement.  
Rho GTPases have a long established role in the regulation of cell morphology, 
motility and invasion (Hall, 2005). One approach to further understanding and 
therapeutically targeting metastasis is to identify the elements of Rho GTPase 
signaling and actin-myosin regulation required for cancer cell invasion; with the 
aim of developing inhibitors that could be useful in suppressing metastatic 
spread. The LIM kinases 1 and 2 (LIMK1 and LIMK2) are activated downstream of 
the Rho-ROCK, Rac-PAK and Cdc42-MRCK pathways, thereby acting as a 
convergence point for the signaling pathways that regulate the actin 
cytoskeleton (Scott & Olson, 2007). LIM kinases may therefore provide a 
vulnerable point in actin regulation which when targeted could result in 
inhibition of invasion, independent of the upstream signaling pathway utilised.  
The work in this thesis aimed to determine the role of LIMK in motility and 
invasion, and validate LIMK as a target for cancer therapeutics. The introduction 
to this thesis describes previous literature relevant to the data presented within, 
relating to LIM Kinases and the field of cancer cell motility and invasion. 
14 
1.1 Introduction to LIM Kinases 
The LIM-kinase protein family has two highly-related members, LIM kinase 1 
(LIMK1) and LIM kinase 2 (LIMK2), which are encoded by separate genes located 
on human chromosomes 7q11.23 and 22q12.2 respectively. The LIMK1 gene spans 
39,499 base pairs with 16 exons. Alternative splicing results in the generation of 
two LIMK1 mRNAs, one encoding the full-length protein (GenBank NM_002314) 
while the second has a 61 base deletion that results in the production of a 
truncated protein lacking the carboxyl-terminal kinase domain 
(http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=8051616&itemID=2&view
=gbwithparts). The LIMK2 gene spans 68,617 base pairs, comprising 19 potential 
exons. Alternative splicing results in three LIMK2 isoforms; variant 1 (GenBank 
NM_001031801) is the largest protein, 2a (GenBank NM_005569) differs in both 
the 5’ and 3’ untranslated regions (UTR) and coding sequences resulting in the 
production of a smaller protein with distinct amino- and carboxyl termini, and 
2b (GenBank NM_016733) differs in the 3’ UTR and coding sequences to generate 
a protein identical to variant 1 at the amino-terminus and to 2a in the carboxyl 
terminus. Functional differences between the various isoforms have not been 
determined, although there is some data indicating that their expression may 
vary in different tissues. To date, LIM Kinase homologues have been identified in 
a variety of species (Figure 1.1) including; humans (Mizuno et al, 1994);(Nunoue 
et al, 1995); (Okano et al, 1995), mice (with mouse LIMK1 initially named Kiz-
1(Bernard et al, 1994)), rats (Nunoue et al, 1995) and chicken(Koshimizu et al, 
1997), with related LIMK1 homologues also expressed in more distantly related 
species such as; Xenopus laevis (XLIMK;(Takahashi et al, 1997)), Drosophila 
melanogaster (DLIMK;(Ohashi et al, 2000a)) and the African malaria mosquito 
Anopheles gambiae. The majority of research reported in the literature has 
focused on LIMK1, likely due to the fact that it was isolated first, in fact many 
reports use the generic term “LIMK” without defining the kinase to which it 
refers. In this thesis, references to LIMK imply both kinases, specific reference 
to either one will be made where differences between the two proteins have 
been established, or where only one of the LIM kinases has been investigated. 
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Figure 1.1 Phylogenetic dendrogram of LIMK1 and LIMK2 across species.  
Protein sequences of LIMK1 and LIMK2 from a number of species were aligned using the MultAlin 
multiple sequence alignment program (Corpet, 1988). For brevity, only genus names are indicated 
on the diagram for Homo sapiens, Pan troglodytes, Canis familiaris, Mus musculus, Rattus 
norvegicus, Bos taurus, Gallus gallus, Drosophila melanogaster, Xenopus laevis, Anopheles 
gambiae, Danio rerio. The LIMK present in the representative Insectae species is most similar to 
LIMK1. 
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The most extensively characterised substrates of LIMK are Cofilin1 (also known 
as non-muscle Cofilin, found on human chromosome 11q13), Cofilin2 (a.k.a. 
muscle Cofilin, chromosome 14q12) and destrin (also known as actin 
depolymerizing factor or ADF, chromosome 20p12.1). Similar to the ambiguous 
use of the term “LIMK” in some publications, the substrates are often generically 
referred to as “Cofilin” without precise identification of which of the three 
proteins is actually being studied. Although this may not be a major problem, 
there are indications that each of the three proteins may have different 
biochemical properties which may have significant implications upon the 
regulation of actin dynamics in specific cell types (Vartiainen et al, 2002). In this 
review, I will use the generic term “Cofilin” except where specific differences 
between the proteins have been determined. In addition to Cofilin proteins, 
recent research has identified the nuclear transcription factors CREB (Yang et al, 
2004a) and Nurr1 (Sacchetti et al, 2006)as putative LIMK substrates in neurons. 
Although not as well validated as Cofilin proteins as bona fide LIMK substrates, 
given that both LIMK1 and LIMK2 undergo nuclear/cytoplasmic shuttling in 
certain circumstances and the previous suggestion of nuclear LIMK targets (e.g. 
(Roovers et al, 2003)), the identification of these proteins as LIMK substrates 
should be given due consideration. 
The Cofilin proteins were originally identified on the basis of their ability to 
depolymerise filamentous actin (F-actin) in vitro (reviewed in reference 
(Bamburg, 1999)). As well as depolymerising actin in vitro, it has been proposed 
that a primary function of Cofilin in vivo is to sever F-actin filaments to generate 
barbed ends that can serve as de novo actin nucleation sites (Ghosh et al, 2004) 
(Lorenz et al, 2004). LIMK plays a central role in the regulation of the actin 
cytoskeleton by phosphorylating Cofilin on Serine 3 and inactivating its actin 
severing activity (Amano et al, 2001; Maekawa et al, 1999; Ohashi et al, 2000a; 
Sumi et al, 1999), altering the rate of actin depolymerisation and/or barbed end 
formation (Figure 1.2). Some researchers in the field see Cofilins role in actin 
dynamics as a recycling protein, and those that see Cofilin as a promoter of actin 
nucleation (Condeelis, 2001; Cramer 1999). I believe Cofilin is both of these 
things as actin nucleation is dependent upon free barbed ends to act as nuclei, 
Arp2/3 prefers barbed ends to bind toand thus it can amplify the nucleation 
activity of Arp2/3 (Des Marais et al, 2004). Although Cramer might suggest that 
17 
Cofilin merely mediates the depolymerisation of actin filaments to provide actin 
monomers for ongoing filament assembly, such as in migrating chick embryos, I 
believe both the nucleation and recycling qualities of Cofilin are important for 
cell motility and invasion(Cramer,1999). Actin monomers are required for 
filament assembly aswell as the new barbed end sites for actin nucleation, both 
are provided by Cofilin (Cramer, 1999). 
Although Cofilin is the principal LIMK substrate (Arber et al, 1998; Yang et al, 
1998b) (Takahashi et al, 2001), other kinases have also been reported to 
phosphorylate Cofilin such as TESK1 (Toshima et al, 2001a), TESK2 (Toshima et 
al, 2001b) and NRK/NESK (Nakano et al, 2003), indicating that Cofilin may be a 
significant point of upstream signal integration. The function LIMK manifests in 
cytoskeleton dynamics makes it an interesting prospective target for anti-
metastatic drug development, given that a role for LIMK in cancer metastasis has 
been proposed (Davila et al, 2003) (Yoshioka et al, 2003) (Suyama et al, 2004). 
Disruption of LIMK signalling has also been associated with the human genetic 
condition Williams syndrome (Hoogenraad et al, 2004), which results in a range 
of developmental abnormalities, and has more recently been proposed to have a 
role in primary pulmonary hypertension (Foletta et al, 2003) and the formation 
of intracranial aneurysms (Akagawa et al, 2006). The association of LIMK with a 
variety of human diseases emphasises the critical importance of proper dynamic 
regulation of actin cytoskeletal structures. 
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Figure 1.2 LIM Kinases phosphorylate and inactivate Cofilin.  
LIMK1 and LIMK2 phosphorylate and inactivate members of the Cofilin protein family (Cofilin1, 
Cofilin2 and actin depolymerising factor/destrin), which results in reorganisation of the 
cytoskeleton. LIMK increases stress fibre and focal adhesion formation by reducing actin 
depolymerisation. LIMK initiated changes in F-actin severing also leads to reduced barbed end 
formation and leading edge protrusions. 
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1.2 LIM Kinase protein organisation 
LIM kinases have a unique organization of signalling domains, with two amino-
terminal LIM domains (each containing double zinc finger motifs), adjacent PDZ 
and proline serine (P/S) rich regions, followed by a carboxyl-terminal kinase 
domain (Figure 1.3). The LIM domains have been shown to play an important role 
in regulating kinase activity (Nagata et al, 1999) (Tomiyoshi et al, 2004) and 
likely also contribute to LIMK function by acting as sites of protein:protein 
(Hiraoka et al, 1996) and possibly protein:DNA interactions (Nishiya et al, 1998), 
although a direct demonstration of DNA binding activity of these LIM domains has 
not been reported. LIMK1 and LIMK2 have 50% overall identity, with 70% identity 
in the kinase domain (Mizuno et al, 1994) (Nunoue et al, 1995). The regulatory 
LIM domains are also 50% identical when compared between kinases, with 20% 
identity between LIM domains within each kinase including complete 
conservation of the zinc-binding Cys and His residues. The PDZ domains are 
almost as well conserved as the LIM domains between kinases with just under 
50% identity. Although perhaps best known as a protein:protein interaction 
domain, the PDZ of LIMK influences nuclear/cytoplasmic shuttling with two 
leucine-rich nuclear export signals(Yang et al, 1998a; Yang & Mizuno, 1999). 
Translocation into the nucleus is driven by nuclear localization signals, one of 
which is found between the PDZ and kinase domains in both LIMK1 and LIMK2 
and a second being found only in the kinase domain of LIMK2 (Goyal et al, 2006). 
The presence of both nuclear export and nuclear import sequences suggests that 
nuclear/cytoplasmic shuttling might be a regulated process and that LIMK may 
have active functions in the nucleus. 
Primary sequence analysis does not make it immediately clear whether LIMK is 
likely to be a serine/threonine or tyrosine kinase. Given that the diagnostic 
sequence motif for a serine/threonine kinase is DLKXXN and for a tyrosine kinase 
is DLAARN or DLRAAN (Hanks et al, 1988), the presence of a less than diagnostic 
DLNSHN motif in the kinase VIB subdomain has resulted in LIMK being grouped in 
the Tyrosine Kinase-Like (TKL) subfamily along with others such as the next most 
closely related TESK kinases (Figure 1.4).  
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Early characterization described LIMK1 as a strict threonine/serine kinase 
(Nunoue et al, 1995; Okano et al, 1995)although tyrosine autophosphorylation 
has also been reported (Proschel et al, 1995). Although the related Cofilin1, 
Cofilin2 and destrin proteins were initially reported to be the only physiological 
substrates, the identification of CREB (Yang et al, 2004b) and Nurr1 (Sacchetti et 
al, 2006) as LIMK substrates and the ability of LIMK to phosphorylate myelin basic 
protein and histone in vitro suggests that LIMK may be more promiscuous than 
previously thought and that there may be additional in vivo substrates. 
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Figure 1.3 LIM Kinase structure and homology.  
LIMK1 and LIMK2 share 50% overall identity. LIMK1 and LIMK2 consist of 2 amino-terminal LIM 
domains, adjacent PDZ and proline/serine rich regions, followed by a carboxyl-terminal protein 
kinase domain, with the identities between homologous domains indicated. 
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Figure 1.4 Relationship of LIMK kinase with members of the Tyrosine Kinase-Like family.  
Protein sequences of human LIMK1 and LIMK2 kinase domains were aligned  with the kinase 
domains of other members of the Tyrosine Kinase-Like family using the MultAlin multiple sequence 
alignment program (Corpet, 1988). The most closely related kinases to LIMK1 and LIMK2 are 
TESK1 and TESK2, which also share the ability to act as Cofilin kinases, suggesting that there may 
be some degree of functional redundancy between these proteins. 
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1.3 Activation and regulation  
In addition to the possible function of the LIM and PDZ domains in mediating 
protein:protein interactions, they are also involved in regulating LIMK activity. 
Deletion, or mutation of conserved Cysteine residues, of the LIM domains results 
in significantly increased kinase activity in vitro and deletion of both LIM and 
PDZ domains results in further kinase activation (Nagata et al, 1999). In 
addition, purified recombinant LIM domains interact with the kinase domain and 
result in dose-dependent inhibition of in vitro kinase activity, consistent with a 
role of the LIM domains in regulating LIMK activity via direct protein interaction 
(Nagata et al, 1999). 
Similar to many other kinases, phosphorylation in the activation loop results in 
increased LIMK activity. Both LIMK1 and LIMK2 are phosphorylated by the Rho 
effector ROCK on conserved threonine residues, Thr-508 in LIMK1 and Thr-505 in 
LIMK2, and these phosphorylation events are required for activation above basal 
levels (Figure 1.5 andFigure 1.6) (Amano et al, 2001; Ohashi et al, 2000b; Sumi 
et al, 2001a). Pak1 (shown to work on LIMK1; (Edwards et al, 1999)), Pak4 
(LIMK1; (Dan et al, 2001)) and the myotonic dystrophy kinase-related Cdc42-
binding kinase (MRCKα; LIMK1 and LIMK2; (Sumi et al, 2001b)) have each been 
reported to phosphorylate and activate the indicated form of LIMK. In addition, 
data consistent with a similar role for Pak2 in regulating LIMK activity has been 
reported (Misra et al, 2005; Wu et al, 2003). Therefore, LIMK acts to integrate 
signals from a number of upstream pathways in regulating the actin 
cytoskeleton. 
Transphosphorylation also appears to regulate LIMK activity in two ways. Firstly, 
unphosphorylated LIMK1 is relatively unstable with a half life of ~4 hours, 
association with Hsp90 promotes homodimerization and transphosphorylation 
leading to the production of stable LIMK1 dimers (Li et al, 2006). Secondly, 
transphosphorylation at numerous sites in the kinase domain elevates LIMK1 
specific activity (Li et al, 2006). The region of the LIMK1 kinase domain that 
interacts with Hsp90 was identified by homology with ErbB-2 as being between 
amino acids 387-402, with a critical amino acid for this interaction determined 
to be Proline 394 (Figure 1.6). Treatment of cells with Hsp90 inhibitors such as 
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17AAG reduced LIMK1 and LIMK2 levels, and led to decreased levels of phospho-
Cofilin, suggesting that Hsp90 regulates the activity of both kinases and that the 
LIMK-Hsp90 interaction is important for the regulation of actin cytoskeletal 
structures.  
Although LIMK1 was reported to autophosphorylate when expressed in bacteria 
(Proschel et al, 1995), it was suggested that because the sequence surrounding 
Thr508 in the LIMK1 activation loop was very different from the sequence 
adjacent to Ser3 in Cofilin, trans-autophosphorylation of the activation loop was 
unlikely (Edwards & Gill, 1999). Autophosphorylation of LIMK1 was exclusively on 
Serine and Tyrosines, indicating that Thr508 was not a substrate (Proschel et al, 
1995). In addition, a recent report showed that a T508V LIMK1 mutant 
autophosphorylated to the same extent as wild-type when corrected for enzyme 
activity (Kobayashi et al, 2006). These results indicated that 
autophosphorylation does occur but is unlikely to be at the activation loop 
Threonine. To date, the sites of autophosphorylation, and how they may 
regulate LIMK activity or function, have not been determined. 
Proteins regulated by phosphorylation are typically reverted to their basal 
unphosphorylated state by phosphatases. One phosphatase that has been found 
to dephosphorylate and inactivate LIMK1 is slingshot 1 (SSH1) (Soosairajah et al, 
2005), which previously had been identified as a Cofilin phosphatase (Niwa et al, 
2002)(Figure 1.5 and Figure 1.8).  
SSH1 bound directly to the kinase domain where it catalysed the 
dephosphorylation of Threonine 508, as well as autophosphorylated Serine 
residues, resulting in reduced LIMK1 phosphorylation of Cofilin. LIMK1 was a 
better substrate for SSH1 than was LIMK2, suggesting that there may be 
differential regulation of these two kinases. The activity of SSH1 is dependent on 
binding to F-actin and is negatively regulated by PAK4 mediated 
phosphorylation. These results indicate that kinases such as PAK4, and possibly 
others including ROCK and MRCKα, increase LIMK1 activity both by direct 
phosphorylation and by inhibition of the LIMK1 dephosphorylating activity of 
SSH1. In addition, low levels of F-actin in the cell, either globally or locally, 
would reduce SSH1 activity thereby favouring the activation of LIMK1 and 
increasing phospho-Cofilin levels.  
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Figure 1.5 LIMK is a convergence point for upstream signals.  
LIMK1 and LIMK2 integrate signals from a number of Rho GTPase family signalling pathways to 
regulate the actin cytoskeleton. Both ROCK I and II have been shown to phosphorylate and 
activate LIMK and a similar role in LIMK regulation has been identified for PAK1, 2 and 4 and 
MRCKα. Cofilin phosphatases such as SSH and CIN counteract the phosphorylation and 
inactivation of Cofilin.  
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Figure 1.6 LIM Kinase modifications.  
LIMK1 and LIMK2 are modified by a variety of proteins, which alter kinase activity or subcellular 
localisation. Sites of phosphorylation or proteolysis for LIMK1 (above) and LIMK2 (below) are 
indicated.  
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Figure 1.7 Regulation of LIMK nuclear/cytoplasmic localisation.  
Nuclear import of LIMK1 can be influenced by association with the cyclin dependent kinase 
inhibitor p57KIP2. Once associated, the LIMK1:p57KIP2 complex is translocated from the 
cytoplasm to the nucleus where it appears to be sequestered. LIMK2 nuclear localisation can be 
inhibited through phosphorylation of residues within nuclear localisation sequences by PKC. 
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LIMK1 has also been reported to be activated by MAPKAPK2 in VEGF-stimulated 
endothelial cells, by phosphorylation at Serine 323 between the PDZ and kinase 
domains (Kobayashi et al, 2006) (Figure 1.6). Unlike the more well characterised 
mechanisms of kinase-induced LIMK activation, phosphorylation of Threonine 508 
was not required for LIMK1 activation by VEGF or by kinases upstream of 
MAPKAPK2 including MKK6 or p38. Although p38 was capable of directly 
phosphorylating LIMK on Serine 310, there was no effect on kinase activity, 
therefore the role of p38 in LIMK regulation works via MAPKAPK2 (Fig. 1.6). The 
proposed mechanism to explain the positive effect of Serine 323 phosphorylation 
on kinase activity is that the autoinhibitory amino-terminal domains are 
displaced from binding to the kinase domain, however, direct experimental 
evidence confirming this hypothesis has not yet been reported. 
In addition to activation loop phosphorylation contributing to LIMK activity, an 
insert region consisting of 11 basic amino acids amino-terminal to Thr508 
appears to be necessary for LIMK-induced effects on actin structures in cells, but 
not for kinase activity in vitro, suggesting that this activation loop region might 
be involved in substrate recognition (Edwards & Gill, 1999). Phosphorylation on 
residues outside the kinase domain have been shown to regulate the biological 
function of LIMK by influencing nuclear/cytoplasmic shuttling. Phosphorylation 
of LIMK2 by protein kinase C at Serine 283 alone (Goyal et al, 2005), or in 
combination with Threonine 494 phosphorylation has been reported to prevent 
nuclear import in endothelial cells by inhibiting the function of nuclear import 
sequences (Goyal et al, 2006) (Figure 1.6 and Figure 1.7). 
Nuclear import of LIMK1 is also influenced by association with the cyclin-
dependent kinase (CDK) inhibitor p57KIP2 (Yokoo et al, 2003). The 
LIMK1:p57KIP2 interaction results in translocation of LIMK1 from the cytoplasm 
to the nucleus where the complex then appears to be anchored, possibly due to 
the masking of LIMK nuclear export signals (Figure 1.7). The central portion of 
p57KIP2, which is unique among CDK inhibitors, associates with the LIM domains. 
Consistent with a role in LIMK regulation through subcellular localization, 
p57KIP2 binding did not inhibit LIMK1 kinase activity, although transfection of 
p57KIP2, but not the related CDK inhibitor p27KIP1, resulted in a reduction in 
LIMK1-induced stress fibres (Yokoo et al, 2003). It is also possible that LIMK1 is 
performing a specific role within the nucleus, consistent with its ability to 
29 
phosphorylate the transcription factors CREB (Yang et al, 2004a) and Nurr1 
(Sacchetti et al, 2006). The effects of p57KIP2 on LIMK1 and consequently on the 
actin cytoskeleton is reminiscent of the inhibition of ROCK by the CDK inhibitor 
p21Waf1/Cip1 (Lee & Helfman, 2004) (Tanaka et al, 2002). These data are 
consistent with the increasingly clear role of cell cycle regulatory proteins in the 
regulation of the actin cytoskeleton (Besson et al, 2004). 
The polarity protein Par-3 ordinarily plays an important role in the proper 
assembly of tight junctions in mammalian epithelial cells (Chen & Macara, 2005) 
and the specification of epithelial apical-basal polarity (Hurd et al, 2003). 
Reduction in Par-3 levels by siRNA-mediated knockdown resulted in a substantial 
increase in Cofilin Serine 3 phosphorylation, while overexpression of Par-3 
reduced lysophosphatidic acid stimulation of Cofilin phosphorylation, suggesting 
that Par-3 might influence the activity of a Cofilin kinase or phosphatase (Chen 
& Macara, 2006). The elevated Cofilin phosphorylation observed when Par-3 was 
knocked down could be reversed by treatment with a reported activator of the 
Cofilin phosphatase slingshot, Neuregulin-1β (Nagata-Ohashi et al, 2004), 
consistent with the target of Par-3 not being a phosphatase. Instead, a carboxyl-
terminal fragment of Par-3 was found to interact with LIMK2 (but not LIMK1) in a 
LIM domain dependent manner (Chen & Macara, 2006) (Figure 1.8). The 
association between Par-3 and LIMK2 inhibits kinase activity in vitro without 
affecting LIMK1 activity. Knockdown of LIMK2, or expression of a non-
phosphorylatable Cofilin, reversed the loss of tight junctions in MDCK canine 
kidney epithelial cells induced by Par-3 knockdown, indicating that the inhibition 
of LIMK2 and consequent inactivation of Cofilin is a critical action of Par-3 in 
regulating tight junctions.  
The lats gene was first identified as a tumour suppressor in Drosophila, and the 
two mammalian homologues that have been identified are also believed to 
function similarly. Mice deleted for the lats1 gene develop a limited spectrum of 
cancers (St John et al, 1999) while the human LATS1 gene is lost in sporadic 
cases of sarcoma (Hisaoka et al, 2002) and breast cancer (Morinaga et al, 2000). 
In an attempt to further characterize the downstream signalling events, a 
suppressor screen was undertaken in lats-overexpressing flies (Yang et al, 
2004a). The Drosophila Cofilin homologue twinstar was identified as a dominant 
suppressor, although further analysis revealed that lats and twinstar did not 
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interact directly. Instead, mammalian Lats1 and LIMK1 were found to interact, 
resulting in inhibition of kinase activity (Figure 1.8).  
 
Overexpression of LIMK1 has been reported to result in defective cytokinesis and 
the production of multinucleate cells, suggesting that LIMK1 may play an 
important role in cell division (Amano et al, 2002). Consistent with LATS1 being 
a regulator of LIMK1 in vivo, co-expression of LATS1 with LIMK1 reversed the 
cytokinesis defect induced by LIMK1 overexpression, while knockdown or genetic 
deletion of LATS1 resulted in significant levels of multinucleate cells being 
produced (Yang et al, 2004a). Therefore, it appears that LATS1 plays a 
significant role in cell division, acting via LIMK1-mediated regulation of actin 
cytoskeletal structures. 
Normal cell morphology is influenced by the actin cytoskeleton, in addition, the 
morphological responses observed during apoptosis are due to profound 
alterations in cytoskeletal architecture. Playing a central and critical role in the 
cell contraction and membrane blebbing that occur during apoptosis is ROCK I, 
which undergoes caspase-mediated proteolysis resulting in the generation of an 
active kinase fragment (Coleman et al, 2001; Croft et al, 2005; Sebbagh et al, 
2001). Similarly, LIMK1 has been found to be cleaved at a caspase 3 type site 
DEID (amino acids 237-240) to generate a constitutively active fragment during 
apoptosis (Tomiyoshi et al, 2004)(Figure 1.6). The cleavage site is conserved in 
vertebrate LIMK1 homologues, but is not present in LIMK2. The truncated LIMK1 
has elevated kinase activity in vitro and when expressed in cells results in 
membrane blebbing. Knockdown of LIMK1 by siRNA partially reduced Cofilin 
phosphorylation and membrane blebbing in Fas ligand treated cells, suggesting 
that although LIMK1 is the only reported Cofilin kinase found to be activated by 
caspase cleavage, additional pathways might lead to Cofilin phosphorylation and 
actin rearrangements in apoptotic cells (e.g. cleaved ROCK I >LIMK2 > Cofilin). 
Consistent with this possibility, overexpression of LIMK2 resulted in plasma 
membrane blebbing, which was dependent on ROCK-mediated phosphorylation 
of the activation loop Threonine 505 (Amano et al, 2001). The role of LIMK1 
cleavage during apoptosis may be to amplify ROCK I induced effects on the actin 
cytoskeleton that result in membrane blebbing.  
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Proteolysis of LIMK1 has also been shown to occur via the proteasome-mediated 
degradation in neuronal cells (Tursun et al, 2005). The RING finger E3 ubiquitin 
ligase Rnf6 is expressed at high levels in the axons of developing neurons during 
mouse embryogenesis, and can influence axon outgrowth of cultured 
hippocampal neurons. Rnf6 binds to and catalyzes the polyubiquitination of 
LIMK1, which leads to its degradation by the proteasome. Changes to axon 
outgrowth of cultured neurons were reciprocally regulated by LIMK1 and Rnf6, 
indicating that the two proteins are functionally linked (Figure 1.8). LIMK1 
protein levels are also regulated in the brain by the microRNA miR-134, which 
binds to the 3’ UTR of the LIMK1 mRNA and blocks translation during synapse 
development (Schratt et al, 2006)(Figure 1.8). Therefore, in addition to 
phosphorylation/dephosphorylation, LIMK activity may be regulated via the 
modulation of protein levels, further research will reveal whether these 
mechanisms also contribute to actin regulation in additional cell types.  
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Figure 1.8 LIMK Inhibitors.  
LATS1, miR134, Rf6 and SSH1 have each been shown to inhibit LIMK1 activity by different 
mechanisms as described in the text, reducing its ability to phosphorylate Cofilin. Par 3 has been 
shown to specifically inhibit LIMK2 kinase activity.  
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1.4 Cell biological functions  
The most well characterised function of LIMK is the phosphorylation and 
consequent deactivation of Cofilin family proteins, which results in 
reorganisation of the actin cytoskeleton. A model describing the role of LIMK-
mediated Cofilin phosphorylation on actin dynamics is found in Figure 1.2. 
Given the importance of the actin cytoskeleton, it is perhaps not surprising that 
the LIM kinases play central roles in numerous biological processes, particularly 
in the regulation of cell morphology and motility. Additional more specialized 
activities also appear to be influenced by LIMK, for example, internalisation of 
fluorescently-labelled EGF into invasive tumour cells that over-expressed LIMK1 
was markedly lower than mock transfected control cells (Nishimura et al, 2004), 
while over-expression of a dominant-negative LIMK1 or a non-phosphorylatable 
Cofilin restored EGF internalization in MDA-MB-231 cells that have elevated 
levels of endogenous LIMK1 (Nishimura et al, 2006). 
Although LIMK is likely to contribute significantly to the morphology of numerous 
cell types, it is in the regulation of neuronal morphology and neuritogenesis 
where LIMK is particularly important. Some of the most compelling data comes 
from the limk1 knockout mouse, in which neurons had reduced or absent growth 
cones and abnormal dendrite morphology (Meng et al, 2002). Genetic deletion of 
limk2 did not affect neuronal morphology, but the double limk1 limk2 knockout 
had a more pronounced neuronal phenotype than the single limk1 deletion (Meng 
et al, 2004). Consistent with these results, expression of wild-type LIMK1 in 
cultured hippocampal pyramidal neurons induced growth cone formation and 
neuritogenesis at early time points (Rosso et al, 2004). However, at longer time 
points, LIMK1 expression led to retraction of growth cones and neurites, 
ultimately resulting in axon retraction. These results are similar to other studies 
reporting a role for LIMK in the retraction of growth cones and neurites (Endo et 
al, 2003) (Aizawa et al, 2001; Heredia et al, 2006). The seemingly contradictory 
conclusions of both positive and negative roles of LIMK in the regulation of 
neuronal morphology likely reflect a requirement for precise temporal and 
spatial LIMK regulation for proper development and maintenance of neuronal 
cytoarchitecture. Extrinisic factors that affect neuronal morphology include: 
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bone morphogenetic protein (BMP) 7, which acts via the BMP type II receptor 
(BMPRII) to activate LIMK1 and induce dendritogenesis (Lee-Hoeflich et al, 2004), 
Semaphorin 3A which activates LIMK1 to induce growth cone collapse (Aizawa et 
al, 2001) and fibrillar amyloid beta which activates LIMK to induce 
reorganization of actin filaments and neurite deformation (Heredia et al, 2006). 
The requirement for precise control of LIMK activity in the nervous system is 
reflected by additional layers of regulation including microRNA modulation of 
translation (Schratt et al, 2006) and proteasome-mediated degradation of LIMK1 
(Tursun et al, 2005). 
Cell cycle regulation appears to be influenced by LIMK at several points. In early 
stages of the cell cycle, it has been reported that LIMK2 mediates the ROCK-
induction of cyclin A2 in fibroblasts (Croft & Olson, 2006). At later stages of the 
cell cycle, LIMK regulation of Cofilin is reported to contribute significantly to 
mitosis and cytokinesis. In cells synchronized in S phase by a double thymidine 
block, LIMK1 became hyperphosphorylated and activated in prometaphase and 
metaphase, gradually returning to basal levels of phosphorylation and activity as 
cells entered telophase and cytokinesis (Amano et al, 2002; Sumi et al, 2002). 
Cofilin phosphorylation mirrored the effects on LIMK1, with increased 
phosphorylation during prometaphase and metaphase, with a gradual return to 
basal levels during telophase and cytokinesis (Amano et al, 2002; Sumi et al, 
2002). Interestingly, the increased LIMK1 activity could be blocked by the broad 
specificity cyclin-dependent kinase inhibitor Roscovitine, suggesting that CDKs 
may activate LIMK1 (Sumi et al, 2002). Consistent with these findings, SSH1 
activity was decreased during early mitosis and returned to basal levels during 
telophase and cytokinesis (Kaji et al, 2003). Overexpression of LIMK1 or a 
phosphatase-inactive SSH1 resulted in increased levels of phospho-Cofilin and 
the production of multi-nucleated cells, an effect that could be rescued by 
overexpression of Cofilin in the case of inactive SSH1 (Amano et al, 2002; Kaji et 
al, 2003). In contrast, partial reduction of LIMK1 levels resulted in a G2/M cell 
cycle block (Davila et al, 2003). During interphase and prophase, LIMK1 was 
found associated with cell-cell adhesion sites, localizing at the spindle poles 
from prophase to metaphase (Sumi et al, 2006). LIMK1 disappears from these 
regions during late anaphase and appears again at the contractile ring and 
cleavage furrow during cytokinesis, where SSH1 was also found to accumulate 
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(Kaji et al, 2003). These results indicate that the effects on Cofilin 
phosphorylation during mitosis likely result from the concerted regulation of 
kinase and phosphatase activities, which together contribute to the processes of 
mitosis and cytokinesis. 
In contrast to LIMK1, the activity of LIMK2 did not change after cells were 
released from an S phase cell cycle block (Sumi et al, 2006). However, when 
cells were treated with nocodazole or taxol to disrupt microtubules and induce 
an M-phase block, LIMK2 was activated suggesting that LIMK2 might be 
responsive to a spindle checkpoint. During prophase and prometaphase LIMK2 is 
concentrated at the centrosomes, associating with mitotic spindle microtubules 
during metaphase and early anaphase. As cells progress through late anaphase 
and telophase, LIMK2 localized at the spindle midzone where it was seen to co-
localise with midzone microtubules. The distinct subcellular localization and 
activities displayed by LIMK1 and LIMK2 during the late stages of the cell cycle 
suggest that the two related kinases likely have different functions in mitosis 
and cytokinesis (Amano et al, 2002; Sumi et al, 2006; Yang et al, 2004a). 
The regulation of gene transcription by the serum response factor (SRF) has been 
shown to be influenced by LIMK (Geneste et al, 2002; Sotiropoulos et al, 1999). 
By modulating the ratio of G-actin to F-actin through its actions on Cofilin, LIMK 
influences the nuclear translocation of the actin-binding SRF co-factor MAL 
(Miralles et al, 2003). When released from G-actin in the cytoplasm, MAL 
associates with SRF to promote the transcription of SRF target genes including 
vinculin, cyr61 and SRF itself.  
Identification of the transcription factors CREB (Yang et al, 2004a) and Nurr1 
(Sacchetti et al, 2006) as LIMK1 substrates suggests that there may also be a 
direct link through LIMK to transcriptional regulation. In the case of CREB, which 
regulates expression of numerous “cyclin-AMP responsive” genes by binding to 
gene promoter cAMP-response elements, LIMK1 activation by basic fibroblast 
growth factor in immortalized hippocampal progenitor cells led to increased 
CREB phosphorylation and CREB-responsive promoter activity (Yang et al, 
2004a). Nurr1 is an orphan member of the nuclear receptor family that regulate 
gene transcription via hormone response elements in promoter sequences. 
Purification of Nurr1 binding proteins from immortalized CSM14.1 mesencephalic 
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neurons identified LIMK1, further analysis revealed that LIMK1 phosphorylated 
Nurr1 leading to diminished transcriptional activity from a promoter/reporter 
construct (Sacchetti et al, 2006). The effects of LIMK1 were in opposition to the 
enhanced transcription induced by activated ERK2. The interaction of full-length 
LIMK1 with Nurr1 could be recapitulated with isolated LIM or kinase domains. 
Given that Nurr1 and LIMK1 each interact with p57Kip2 (Joseph et al, 2003; 
Yokoo et al, 2003), and both LIMK1 and p57Kip2 negatively regulate Nurr1 
transcription activity, it is tempting to speculate that there might be a 
functional relationship between these three proteins. In addition to these, the 
microtubule bundling protein p25/TPPP has recently been identified as a novel 
substrate of LIMK (Acevedo et al, 2007). Future experiments will validate CREB 
and Nurr1 as LIMK targets, to reveal whether these additional substrates are 
cell-type specific, and potentially lead to the identification of further novel LIMK 
substrates. 
1.5 Tissue distribution 
Early studies on LIMK tissue distribution made use of RNA-based methodologies 
such as Northern blotting (Ikebe et al, 1998; Koshimizu et al, 1997; Mizuno et al, 
1994) (Cheng & Robertson, 1995; Nunoue et al, 1995), RNase protection (Nomoto 
et al, 1999), RT-PCR (Ikebe et al, 1998) and in situ hybridization (Mori et al, 
1997; Proschel et al, 1995) (Cheng & Robertson, 1995). Although these studies 
generally report widespread distribution of LIMK1 and LIMK2, the existence of 
multiple splice forms, which wasn’t necessarily recognized in early studies, 
could complicate interpretation. As noted above, additional factors regulate 
LIMK protein stability and translation, meaning that mRNA expression does not 
necessarily reflect protein levels. Recent studies have made use of specific 
monoclonal antibodies to determine the patterns of LIMK1 and LIMK2 expression. 
LIMK1 was found to be expressed widely in embryonic and adult tissues, with 
notably high expression in the brain, kidney, lung, stomach and testis (Foletta et 
al, 2004). Similarly, LIMK2 was found to be expressed in almost all embryonic 
and adult tissues examined, with the exceptions of glial cells, kidney glomeruli 
and the testis, save for elongated spermatids (Acevedo et al, 2006). However, 
given that a testis-specific form of LIMK2 has been described (LIMKt) that lacks 
the amino-terminal LIM domains and half of the PDZ domain (Ikebe et al, 1998), 
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it is possible that a testis-specific form of LIMK2 which lacks the monoclonal 
anti-LIMK2 antibody epitope, is expressed in the spermatogonia, Sertoli cells, 
and primary and secondary spermatocytes (Acevedo et al, 2006). 
1.6 LIMK in development and disease  
1.6.1 Genetic deletion  
Despite the wide distribution of LIMK1 and LIMK2 expression, deletion of either 
gene resulted in relatively mild phenotypes in mice. Deletion of limk1 led to 
abnormalities in synaptic structure and spine development most likely due to 
aberrant regulation of the actin cytoskeleton, and manifested behavioural 
alterations, such as a deficit in re-learning spatial information, similar to those 
observed in the human disorder Williams syndrome (Meng et al, 2002). Williams 
syndrome is a rare genetic disorder characterized by mild to moderate mental 
retardation or learning difficulties, with the most significant medical problem 
being cardiovascular disease caused by narrowed arteries (Meyer-Lindenberg et 
al, 2006). The syndrome has been mapped to deletion of chromosome 7q11.2, 
which contains more than 20 genes including LIMK1. Although it is possible that 
the deletion of LIMK1 is a major component of Williams syndrome, particularly 
the behavioural and developmental defects in the central nervous system, 
additional genes in this region may contribute to the overall spectrum of 
symptoms, such as CYLN2 which codes for the microtubule-binding protein CLIP-
115 (Hoogenraad et al, 2002) and the elastin gene ELN  which plays a key role in 
arterial development (Li et al, 1998a; Li et al, 1998b). 
Mice deleted for limk2 had reduced spermatogenic ability, likely due to 
diminished viability and differentiation of spermatogenic germ cells (Takahashi 
et al, 2002). The reported restriction of LIMK2 expression to elongated 
spermatids (Acevedo et al, 2006) does not seem consistent with an apparently 
critical role of LIMK2 in spermatogenesis (Takahashi et al, 2002). One possibility 
is that the requirement for LIMK2 function are fulfilled by alternative forms of 
LIMK2 protein, such as LIMK2t (Ikebe et al, 1998), which might be undetectable 
with the anti-PDZ domain monoclonal antibody that was used to determine 
tissue expression patterns (Acevedo et al, 2006). The double limk1/limk2 null 
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mice were more profoundly affected for impaired synaptic function than either 
single knockout, suggesting that there may be some compensation between the 
proteins (Meng et al, 2004). The fact that the double limk1/limk2 knockout was 
not embryonic lethal suggests that either these kinases have very tissue specific 
functions and are relatively unimportant in most tissues, or that there is 
significant redundancy with other proteins, such as TESK1 or TESK2, for essential 
functions. 
1.6.2 Cancer cell metastasis 
As tumour cells become metastatic, the normal mechanisms that control the 
actin cytoskeleton, cell shape and motility may be subverted so as to promote 
invasiveness. Numerous lines of evidence indicate that the LIM kinases play 
central and critical roles in tumour cell invasion and metatasis. It has been 
proposed that the balance between phosphorylated and non-phosphorylated 
Cofilin determines the metastatic potential of tumour cells. Consistent with this 
proposal, LIMK1 has been found to be overexpressed in malignant melanoma 
cells (Okamoto et al, 2005), breast cancer tumours (Bagheri-Yarmand et al, 
2006) and tumour cell lines (Yoshioka et al, 2003), and in prostate tumours 
(Davila et al, 2003) and tumour cell lines (Davila et al, 2003) (Yoshioka et al, 
2003) where increased phosphorylated Cofilin was also observed (Davila et al, 
2003). In addition, LIMK1 and Cofilin were co-ordinately up-regulated in invasive 
carcinoma cells, relative to non-invasive cells, within primary mammary tumours 
(Wang et al, 2004). Ectopic overexpression of LIMK1 increased motility (Yoshioka 
et al, 2003), invasiveness and metastatic ability of human breast cancer cells 
(Bagheri-Yarmand et al, 2006) as well as promoted the acquisition of an invasive 
phenotype by benign prostate epithelial cells (Davila et al, 2003). Conversely, 
over-expression of Cofilin inhibited the invasiveness of human lung cancer cells 
(Lee et al, 2005) and the motility of glioblastoma tumour cells (Yap et al, 2005). 
However, it has also been reported that over-expression of LIMK1 kinase domain 
(Zebda et al, 2000) or siRNA-mediated knockdown of Cofilin1 or destrin 
(Hotulainen et al, 2005) reduced cell motility. These results suggest that 
perturbing the balance between phospho-Cofilin and non-phospho Cofilin, for 
example by inhibiting LIMK activity, would result in reduced invasiveness and 
metastasis. In support of this conclusion, it has been reported that interfering 
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with LIMK function by anti-sense mediated inactivation of LIMK1 in metastatic 
prostate cancer cells (Davila et al, 2003), by overexpression of a dominant 
negative form of LIMK1 in metastatic breast cancer cells (Yoshioka et al, 2003) 
or by ribozyme-mediated knockdown of LIMK2 in metastatic fibrosarcoma cells 
(Suyama et al, 2004) inhibited motility, invasiveness and/or metastasis. These 
data are consistent with the hypothesis that LIMK inhibition would effectively 
reduce cancer metastasis. 
1.7 Cancer Metastasis 
In order to metastasise, cancer cells must break down cell:cell contacts to 
detach from the initial tumour mass and acquire migratory and invasive 
capabilities. These cells must be motile, able to reorganise sites of cell-matrix 
adhesion and secrete proteinases to degrade paths through the extracellular 
matrix (ECM). The generated paths made by degradation and force facilitate 
invasion through local tissue, cells travel along paths of chemo-attraction to 
reach circulation in either lymph or blood (Yilmaz & Christofori, 2009). This 
process is similar to one that occurs during embryonic development, the 
transdifferentiation of epithelial cells into mesenchymal cells, known as 
epithelial–mesenchymal transition (EMT). EMT facilitates the organised 
movement of cells during development and involves the loss of epithelial cell 
traits including; loss of E-cadherin, plakoglobin, cytokeratins and dismantling of 
adherens junctions. As cells become more mesenchymal they gain a more 
elongated fibroblast-like morphology and invasive features such as the 
expression of; α-smooth-muscle actin, N-cadherin, fibronectin and 
metalloproteinases (Gavert & Ben-Ze'ev, 2008; Hay, 2005). Motile invasive 
carcinoma cells use a mesenchymal-like state to facilitate migration and 
invasion and have been found to share some of the key phenotypic and 
molecular characteristics of EMT (Gavert & Ben-Ze'ev, 2008) (Yilmaz & 
Christofori, 2009).  
Initial stages of metastasis involving the breakdown of cell:cell junctions and 
detachment from the primary tumour are tightly associated with EMT,  but once 
individual cells move away their motility is not solely limited to the 
mesynchymal form. Cells can also move in an amoeboid manner and change 
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between the two forms dependent on extracellular factors or intracellular 
signalling.  
1.8 Individual cell invasion 
Cells can invade using either amoeboid or mesenchymal modes of motility, 
interchanging between the two depending on the up or down regulation of 
specific molecular pathways governing the mode of motility. While EMT is quite 
a rigid process requiring extensive changes in gene transcription, switching 
between mesenchymal and amoeboid forms of motility (and vice versa) is more 
easily achieved and is probably used to facilitate movement at different stages 
of metastasis depending on the demands of the microenvironment (Pankova et 
al, 2009). 
Mesenchymal cell migration is similar to fibroblast-like motility, cells are 
elongated and spindle like, and in 3D are polarised with leading pseudopods and 
a lagging cell body (Figure 1.9 part A). Mesenchymal cells move by the formation 
of actin rich filopodia and lamellipodia at the leading edge, driven by Rho 
GTPases Rac and Cdc42 (Daisuke et al, 2005). Cells attach to the ECM at both 
ends of the cell, clustering integrins which give rise to focal adhesions.  
Proteolytic enzymes such as matrix metalloproteases are then recruited to the 
focal adhesions (Brooks et al, 1996) and lead to ECM degradation and 
remodelling to generate a cell path. 
Amoeboid motility is characterised by cycles of expansion and contraction of the 
cell body, mediated by cortically localised actin and myosin (Pankova et al, 
2009). Amoeboid motility is independent of ECM degradation, cells squeeze 
through existing gaps in the ECM without clustering integrins or concentrating  
proteinases to sites of adhesion (Wolf et al, 2003). This method of motility is 
promoted by Rho/ROCK signalling and the tension maintained by cortical 
actomyosin promotes membrane blebbing which contributes to cell motility 
(Keller & Eggli, 1998). The low levels of attachments made by amoeboid 
migrating cells is believed to allow them to move at higher velocities through 3D 
environments than their mesenchymal counterparts (Pankova et al, 2009).  
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When mesenchymal HT1080 and MDAMB231 cells were subject to protease 
inhibitors in 3D they changed from an elongated morphology to a more rounded 
amoeboid morphology and mode of motility (Wolf et al, 2003). It has also 
recently been proposed that Rab5 may play a role in the process of amoeboid to 
mesenchymal transition of cancer cells (Palamidessi et al, 2008). These findings 
suggest that migrating cancer cells can compensate to environmental factors, 
changing from a mesenchymal ‘path generating’ form of motility to an amoeboid 
‘path finding’ mode (Wolf et al, 2003). 
1.9 Collective cell invasion 
The ability of tumor cells to move through tissues is the outcome of two 
processes: extracellular matrix (ECM) deformation/degradation to generate a 
path of reduced mechanical resistance, and cell motility to follow the path. 
Although considerable recent effort has been directed understanding how tumor 
cells invade three-dimensional environments as individual cells, epithelial cancer 
cells commonly invade collectively in strands, sheets and clusters, particularly in 
highly differentiated tumours that maintain epithelial characteristics (Friedl & 
Wolf, 2008). The cell collective may remain in contact with the primary mass, or 
may detach and spread away from the primary site. In this form of invasion, 
leading cells generate paths of low physical resistance by focalizing protease 
activity and/or generating force to remodel the extracellular matrix for the 
remainder of the collective to follow. Therefore, distinct cells in strands may 
have different roles; for example path generation which would require ECM 
remodelling activities such as those attributed to cells using a mesenchymal 
mode of motility, whereas path following cells which would only require more 
amoeboid features for cell motility (Friedl & Wolf, 2008; Wolf et al, 2003) see 
Figure 1.10. 
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Figure 1.9-Mesenchymal vs. Amoeboid invasion.  
A. A comparison of the main phenotypic characteristics of the mesenchymal and amoeboid modes 
of invasion. Mesenchymal cells are elongated and polarised and degrade the ECM, amoeboid cells 
are rounded in morphology and move in a proteolysis independent manner. Adapted from 
(Pankova et al, 2009) B. Interactions among the components of signaling pathways documented to 
be involved in the MAT/AMT transitions of cells in a 3D environment. The inhibition of the activity of 
the proteins highlighted in red was shown to trigger amoeboid to mesenchymal transitions. 
Inactivation of the proteins depicted in green induces a conversion from the mesenchymal to the 
amoeboid mode of invasiveness. Solid lines direct connections, dashed lines indirect connections. 
Figure taken from (Pankova et al, 2009). 
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Figure 1.10- Individual vs. Collective invasion  
A. Individual invasion. Single-moving proteolytic cells cause ECM reorganisation. After protrusion 
of an anterior pseudopod (step I) and traction force generation (step II), focal cleavage of individual 
ECM fibers is executed slightly backward to leading adhesion sites (step III). Transport of loose 
fiber ends (step IV) results in a small microtrack detected upon forward gliding of the cell rear (step 
V). B. Collective invasion. ECM reorganisation is executed by multiple cells that collectively fill a 
small pre-existing tissue gap while remaining connected. By focalizing proteolytic activity toward 
the cell-ECM interface, a near-continuous ECM layer is generated and further cleaved. Yellow, 
proteases and MT1-MMP; green, degraded collagen; blue, β1 integrin; red, Filamentous-actin. 
Figure taken and adapted from (Friedl & Wolf, 2008). 
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1.10 Role of the actin cytoskeleton in invasion 
Motility required for cancer cell metastasis is driven by remodelling of the actin 
cytoskeleton and cell:ECM contacts. RhoGTPases are regulators of both the actin 
cytoskeleton and cell adhesion (Sahai & Marshall, 2003). Activated Rac and 
Cdc42 induce cytoskeleton reorganisation at the leading edge of cells, from 
which localised actin polymerisation pushes the polarised cell membrane 
forward in filopodia or lamellipodia, propelling the cell forward (Nobes & Hall, 
1995). Actin polymerisation from globular actin subunits (G-actin) into 
filamentous actin (F-actin) is then used by the cell to form either branched 
filaments, for sheet like protrusions, or bundled filaments for spike like 
membrane protrusions (Insall & Machesky, 2009). Branched filament networks 
are assembled by the Arp2/3 complex, an assembly of 7 subunits that include 
two actin related proteins Arp2 and Arp3 and five non-Arp components, p41/ 
ARPC1, p34/ARPC2, p21/ARPC3, p20/ARPC4 and p16/ARPC5 (Machesky & Gould, 
1999). Arp2/3 promotes the formation of new branches of F-actin at 70˚ from 
the original filament. Formins, on the other hand, are dimers that mediate the 
elongation of unbranched F-actin. Both formins and the Arp2/3 complex utilise 
profilin to recruit monomeric actin to the growing ‘plus’ ends of filaments 
(Figure 1.11). Wasp proteins, WASP, N-WASP, and WAVE1-3 disseminate 
extracellular signals to the actin reorganisation machinery. They regulate 
membrane protrusions by VCA binding of the Arp2/3 complex, a multi domain 
module of the WASP family consisting of a verprolin-homology domain (V), a 
Cofilin-like (C) and an acidic domain (A). This binding activates the Arp2/3 
complex, catalysing Arp2/3 mediated actin polymerisation (Daisuke et al, 2005). 
Growing filaments push the cell membrane forward, moving the cell. Contractile 
acto-myosin filaments, regulated by Rho through downstream effectors such as 
ROCK, pull in the tail of the cell and promote the translocation of the cell body 
(Daisuke et al, 2005). Coordinated protrusion of the leading edge and retraction 
of the tail of the cell results in forward movement of the cell.  
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Figure 1.11 Actin cycling at the leading edge 
Cells move through the rapid rearrangement of the actin cytoskeleton. In the, (1) several signaling 
pathways (2) converge to (3) activate WASp/Scar proteins, which in turn (4) activate the Arp2/3 
complex. (5) Active Arp2/3 complex binds to the side of an existing filament and nucleates (6) new 
filament growth towards the cell membrane. The combined force from many growing filaments 
pushes the cell membrane forward, moving the cell. Actin binding proteins, including (7) capping 
protein, (9) ADF/cofilin, (10) profilin, tropomyosin, formins, and Ena/VASP, modulate these events. 
Figure taken from the Website of J.Kuhn www.biol.vt.edu/faculty/kuhn/research.html. 
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1.11 Invadopodia 
Invadopodia and podosomes are both forms of actin rich protrusions that attatch 
to and degrade the cellular substrate. Invadopodia and podosomes contain an 
actin core with proteins important for actin nucleation (WASP, N-WASP, WIP, 
Cotrtactin and the ARP 2/3 complex), this core is surrounded by integrins and 
associated proteins such as vinculin, talin and paxillin (Mueller et al, 1992; Desai 
at al, 2008; Albiges-Rizo et al, 2009). The integrins and integrin associated 
proteins form an ‘adhesive ring’ colocalising with part of the polymerised actin 
(the ‘actin cloud’) to cluster rings or chains of invadapodia or podosomes 
together (Albiges-Rizo et al, 2009). Figure 1.12, adapted from Albiges-Rizo et al, 
outlines the locations of these proteins and the manner in which invadapodia 
and podosomes are formed. 
Invadopodia are more associated with carcinoma cells whilst podosomes are 
considered to be more common in monocytic cells such as macrophages and 
osteoclasts. Podosomes typically occur in cells such as osteoclasts as evenly 
spaced ‘polka dots’ or in rosette formations, whilst invadapodia are typically 
more condensed in small clusters in carcinoma cells (Linder et al, 2007). 
Podosomes are rapidly  turned over, as fast as 2-4 minutes where as invadapodia 
are thought to be longer lived, up to 30 minutes (Ochoa et al, 2000; Destaing et 
al, 2003; Badowski et al, 2003). There is some speculation that podosomes may 
be the precursors of invadapodia, and Src has been used to speed up the turn 
over of invadapodia to times similar to podosomes, but there is little evidence to 
show a mechanism by which to transform podosome structures into more 
aggressive invadapodia. Cofilin localises to invadapodia and is important for 
formation of free barbed ends in these cellular structures (Oser et al, 2009; 
Yamaguchi et al, 2005). Cofilin is believed to cycle between two compartments 
near invadapodia, the F-actin and cytosol compartments (Oser and Condeelis 
2009). When bound to cortactin in the F-actin compartment Cofilin is inactive. 
Following Cortactin tyrosine phosphorylation Cofilin is no longer inhibited and is 
able to severe actin filaments, leading to the generation of barbed ends (as 
outlined in Figure 1.11) and actin polymerisation. Cofilin is then inactivated by 
phosphorylation by LIMK until Cofilin and Cortactin are dephosphorylated and 
the cycle begins again (Oser and Condeelis 2009). 
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Figure 1.12 Schematic view of signalling pathways that lead to actin organisation at 
invadapodia or podosomes. 
A. At the initial stage of adhesion formation, integrins or other unidentified receptors bind to 
components of the ECM (grey), leading to clustering of receptors into PtdIns(4,5)P2-enriched areas 
of plasma membrane. B. Recruitment of Src to adhesion sites leads to phosphorylation of several 
proteins such as cortactin, WASP, FAK and regulators of small GTPases. Continuous actin 
nucleation relies on the continuous and strong activation of the Arp2/3 complex at the membrane 
through the synergistic action of cortactin and WASP-family proteins. C. DRF/mDia1 elongates 
actin filaments into columnar structures from the branched actin network that was previously 
induced by N-WASP, the Arp2/3 complex and cortactin. D. Podosomes or invadapodia are 
mechanically connected through a network of radial actin filaments that lie parallel to the 
substratum. 
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2 Materials and Methods 
2.1 Chemicals and Reagents 
All Chemicals were purchased from Sigma-Aldrich or Fisher Scientific UK unless 
stated otherwise. 
2.2 Bacterial techniques 
2.2.1  Reagents 
Agarose gel DNA 
loading buffer 
(10X) 
20 mM EDTA, 0.05% (w/v) bromophenol 
blue, 50% v/v glycerol 
 
Ampicillin  
Chloramphenicol 
 Sigma-Aldrich 
Sigma-Aldrich 
DNA Ladder 100bp and 1kb Invitrogen 
LB Agar 1% w/v bacto tryptone, 86 mM NaCl, 
0.5% w/v yeast extract, 1.5% w/v agar,  
Beatson Institute 
Central Services 
LB medium 1% w/v bacto tryptone, 85.5 mM NaCl, 
0.5% w/v yeast extract 
Beatson Institute 
Central Services 
TBE 89 mM Tris Base, 89 mM boric Acid, 3.2 
mM EDTA 
 
2.2.2 Enzymes and kits 
DNA polymerase and 10x reaction buffer Stratagene 
DNA Purification Kit QIAGEN 
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Ethidium Bromide Invitrogen Ltd 
QIAGEN Plasmid Maxi Kit QIAGEN 
QIAprep Spin Mini-Prep Kit QIAGEN 
QIAquick Gel Extraction Kit QIAGEN 
QuikChange® Multi Site-Directed Mutagenesis Kit QIAGEN 
Rapid DNA Ligation Kit Roche 
Restriction enzymes and reaction buffers Invitrogen Ltd 
Restriction enzymes and reaction buffers New England Biolabs Ltd 
Shrimp Alkaline Phosphatase Promega 
SybrGreen (10000X stock) Invitrogen Ltd 
2.2.3 Bacterial strains 
All cloning was undertaken in E.Coli DH5α. Recombinant protein synthesis was 
performed in E.Coli BL21 (P Lys). Both were supplied by the Beatson Institute 
Central Services. 
2.2.4 Bacterial Transformation and culture 
E. coli DH5α competent cells were thawed on ice and 50µl mixed with 2µlof 
plasmid DNA (various concentrations) or ligation reaction in a pre-chilled 
polypropylene tube. After incubation on ice for 45min, cells were subjected to 
heat-shock at 42°C for 45 seconds and then chilled on ice for a further 2 minutes 
before the addition of 180µl of SOC medium and incubation at 37°C whilst 
shaking. The transformation mixture was spread onto LB agar plates containing 
appropriate antibiotics and incubated overnight at 37°C. 
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Single bacterial colonies were picked from LB-agar plates and inoculated into 
5ml of LB medium containing the appropriate antibiotics, this culture was then 
grown overnight at 37°C whilst shaking. For long-term storage, 500μl of this 
bacterial culture were mixed with 500μl of sterile glycerol in a cryo-tube for 
storage at -70°C. 
2.2.5  Small-scale plasmid DNA preparation 
1.5ml of an overnight bacterial culture was pelleted by centrifugation at 
3000rpm for 5min in a micro-centrifuge. The pellet was resuspended and 
processed using the QIAprep Spin Mini-Prep Kit according to the manufacturer’s 
instructions. The eluted DNA was stored at -20°C. 
2.2.6  Large-scale plasmid DNA preparation 
100ml of bacterial overnight culture was pelleted by centrifugation at 3500rpm 
for 20min at 4°C in a Beckman Coulter J6-M1 centrifuge (JS-4.2 series rotor). 
The pellet was resuspended and processed using the QIAGEN Plasmid Maxi Kit 
according to the manufacturer’s instructions. The concentration and purity of 
the eluted DNA was determined using an Eppendorf biophotometer. The DNA was 
stored at -20°C. 
2.2.7 Quantification of DNA 
Double stranded DNA was quantified using an Eppendorf biophotometer. Nucleic 
acid solutions were diluted in H2O before reading at an absorbance of 260nm. 
2.2.8 Plasmids 
Plasmids used throughout this thesis are listed below in Table 1.  
Table 1 Plasmids 
Plasmid Mutant used 
pGEX-KG-hCofilin WT, S3A, S3E, Tr (truncated) 
mRFP-C3-6xG  
pBABE Puro hLIMK hER WT, E, EE 
pCMV6, pCMV6 –XL4 LIMK2a  
pCDNA 3.1, pCDNA 3.1 LIMK1  
pMAX GFP  
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2.2.9 Cloning protocols 
2.2.9.1 Restriction enzyme digestion 
DNA restriction digests were performed using the appropriate restriction enzyme 
and the corresponding reaction buffer from Invitrogen or New England Biolabs 
Inc. Typically, 1µg plasmid DNA or 10 µl PCR amplified fragment was added to 1 
unit (U) of restriction enzyme, 2µl appropriate 10X reaction buffer and the 
volume adjusted to 20µl with H2O. Digestion was carried out at the appropriate 
temperature recommended by the manufacturer, usually for around 2 hours. 
2.2.9.2 Phosphatase Treatment 
Digested vector DNA in ligation reactions was treated with Shrimp Alkaline 
Phosphatase to remove 5’ phosphate groups and prevent vector re-ligation. One 
unit of phosphatase was added per 20µl of restriction digest along with the 
appropriate volume of reaction buffer. 
2.2.9.3 Agarose gel electrophoresis 
Gels for DNA electrophoresis were composed of 1% (w/v) ultra pure 
electrophoresis grade agarose in 1xTBE buffer and 2µg/ml ethidium bromide 
(except in cases where 1µl of a 1:400 dilution of SybrGreen was added to the 
sample, in which case no ethidium bromide was required in the gel). Once set 
the gels were placed in a horizontal gel apparatus from Stratagene containing 
1xTBE running buffer. DNA samples were diluted in 1x DNA loading buffer and 
loaded alongside suitable DNA ladder markers in the outermost wells of the gel 
(for gels without ethidium bromide 1µl of 1:400 SybrGreen was added to each 
sample). Electrophoresis was performed at 80-100V and the DNA visualised using 
a UV trans-illuminator (UVB). 
2.2.9.4 Acrylamide gel for DNA  
A non-denaturing acrylamide gel can be used to visualise annealed 
oligonucleotides. These gels were set up using 6.6ml10% acrylamide (19:1 40% 
ratio), 13.28ml 1X TBE, 0.1 ml 0.05% APS and 0.02ml 0.1% TEMED up to 20 ml 
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final volume and the comb added directly to this as there is no separate stack. 
1X TBE was used as running buffer an d samples of forward, reverse and 
annealed oligonucleotides were prepared with DNA sample buffer and loaded 
next to an appropriate ladder. The gel was run at 100V until the bromophenol 
blue was two thirds of the way down the gel, then transferred to a tray with 
10µl of 1mg/ml EtBr in 100mls of 1X TBE for 30 minutes for visualisation. 
2.2.9.5 DNA Purification 
DNA from restriction digests or PCR reactions was purified using the QIAquick 
PCR purification Kit according to the manufacturer’s instructions. In brief, the 
DNA fragment was cut from the agarose gel using a clean scalpel, placed in an 
eppendorf and weighed. Three volumes of QG buffer was added to one volume 
of gel and the mixture incubated on a heat block at 50°C for 10 minutes (or until 
the gel slice dissolved). One gel volume of isopropanol was then added to the 
sample and mixed, and the whole sample spun through a QIAquick column for 1 
minute to bind DNA. Washes were performed with the appropriate buffers and 
the DNA eluted in EB buffer.  
2.2.9.6 Phosphorylation and Ligation 
T4 kinase was used to phosphorylate annealed oligonucleotides in standard 30µl 
reactions. In brief, 20 U of T4 kinase (2µl), 1 µg annealed oligonucleotides 
(15ul), 3µl of ligation buffer (as ligation follows on from this reaction) and 10ul 
of nuclease free water were mixed and incubated at 37°C for 30 minutes, then 
65°C for 20 minutes before ligation. 
Ligation reactions were performed using T4 DNA ligase. In brief, 1 U of T4 DNA 
ligase with 1X T4 buffer and a 3-fold excess of phosphatased vector to insert 
DNA were incubated at 25°C for at least 2 hours. 
2.2.10 Generation of fragments by PCR 
Each standard 50µl reaction contained 20ng of plasmid DNA template, 25ng of 
each oligonucleotide primer, 2 U Vent DNA polymerase, 1X Thermopol buffer and 
0.2mM dNTPs. PCR programme followed 96°C 30 seconds, 50°C 30 seconds, 72°C 
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1 minute for 25 cycles and the samples were then run on agarose gels for 
analysis. 
2.2.11 Annealing oligonucleotides 
Complementary oligonucleotides were mixed together at a 1:1 molar ratio in a 
micro-centrifuge tube and diluted to a final concentration of 1 pmol/µl with a 
Tris buffer containing salt; 10 mM Tris, 1 mM EDTA, 50 mM NaCl. A large glass 
beaker of water (400 ml) was brought to the boil and the small tube of 
oligonucleotides placed in the boiling water, then left to slowly cool to room 
temperature. 
2.2.12 Cloning 
DNA fragments for cloning amplified using oligonucleotide primers. Following 
PCR, samples were purified by agarose gel electrophoresis and spin columns 
before digestion and ligation as described. Constructs subject to cloning 
procedures were sequenced to identify desired clones; sometimes these were 
prescreened by ‘wiggles’.  
2.2.13 PCR directly from Bacteria 
A PCR-based approach for screening antibiotic resistant bacterial colonies 
transformed from ligation reactions for positive clones. A single bacterial colony 
was picked with a sterile pipette tip and sequentially dipped in a standard PCR 
reaction and dropped into 15ml round bottomed tube containing 3ml of LB 
media. In general wiggle reactions used a 5’ oligonucleotide specific to the 
vector backbone, and a 3’ oligonucleotide specific to the insert to be sub-cloned 
in order to identify positive clones with the correct insert orientation. Following 
agarose gel electrophoresis to identify clones from which the correct size 
product was amplified, the corresponding bacterial cultures of these positive 
clones were amplified and plasmid DNA isolated as described. 
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2.2.14 Mutagenenis 
Mutagenesis of both LIMK1 and Cofilin 1 was performed using the QuickChange 
site-directed mutagenesis kit from Stratagene, exactly as described in the 
manufacturers instructions. The oligonucleotides used were designed following 
the manufacturers guidelines and are described in the Table of oligonucleotides. 
Briefly, sample reactions contained 5µl 10X reaction buffer, 5µl (50ng) of 
template DNA, 1µl (125 ng) of forward primer, 1µl (125 ng) of reverse primer, 
and 1µl (10 nM) dNTP mix and made up to 50µl of dH2O before the addition of 
2.5 U (1µl) Pfu Turbo DNA polymerase and thermal cycling was programmed on 
the PCR machine as follows; 
Segment 1 1 cycle 95°C 0.5 minutes 
Segment 2 18 cycles 95°C 
55°C 
66°C 
0.5 minutes 
1 minute 
1 minute per kb of plasmid  
(e.g. 9minutes for LIMK:ER mutagenesis) 
Segment 3 1 cycle 4°C Until recovered 
Following generation of nicked circular strands that incorporate the mutant 
oligonucleotides, methylated parental DNA was digested with 10U DpnI 
restriction enzyme per sample at 37°C for 1 hour. The remaining circular double 
stranded mutant DNA was then transformed into DH5α as described. Five to ten 
colonies were picked per mutant, the DNA purified and the insert sequenced to 
identify clones with the desired mutation. Usually around four out of five 
positive clones were identified using this technique. 
To create a truncated Cofilin 1 initially a gradient block PCR reaction was 
performed to identify optimal PCR conditions. Each sample reaction contained 
2.5µl 10X Picomaxx reaction buffer, 1µl of template DNA, 1µl (125 ng) of forward 
primer, 1µl (125 ng) of reverse primer, and 1µl (10 nM) dNTP mix and made up to 
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25µl of dH2O before the addition of 2.5µl Picomaxx Taq (hot start reader) DNA 
polymerase. Using the Tm values of the oligonucleotides (designed to truncate 
the Cofilin1 insert) minus 4°C as top and bottom temperatures a gradient block 
PCR programme was set up to give a range of 6 different annealing temperatures 
as follows: 
 Segment 1 1 cycle 95°C 5 minutes 
Segment 2 34 cycles 94°C 
50°C – 62°C 
72°C 
45 seconds 
45 seconds  
3 minutes 
Segment 3 1 cycle 72°C 7 minutes 
Segment 4 1 cycle 4°C Until recovered 
Products were then run on a 1% agarose gel to identify the optimal temperature 
for PCR. The remaining product from the optimal temperature was run on a 1% 
agarose gel, excised and purified as described and sequenced to confirm the 
correct truncations had been performed. 
2.2.15 Sequencing 
Plasmid inserts were sequenced by Beatson Molecular Technology Services. 
Routine sequencing of plasmids or PCR products by this service was performed 
on an Applied Biosystems 3130xl (16 capillary) sequencer. The Applied 
Biosystems (BigDye 3.1) DNA sequencing protocol was used for the setup of 
sequencing reactions, precipitation of sequenced DNA and preparation for 
loading into the sequencer. The service analysed the sequencing data before 
releasing the sequencing data to help troubleshoot or solve any sequencing 
failures. 
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2.2.16 Primers 
Oligonucleotides and Primers generated and used in this project are detailed 
below in Table 2.  
Table 2 Oligonucleotides and Primers  
 5’ -3’ 
LK1 Bam For (LIMK1 sequencing) 
 
GGG GGA TCC ATC GAC AGG TCT CCG 
LK1 Eco Rev (LIMK1 sequencing) GGG GAA TTC CGT CGG GGA CCT CAG 
GGT G 
Cofilin Val7 for (sequencing) 
 
GGG GCC ATG GTC TCT GAT GGT GTC 
Cofilin Asp9 for (sequencing) 
 
GGG GCC ATG GAT GGT GTC ATC AAG 
TAT FLAG Forward (generation of TAT 
Cofilin protein) 
AAT TTA TGC GCG TGC GGC GGC GCG 
TCA GGC GCG TGC GGG TGG TGA TTA 
TAA AGA TGA TGA TGA TAA AGC 
TAT FLAG Reverse (generation of TAT 
Cofilin protein) 
CAT GGC TTT ATC ATC ATC ATC TTT 
ATA ATC ACC ACC CGC ACG CGC CTG 
ACG CGC CGC CGC ACG CGC ATA 
Cofilin S3E forward (SDM) CTA GAC TCC ATG GCC GAA GGT GTG 
GCT GTCC TC 
Cofilin S3E Reverse (SDM) GAG ACA GCC ACA CCT TCG GCC ATG 
GAG TCT 
PTD Cofilin S3E forward (SDM) GAT AAA GCC ATG GCC GAG GGT GTG 
GCT GTC TC 
PTD Cofilin S3E Reverse (SDM) GAG ACA GCC ACA CCC TCG GCC ATG 
GCT TTA TC 
Cofilin S3A forward (SDM) CTA GAC TCC ATG GCC GCT GGT GTG 
GCT GTCC TC 
PTD Cofilin S3E forward (SDM) GAT AAA GCC ATG GCC GCT GGT GTG 
GCT GTC TC 
 
2.2.17 Recombinant protein preparation 
2.2.17.1 Buffers and reagents 
PBS lysis buffer PBS with 1mM PMSF 
Protein production Buffer A  PBS with 50mM Tris pH7.5, 150mMNaCl, 3mM DTT 
Thrombin cleavage buffer PBS with 50mM Tris pH7.5, 150mM NaCl, 1 mM 
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MgCl2, 1 mM CaCl2, 3 mM DTT 
p-aminobenzamidine beads  Washed in buffer A Sigma 
Protein A-Sepharose 4B Washed in buffer A Sigma 
10ml columns  731-1550 Bio-Rad 
Centifugal Filter Devices  Ultracel YM-3, 3000 MWCO Microcon 
2.2.17.2 Protein preparation 
For large scale protein production, single bacterial colonies of, for example, 
pGEX-KG COFILIN (WT) in BL21 (DE3) pLyss cells were cultured in six 50 ml 
batches of Terrific broth with 100 g/ml ampicillin. Overnight cultures were 
each diluted 1:10 into one of six flasks containing 500 ml Terrific broth including 
100 g/ml ampicillin and grown to OD600 0.6 to 1.0 at 37°C before inducing with 
100 µM IPTG for 3 hours at 37°C. Cells were pelleted by centrifugation in a 
Beckman Coulter J6-M1 centrifuge,  resuspended in 5 ml of phosphate buffered 
saline (PBS) lysis buffer [PBS with 1 mM Phenylmethylsulphonylfluoride (PMSF)] 
and snap frozen in a dry ice/ethanol solution. At this point, samples could have 
been stored at -80 C indefinitely. After thawing in a 37°C water bath, samples 
were kept on ice while being disrupted by three 1 minute rounds of sonication at 
20% intensity using a Branson Digital Sonifier, followed by removal of debris by 
centrifugation at 10,000 g for 20 minutes at 4°C (9092 rpm using a Beckman 
Avanti J-25 centrifuge with a JA 25.50 rotor). Clarified supernatants were 
incubated with 0.5 ml of protein production buffer A [PBS with 50mM Tris pH7.5, 
150mMNaCl, 3mM DTT] washed glutathione-Sepharose (Sigma) bead slurry 
overnight at 4°C to bind GST fusion protein [this can be done in a a 10ml capped 
column (Bio-Rad #731-1550), following overnight rotation the cap can be 
removed and washes performed through the column] . Beads were then washed 
six times with 50 ml of buffer A, followed by two washes with 50 ml of thrombin 
cleavage buffer [ 50mM Tris pH7.5, 150mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 3 mM 
DTT in PBS]. The beads were resuspended in 0.5 ml of thrombin cleavage buffer 
and Cofilin released from the GST moiety by incubation with 25 units of bovine 
thrombin (Sigma) overnight at 4°C. The supernatant was removed, beads were 
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washed twice with 0.5 ml buffer A and the collected supernatants were 
incubated with 30 µl of buffer A-washed p-aminobenzamidine beads (Sigma) for 
1 hour at room temperature (~20°C)to remove thrombin, before snap freezing 
aliquots and storing at -80°C. 
Protein concentration was determined using BCA protein assay kit (Sigma), and 
assessment of expression and purification of prepared was achieved with 1µg, 
3µg and 10µg samples of protein with parallel samples of BSA at the same 
concentrations in 20µl [samples prepared with 6x sample buffer and PBS] and 
10µl SDS-Page broad range standards (Bio-Rad) on 10% SDS-poly-acrylamide gels. 
Gels were stained with SimplyBlue Safe Stain and images acquired at 700nm with 
a Li-Cor Odyssey infrared imaging system. 
2.3 Mammalian cell culture techniques 
All cell culture work was performed using aseptic techniques inside a laminar 
flow hood. 
2.3.1 Reagents 
0.05% Trypsin EDTA GIBCO 
200mM L-Glutamine (100x) GIBCO 
6.5mm Transwells, 8.0um pore size  ThermoScientific 
Calcein AM Invitrogen 
Cell line nucleofector kit V Amaxa 
Complete Matrigel BD Biosciences 
DMEM (Dulbecco’s Modified Eagle’s 
Medium) 
GIBCO 
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ECL Western Blotting Detection 
Reagents 
GE Healthcare 
Foetal Bovine Serum Autogen Bioclear 
Growth Factor Reduced Matrigel BD Biosciences 
Lipofectamine 2000 Reagent Invitrogen 
Oligofectamine Reagent Invitrogen 
OptiMEM 1(Reduced Serum Medium) Invitrogen 
Oris Cell Migration Assay Oris 
Penicillin Streptomycin  GIBCO 
Poly-L-Lysine Sigma-Aldrich 
Puromycin Sigma-Aldrich 
RPMI GIBCO 
Sodium pyruvate 100mM GIBCO 
Sterile distilled water  Beatson Institute Central Services 
Ascorbic acid Sigma 
2% Gelatine (G1393) Sigma  
10 ug/ml DNase I Roche 
CDM Extraction buffer 20 mM NH4OH, 0.5% Triton X-100 in 
PBS 
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Sterile PBS (Phosphate Buffered Saline) Beatson Institute Central Services 
2.3.2 Growth conditions  
BE human colon carcinoma cells and breast cancer cell line MDAMB231 are both 
adherent and were grown at 37°C in 5% CO2 in a humid incubator. The BE and 
MDAMB231 culture medium consists of DMEM supplemented with 10% FBS, 2mM 
L-glutamine plus 10Units/ml pennicillin and 10µg/ml streptomycin. Both cell 
lines were passaged every 3-4 days by brief exposure to 0.05% trypsin-EDTA, 
aided by agitation, and then resuspended in serum containing medium to quench 
the trypsin, and diluted (1:10) into fresh medium.  
BT549 breast cancer cells are adherent and were grown at 37°C in 5% CO2 in a 
humid incubator. The BT549 culture medium consists of RPMI supplemented with 
10% FBS, 2mM L-glutamine plus penn strep. BT549 cells were passaged every 3-4 
days by brief exposure to 0.05% trypsin-EDTA, aided by agitation, and then 
resuspended in serum containing medium to quench the trypsin, and diluted 
(1:10) into fresh medium.  
hTERT –HNCAF were cultured in DMEM supplemented with 10% FCS, 1% ITS, 2mM 
L-glutamine and penicyllin streptomycin. These cells are very slow growing and 
thus were passaged every 7 days (media was changed after 3 days). 
For long-term storage cells were frozen in 10% DMSO in FBS and stored in liquid 
nitrogen vapour phase tanks. 
2.3.3  Transfection with siRNA 
All siRNA reagents were obtained from DHARMACON RNA Technologies. 
Table 3 siRNA duplex sequences 
Target Sequence Catalog # 
LIMK1 (#1) GAACGCAGACCCUGACUACUU 
5’PGUAGUCAGGGUCUGCGUUCUU 
D-007730-01 
LIMK1 (#3) UCAAGGAGGUGAAGGUCAUUU 
5’PAUGACCUUCACCUCCUUGAUU 
D-007730-03 
LIMK2 (#6) GAUCUGAACUCGCACAACUUU 
5’PAGUUGUGCGAGUUCAGAUCUU 
D-003311-06 
LIMK2 (#7) UGACUGAGGUGAAAGUGAUUU D-003311-07 
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5’PAUCACUUUCACCUCAGUCAUU 
ON-TARGETplus 
Non-targeting 
siRNA #1 
Sequence not provided by 
manufacturer; negative control siRNA 
with at least 4 mismatches to any 
human, mouse or rat gene. 
D-001810-01-05 
ON-TARGETplus 
Non-targeting 
siRNA #2 
Sequence not provided by 
manufacturer; negative control siRNA 
with at least 4 mismatches to any 
human, mouse or rat gene. 
D-001810-02-05 
Lamin A/C Control 
siRNA  
Sequence not provided by 
manufacturer. 
D-001050-01-20 
 
Oligofectamine was used for transfection of siRNA on sub-confluent cells, for 
example MDAMB231 cells were seeded at 2x105 per well of 6well dishes 24h prior 
to transfection and Oligofectamine reagents used according to the 
manufacturer’s instructions. In brief, both siRNA (e.g. 50nM of siRNA pool, 
individual duplex or negative control) and Oligofectamine were diluted in 
OptiMEM, incubated at RT for 5min, then combined and incubated for a further 
20 minutes. The cells were washed during this 20 minute incubation period with 
serum free media and covered with a set volume of OptimMEM before addition 
of the siRNA/Optimem/Oligofectamine mixture to the cells. Down regulation of 
protein levels was generally achieved after 24 hours in culture and confirmed by 
Western blotting. 
2.3.4  Transient transfection with plasmid DNA 
For transient transfection of plasmid DNA using Lipofectamine 2000, cells were 
set up at an appropriate density in culture dishes (e.g. 1x105 per well of a 6well 
dish for MDAMB231). 16-24 hours later DNA was transfected according to the 
manufacturer’s instructions. Both DNA (~5-10µg) and Lipofectamine 2000 were 
diluted in OptiMEM, incubated at RT for 5min, then combined and incubated for 
a further 20min before being added directly to the cells. Expression was then 
tested for after 24-48 hours. 
The Amaxa nucleofector kit V was also routinely used for the transient 
transfection of MDAMB231 cells. 1x106 cells were pelleted, resuspended in 100µl 
of solution V and DNA, transferred to a nucleofection cuvette and placed in the 
Nucleofector where Program X13 (optimised to this cell type) was used. Cells 
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were then re-plated on to 6-well culture dishes and allowed to recover for 
(Hennigan RF, 1994)between 24 hours, before being redistributed into the 
desired experiment (e.g. Inverse invasion assays). 
2.3.5 Nucleofection 
Nucleofection provided an alternative method of DNA transfection, with high 
transfection efficiency rates. Cells were transfected using the appropriate 
nucleofection kit of the cell line according to the manufacturers instructions. In 
brief; MDAMB231 cells were passaged 2 days before nucleofection as cells should 
be nucleofected at 70-85% confluency. 5µg DNA was prepared for each sample. 
Nucleofector solution was allowed to warm to room temperature, 500µl of media 
per sample (complete with supplements) was warmed to 37°C. 6 well dishes 
were prepared with 1.5ml media per well and the desired cells harvested and 
counted. 1x106 cells per nucleofection were centrifuged in individual tubes, the 
supernatant removed and the cell pellet resuspended in 100µl of Nucleofector 
solution for a final concentration of 1x106 cells/100µl. The cell suspension was 
then mixed with 5µg DNA, transferred to an amaxa nucleofection cuvette and 
capped. The correct Nucleofector programme was selected for the cell and kit 
type, programme X13 for MDAMB231 cells using kit V, the cuvette inserted into 
the nucleofector and nucleofection carried out. The cuvette was then removed 
from the Nucleofector, 500µl media added and the whole suspension added to 
the prepared well of a 6 well plate. Cells were allowed to recover and settle for 
12 hours before being used, such as for invasion assays. 
2.3.6 Retrovirus Production 
BOSC (or Phoenix) cells were plated out at 0.25 x 106 cells per well of a 6-well 
dish in 10% FBS/DMEM, 48 hours later cells were transfected using Effectene 
(Qiagen) according to the manufacturers instructions.24 hours later cells were 
washed twice with FBS/DMEM (once in morning, once in evening) and add 1.5 ml 
of 10% FBS/DMEM per well. The virus was collected after 48 hoursand 
centrifuged at 1600 rpm for 5 min to collect any cellsand the supernatant 
removed to a clean tube and stored at -80°C. 
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2.3.7 Retrovirus Transduction 
NIH 3T3 (or desired cells already selected for ecotropic receptor expression) 
were plated out at 1.5 x 105 cells per well of a 6 well dish and the next day cells 
were infected with 1ml of virus and 4l polybrene (making a 1:250 final dilution) 
Following incubation for 5-6 hours 2 ml 10% FBS/DMEM was added to each well. 
The next day the media was replaced and when confluent, cells were trypsinised 
and selected for 2 passages before freezing down. 
2.3.8 TAT (PTD) proteins 
PTD FLAG Cofilin1 was generated by the annealing of double standed 
oligonucleotides coding for the PTD peptide (YARAAARQARA) and FLAG epitope, 
and subsequent ligation into pGEX KG Cofilin plasmid. The mutants were 
subsequently produced by site directed mutagenisis and the Cofilin proteins 
expressed in E.coli and purified as described.  
TAT or PTD refers to the transactivator protein of HIV-1, a peptide that can be 
internalised by cells without transfection and is utilised for the delivery of TAT 
fused proteins into cells in tissue culture. The mechanism by which TAT proteins 
enter cells was previous ly poorly understood, it was thought that smaller fused 
proteins entered cells by an energy and receptor-independent process based on 
direct transport through the lipid bilayer but that larger proteins were actively 
imported ina clathryn dependent manner {Richard, 2005 #216}. It is thought that 
heparan sulfate (HS) proteoglycans may act as receptors for extracellular Tat 
uptake {Tyagi, 2001 #215}, however, the uptake of small TAT PTD peptides may 
be mediated by other pathways as internalization of TAT peptide is not ablated 
in cells without surface heparin {Richard, 2005 #216}. The uptake of TAT 
proteins is suggested to be endocytically regulated as it is both temperature and 
ATP dependent {Richard, 2005 #216}. 
2.3.9 Wound healing 
For a classic wound healing assay or ‘scratch’ assay desired cells were seeded 
sub-confluently into 12 well dishes and left to settle and create a monolayer for 
24-48 hours as desired. The monolayer was then disrupted by a p200 tip to 
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generate a wound across the well. The media in the well was gently changed to 
remove any floating cells from the wound interfering in imaging. The 12 well 
dish of ‘wounds’ was then transferred to a timelapse microscope and imaged at 
15 minute intervals for 24 hours (or until the wound is closed). 
2.3.9.1 Oris cell migration assay 
The Oris cell migration assay is a 96well format wound healing assay, on the 
same principles as explained for wound healing assays. Small rubber plugs are 
placed in each well of a 96well plate, occluding a central portion so that cells 
are seeded and settle around the plug. Once cells are settled the plugs are 
removed and each well has an identical central ‘wound’. This assay makes each 
wound far more regular than is achievable by hand alone, and also does not lead 
to ragged edges on the wound. Following a suitable time for cell migration cells 
were imaged on an upright tissue culture microscope using ‘QcapturePro’ and a 
black ‘mask’ was fitted to the base of each plate. The mask used has holes 
corresponded to the area in each well that is kept free from cells during 
seeding. The mask was applied following fluorescent staining of the cells to 
quantify the level of migration into the centre of the well by a fluorescent plate 
reader. Calcein AM is a suitable live cell stain for this approach and was used 
routinely in the quantification of cell migration in this assay. 
2.3.10 Inverse Invasion assay 
This method is a modified version of that previously described (Hennigan RF, 
1994). An aliquot of complete Matrigel was thawed slowly on ice. Once defrosted 
Matrigel was diluted 1:1 in ice cold PBS (along with any other additional 
treatments at 2x concentration in the PBS prior to dilution). 100 l of the diluted 
Matrigel was carefully pipetted into each Transwell (inserted into a well of a 24 
well tissue culture plate) and left to incubate for about 30mins at 37°C to set. 
During this time cell suspensions of 3x105 cells per ml from each pre-treated 
condition (e.g. siRNA) were prepared in their normal growth medium.  
When the Matrigel was set the Transwells were inverted and 100 l of the cell 
suspension (3 x 104 cells) pipetted onto the underside of the filter (which was, 
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at that point, uppermost).The Transwells were then carefully covered with the 
base of the 24 well tissue culture plate, making contact with each droplet of cell 
suspension, and the plate then incubated in the inverted state for 4 hours to 
allow for cell attatchment. Following this time the plates were turned right-
side-up and each transwell washed by sequential dipping into 3 x 1 ml serum 
free medium. The Transwells were left in wash number 3 as the well in which 
the assay would be incubated, it therefore contained any additional drugs or 
treatments required. 100 l of 10% FBS DMEM plus EGF (25 ng/ml) was gently 
pipetted into the Transwell on top of the set Matrigel/PBS mixture, the lid 
replaced and the assay incubated for 5 days at 37°C with 5% CO2. 
4M Calcein AM (acetoxymethyl ester of calcein) was used to stain the assays as 
Calcein is a live cell dye that stains the whole cell green and requires no 
fixation. Transwells were placed in fresh 24 well dishes with 1ml of the stain 
solution pippetted on top of each Transwell as it spills over the sides and stains 
the matrigel plug from the top and bottom. After 1 hours incubation at 37°C 
with 5% CO2 cells were fully stained and ready to be imaged by confocal 
microscopy. PI staining was adopted to visualise nuclei when the assays were 
fixed and before staining for f-actin.  
2.3.11 Gelatin Degradation Assay 
2.3.11.1 Preparation of gelatin coated coverslips 
The working area was coated with a strip of parafilm on which droplets of liquid 
were placed in order to coat coverslips. All stages, except the final step, were 
performed in a fume hood. Sterile, acid washed, 13 mm coverslips were placed 
on top of 100µl droplets of poly L lysine, coating one side, for 15 minutes at 
room temperature. Excess liquid was removed from the coverslip and the coated 
side placed on top of a 100µl drop of 0.5% gluteraldehyde (in PBS) for 10 
minutes. During this time an aliquot of Molecular Probes Oregon Green 488 
conjugated fluorescent gelatin (G-13186) was defrosted on a heat block at 37°C 
and the coverslips were then placed on a 60µl droplet of 488 fluorescent gelatin 
for 15 minutes in the dark. The coverslips were then transferred to a multiwell 
dish and washed gently 3 times with PBS. A 5mg/ml sodium borohydride solution 
66 
in PBS was then prepared (in the fume hood), and the coverslips incubated in 
this for 3 minutes. A further 6 washes with PBS were then performed before 
sterilizing the coverslips in 70% EtOH for 5 minutes. At this, the final step, the 
multiwell dishes containing coverslips were transferred to a tissue culture hood 
where the EtOH was aspirated and the coverslips quenched in 10% FBS DMEM for 
1 hour at 37°C.  
2.3.11.2  Gelatin Degradation 
Cells of interest were counted and made up into 3x105 cell/ml suspensions, any 
desired pre-treatment had been performed by this point. Fluorescent gelatin 
coated 13mm coverslips were placed into 24well dishes containing 500ml of 
complete media with GM6001 MMP inhibitor at 10µM and 100µl of each cell 
suspension/condition added to a well, and the cells allowed to settle and adhere 
at 37°C overnight. The following morning the wells were washed 3 times with 
PBS to remove the MMP inhibitor before the addition of 500ml complete media. 
Where drug inhibition of LIMK was being examined, CRT 101106 was added to the 
well at this point. Cells were allowed between 4- 24 hours, 4 hours for 
MDAMB231, to degrade the gelatin. The coverslips were then washed 3 times 
with PBS before being fixed at room temperature with 4% Paraformaldehyde 
(PFA) for 15 minutes, washed 3 times with PBS, the cells permeabilised with 
0.1% Triton X-100 in PBS for 15 minutes, washed again 3 times with PBS and 
blocked for 30 minutes in 5% BSA in PBS. The blocking solution was then replaced 
with a 1/1000 dilution of Texas Red phalloidin in BSA PBS for 3 hours to stain for 
filamentous actin. The coverslips were then mounted on glass slides using 
ProLong Gold antifade reagent and viewed on an upright fluorescent microscope. 
2.3.12 Cell derived Matrix (CDM) 
2.3.12.1 Generation of CDM  
Coverslips were first cleaned by boiling in MilliQ and autoclaved.Coverslips were 
then distributed into 24-well plates to grow matrix. Following a quick wash with 
sterile PBS the coverslips were incubated with 2ml 0.2% sterile gelatin for 1 hour 
at 37C (2% gelatine stored at 4C, diluted 1:10 in PBS). The gelatine was then 
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aspirated and the coverslips washed twice with PBS, then cross-linked with 2ml 
1% sterile glutaraldehyde (25% stock 1:25) for 30 minutes at room temperature. 
Two washes with PBS were then performed and the cross-linker quenched with 
2ml 1M sterile glycine in PBS (pH~7) for 20minutes at room temperature. The 
coverslips were then washed a further 2 times with PBS and then incubated with 
growth media (DMEM) for 30minutes at 37C. The coverslips were then ready to 
be seeded with cells although could be stored at 4C, if stored in PBS they were 
re-incubated with DMEM before seeding with HDF (human dermal fibroblast), 
grow in DMEM plus 10% serum and P/S. 
Cells were plated onto the prepared coverslips at 5x104 per well of a 24 well 
plate and cultured at 37C in 5% CO2  overnight before changing the media to 
complete media supplemented with 50 ug/ml Ascorbic acid. The ascorbic acid 
media was changed every second day until denudation as a fibronectin-rich 
matrix was desired. The ascorbic acid increases collagen production and 
stabilises the matrix, without it the matrix won’t stick to the plate properly. 
Other protocols suggest changing the media everyday for the course of CDM 
production, 11-14 days. 
The cells were then removed to reveal the matrix below. Firstly the medium was 
aspirated and the cells washed twice with PBS. 750µl pre-warmed extraction 
buffer was then gently added to each well (20 mM NH4OH, 0.5% Triton X-100 in 
PBS). Cell lysis is very quick so is carried out for around 2 minutes, or untill no 
intact cells were visible by phase light microscopy. Matrix is delicate so 
extraction buffer was removed very gently and washed twice with PBS 
containing calcium and magnesium (Sigma). Residual DNA was digested with 10 
ug/ml DNase I in PBS containing calcium and magnesium and incubated for 30 
min at 37C in 5% CO2. DNase was then gently aspirated and the matrix washed 
twice with PBS containing calcium and magnesium. 
The matrix was then stored at 4C in PBS containing calcium and magnesium 
with pen/strep and fungizone before use (up to 3 months). The matrix is visible 
by phase so was checked to be intact before use. 
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2.3.12.2 Cell motility on CDM 
Cell derived matrix was generated as described, following storage at 4C the 
wells were gently washed with PBS and incubated for one hour at 37C with 
DMEM to prepare the wells for cell seeding. Cells were subject to pre-treatment 
as desired for the experiment and seeded sub-confluently into the 12 well dishes 
containing cell derived matrix. The plates were then transferred to a time-lapse 
microscope complete with a 37C, 5% CO2 incubation chamber for one hour to 
allow cells to settle and for the plasticware to equilibrate with the chambers 
conditions. Pictures were then taken using a 10x objective and bright field 
channels at 15 minute intervals over up to 24 hours. Analysis of experimental 
data was performed using ImageJ, or AndorIQ software.    
2.4 Methods in Protein Extraction and Analysis 
2.4.1 Reagents 
Bicinchoninic acid  Sigma 
Copper Sulphate  Sigma 
Eelectrophoresis 
buffer 
25 mM TrisCl, 192 mM glycine, 0.1% 
w/v SDS 
 
Kodak BoMax MR Film  (scientific imaging film) Kodak  
Laemmli buffer (6X) 125mM TrisCl pH 6.8, 6% w/v SDS, 
30% glycerol, 225 mM DTT, 0.05% 
(w/v) bromophenol blue 
 
NuPAGE MOPS SDS 
running buffer  
20x Invitrogen 
Protran Nitrocellulose 
Transfer membrane,  
3mm filter paper Whatman 
International Ltd 
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RIPA Lysis buffer 10mMM Tris pH 7.5,5mM EDTA,      
150 mM NaCl 300,40 mM Nappi,   
1mM Na3VO4,50mM NaF,1% NP40 
0.5% Na Deoxycholate (NADE),  
0.025% SDS, 1mM p-amino- 
ethybenzene sulphonyl fluoride 
(PMSF),1X Complete protease 
inhibitor 
 
SimplyBlue safestain  Invitrogen 
TBS 137 mM NaCl, 5 mM KCl, 25 mM 
TrisCl 
 
Transfer buffer 192 mM glycine, 25 mM TrisCL, 20% 
v/v methanol, 0.036% w/v SDS; pH 
8.3 
 
Tris buffered saline 
(TBS) lysis buffer 
TBS with 1 mM Dithiothreitol (DTT) 
and 1 mM 
Phenylmethylsulphonylfluoride 
(PMSF) 
 
 
2.4.2  Whole cell extracts 
Cells were pretreated as required per experiment and then harvested by 
scraping in Ripa lysis buffer on ice and consequent centrifugation at 14,000rpm 
at 4°C in a cooled micro-centrifuge. Supernatants were removed, analysed for 
protein concentration and stored at -80oC.  
2.4.3 mRNA preparation 
MDAMB231 cells were seeded at 1.5 x106 per 15cm dish, following experimental 
manipulation media was removed from cells and RNA isolated using the Qiagen 
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Rneasy kit according to manufacturers instructions. In brief, cells were scraped 
into 600µl RLT lysis buffer containing 145 mM β-mercaptoethanol before 
homogenization through a Qia-shredder column. 600µl ethanol was added per 
sample before being added to a Rneasy column and removal of contaminants 
with sequential washes using the provided buffers. RNA was then eluted with 
50µl Rnase free water and stored at -20˚C.  
2.4.4 cDNA synthesis 
In order to analyze gene expression RNA must first be transcribed into cDNA, and 
Finnzymes’ Dynamo SYBR Green 2-step qRT PCR kit has all the required reagents 
to do this and was used according to the manufacturers instructions. In brief, for 
each experimental condition RNA a cDNA synthesis premix was prepared by 
mixing 20µl RT buffer, 4µl M-MuLV RNase H+ reverse transcriptase, 2µl Random 
hexamer (300ng/µl), 10µl PCR grade water, 4µl of template RNA (0.5µg/µl) for a 
40µl reaction. The reactions were then placed in a thermal cycler for; 
Step 1 Primer extension 25°C 10 minutes 
Step 2 cDNA synthesis 37°C 30 minutes 
Step 3 Reaction Termination 85°C 5 minutes 
Step 4 Cooling of sample 4°C Until recovered 
 
Extra cDNA was generated for the Control conditions and when not being used 
immediately cDNA was stored at -20°C.    
2.4.5 qPCR  
Finnzymes’ Dynamo SYBR Green 2-step qRT PCR kit was used to perform qPCR on 
a BioRAD DNA Engine thermal cycler, with a Chromo4 realtime PCR detector and 
Opticon Monitor 3. The qPCR reactions were performed as per the manufacturers 
instructions. In brief, the qPCR reaction contained 10µl 2x MasterMix, 2µl primer 
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mix, 6 µl of PCR grade Water and 2µl of cDNA (diluted 1:6 in TE). The plate of 
reactions was placed in the thermal cycler on the appropriate optimized 
protocol.   
2.4.6  Protein quantification: BCA Assay 
Bovine serum albumin (BSA, Pierce’s 2mg/ml BSA vials #23209) was used to 
prepare a dilution series of standard protein concentrations in lysis buffer 
ranging from 0mg/ml to 2mg/ml. 10µl of each BSA standard was added in series 
to a 96 well plate, 10µl of each sample was then added, in duplicate, to the 
following wells. 200µl of developing solution (50:1 of Bicinchoninic acid to 
Copper Sulphate) was added to each well, incubated for 30minutes at 37°C and 
the absorbance values used to generate a standard curve. The protein 
concentrations were determined for each sample from the standard curve. 
2.4.7 SDS-PAGE  
SDS-poly-acrylamide gels were used to run protein samples. Depending on the 
proteins of interest SDS percentage was varied as per Table 4. In general, 50µg 
of protein in SDS sample buffer (4 volumes of 5% SDS, 25% glycerol, 125mM Tris 
pH6.8, bromophenolblue and 1 volume of 1M DTT) were boiled for 5 min and 
then loaded into individual wells alongside a full-range molecular weight 
marker. Gels were run in a gel tank in SDS Running buffer (25mM Tris, 0.1% SDS, 
0.19M glycine) at 20 to 200 V until the dye front migrated to the bottom of the 
gel tank. Gels were transferred onto nitrocellulose by Western blotting. 
Table 4 Acrylamide gel recipe 
  8% 10% 15% Stack 
30% Acrylamide/Bis 5.3ml 6.6ml 9.9ml 2 ml 
1M Tris pH6.8 - - - 1.9 ml 
1M Tris pH8.8 7.5ml 7.5ml 7.5ml - 
10% SDS 200 µl 200 µl 200 µl 150 µl 
Water 6.8ml 5.5ml 2.2ml 10.8 ml 
10% APS 100 µl 100 µl 100 µl 100 µl 
TEMED 100 µl 100 µl 100 µl 100 µl 
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2.4.8  Western blots 
Polyacrylamide gels were transferred onto a nitrocellulose filter using a Bio-rad 
electroblotter. The nitrocellulose and 4 pieces of 3mm paper were soaked in 
transfer buffer and assembled on the blotter, from anode to cathode, 2 pieces 
of 3mm paper, nitrocellulose, resolving polyacrylamide gel, and 2 pieces of 3mm 
paper. The transfer was performed at 110mA, overnight at 4°C for large gels. Or 
200V at room temperature for 1 hour for small blots (small transfers rigs use ice-
packs). The nitrocellulose filter blot was washed briefly in TBST (10mM Tris 
pH7.6, 100mM NaCl, 0.1% (v/v) Tween 20) and then blocked in 5% (w/v) Marvel 
in TBST for an hour. Appropriate dilutions of primary antibody were prepared in 
5% Marvel/TBST or 5% (w/v) BSA in TBST depending on the antibody. The blot 
was incubated for at least one hour at room temperature or over night at 4oC. 
Next, blots were washed 3x 5min in TBST before being incubated in 5% 
Marvel/TBST containing a 1/500 dilution of appropriate horseradish-peroxidase-
conjugated secondary antibody for an hour. After washing once for 15min in 5% 
Marvel/TBST and a further 3x5 min in TBST, the blots were analysed with ECL 
detection reagent or Femto, exposed to film and developed with a Kodak 
processor. 
2.4.9  Immunoprecipitation 
For each sample 2-5µg of antibodies were bound to 30 µl of 50% glutathione-
Sepharose slurry at 4°C for 1 hour before removal of unbound antibody with 
wash buffer. For cells prepared with RIPA lysis buffer this is a modified RIPA 
buffer, RIPA minus sodium deoxycholate, plus 0.5% NP-40. Antibody bound beads 
were then added to whole cell lysates and incubated at 4°C for 1-8 hours. The 
beads were then centrifuged at 5000g for about 10 seconds (or at full speed on a 
bench-top mini centrifuge) and washed 3 times with wash buffer. At this point 
the IP’s could be used in kinases assays, or the addition of 30µl of 6X Laemmli 
buffer to the tubes used to precipitate the complexes. These could then be 
boiled and run out on an acrylamide gel for analysis  
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2.4.10 Antibodies 
Antibodies were routinely used at 1:1000 for western blotting and 1:500 for 
immunofluorescence, unless stated otherwise. Antibodies used are listed below 
in Table 5. 
Table 5 Table of primary antibodies 
Antigen Species Company/Laboratory (Cat. No.) 
Cofilin  Rabbit Cell signalling (3312) 
Cofilin Rabbit Cytoskeleton(ACFL02) 
ERK2 Rabbit Sourced from Chris Marshall 
Lamin A/C (N-18) Goat Santa Cruz (sc6215) 
LIMK1 Rabbit Cell Signalling (3842) 
LIMK2 (H78) Rabbit SantaCruz (Sc5577) 
Tubulin Rabbit Lab generated 
Flag Mouse Sigma F-3165 
Phospho-Cofilin Rabbit Cell Signalling (3841) 
MMP 14 Rabbit Neomarkers RB 1544 
MMP9 Mouse Neomarkers MS 804 
MMP2 Mouse Neomarkers MS 816 
 
2.5 Kinase activity 
The activity of LIM Kinase against a selection of potential substrates was 
determined by a variety of different kinase assay techniques. 
2.5.1 Buffers and reagents 
Active LIM Kinase 1 (14-646) Upstate 
Gamma 32P ATP  500uCi (18.5MBq) Amersham 
Kinase Buffer  1.25% BSA, 62.5 mM TrisCl pH 
7.5, 1mM BME (0.1%), EGTA 
0.5mM, Brij35 0.01% 
 
NaCl-Tx 1% Triton X-100, 2M NaCl  
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PBS-Tx 1% Triton X-100 in PBS  
Pepscan Kinase mastermix 
(2X) 
125 mM TrisCl, 0.2M MgCl,       
20% (v/v) Glycerol, 0.02mg/ml 
BSA, 0.02% (v/v) Brij-35   
 
P81 Chromatography paper 
(Cation exchanger) 
(3698-915) Whatman 
International Ltd 
Phosphoric acid   Fisher 
pre-stained SDS-PAGE 
broad range standards 
 Bio-Rad 
2.5.2 In Vitro Kinase assay 
All work was carried out behind a perspex screen on a designated radioactivity 
work bench to isolate and protect myself from the radioactive isotope used.  
A heated shaking block was set to 30°C and allowed to come to temperature 
whilst 2 cm2 squares of p81 paper were prepared, numbered in pencil to denote 
the condition/time-point in the assay. A rinsing basket was filled with 0.5% 
phosphoric acid (1:200 dilution) and each assay condition made up, on ice, to 
contain 1.25% BSA, 62.5 mM TrisCl pH 7.5, 1mM BME (0.1%), EGTA 0.5mM, Brij35 
0.01% (buffer A), 0.02µg LIMK plus 500µM peptide substrate or 0.2µg of Cofilin in 
a 50µl reaction, but was initially made up to 40µl as a further 10µl is added at 
the start point of the assay. In a separate screw top eppendorf a 0.1M MgCl and 
1mM ATP solution (10µl per reaction/time point) was spiked with 3µl of fresh 
γ32P. 10µl of this mix was added to each condition/time-point and the 
phosphorylation reaction started on the heat block with shaking at 1400 rpm. 
The clear perspex eppendorf holder from the heated shaking block was removed 
and placed in a tray of ice so that all eppendorfs could be given the ATP mix and 
transferred to the heat block simultaneously. To stop the reaction, at each time 
point 40µl of the 50µl reaction was pipetted with a filtered tip onto the 
corresponding (labelled) piece of p81 paper (held with forceps) and gently 
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dropped into the rinsing basket of phosphoric acid minimising the contact 
between the pieces of paper before they were fully submerged and ‘fixed’. 
Once the time course was complete or all the reactions complete the papers 
were rinsed for five to fifteen minutes in the phosphoric acid fix. The rinse was 
then carefully poured off down a radiation approved sink (with lots of water) 
and the papers rinsed with fresh phosphoric acid twice more for five to fifteen 
minutes. The last phosphoric acid rinse was removed, and the papers given a 
final five minute rinse in acetone to displace water. The acetone was removed 
(and saved to be used in the next kinase assay) and the rinsing basket filled with 
acetone soaked p81 papers transferred to a perspex box, with a cardboard grid 
covering the open basket. In a chemical fume hood, from behind perspex, the 
papers were dried with a hairdryer through the grid. This was done with caution, 
from a distance, to prevent the cardboard and acetone from catching alight. 
Once the papers were dry, they were folded and placed into eppendorfs 
corresponding to each papers pencilled label. Into two spare eppendorfs, 2µl of 
the γ32P spiked ATP mix was aliquoted to be used as controls on the Cerenkov 
counter. The eppendorfs were then transferred to a scintillation counter and the 
incorporation of ATP calculated from the values generated by the Cerenkov 
count. 
2.5.3 IP-Kinase Assay 
An immunoprecipitation (IP) was carried out, as described, until the final 
washes. At this point the beads were washed twice with RIPA lysis buffer and 
then twice with IPK (IP Kinase assay) wash buffer (10X IP Kinase buffer; 0.5M 
TRIS pH7.5, 0.1mM EGTA). On ice, 40µl of kinase buffer (plus 500µM peptide 
substrate or 0.2µg of Cofilin) was added to ~10µl bound beads for each 
condition/time point. In a separate screw top eppendorf a 0.1M MgCl and 1mM 
ATP solution (10µl per reaction/time point) was spiked with 3µl of fresh γ32P. 
10µl of this mix was added to each condition/time-point and the phosphorylation 
reaction started on the heat block with shaking at 1400 rpm and the reaction run 
at 30°C. The reaction was stopped after the desired amount of time (20 minutes 
for instance) by addition of 6X Laemmli buffer, boiled to remove the bound LIMK 
from the beads and the samples were then run on an SDS page gel. The gel was 
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dried onto Whatman paper using a gel drier and exposed to film and/or a 
phosphor-imager phosphor-storage screen for analysis. Where the assay was 
performed ‘cold’ western blotting was performed to determine the level of 
phosphorylated substrate using a phosphor specific antibody. Care to use 
appropriate safety methods and shielding during the handling of radioactive 
material was taken. 
2.5.4 Pep-Scan Peptide Array 
Pepchip kinase slides were used in attempts to identify novel substrates of 
LIMK1. On each slide is a glass mounted peptide array covering over 400 proteins 
and 1400 individual phosphorylation sites. Each array was performed in 
accordance with the manufacturers instructions. In brief, these slides fulfil the 
role of substrate and as such were submerged into γ32P kinase reactions in order 
to identifywhish peptides were phosphorylated by LIMK1. Taking care to use 
appropriate safety methods and shielding, a 60µl reaction mixture was set up for 
each slide; pepscan kinase mastermix (filtered through 0.22 micron syringe 
filter), 500ng/ml kinase, 10µM ATP and 300µCi/ml γ32P. 50µl of this reaction 
mixture was then pipetted into the centre of a coverslip and the slide and gently 
lowered onto it, spreading the mixture over the array by capillary action. The 
slide was then turned and incubated in a humidified chamber at 30°C for 2 hours 
before having the coverslip washed off in PBS-Tx. The slide was then transferred 
to a NaCl-Tx wash for two 5 minute washes at room temperature (with shaking). 
Three 5 minute washes with dH2O were performed before the slides were air 
dried. The dried slides were then transferred to exposure cassettes and exposed 
overnight to film or a phosphor-storage screen. The resulting films or screens 
were analysed by aligning the provided grid image for orientation of which 
positive result correlated with which peptide in Adobe Photoshop. 
2.6 F-actin severing assays 
F-actin severing assays were used to determine the activity of PTD FLAG WT 
Cofilin proteins in vitro. Pyrene fluorescence increases 10-20 fold when G-actin 
is incorporated into filaments and the converse of this was utilised to quantify f-
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actin depolymerisation using steady state fluorescence (Ex = 339 nm; Em = 
384nm). 
2.6.1 Buffers 
G Buffer 2 mM Tris–Cl (pH 8.0), 0.2 mM ATP, 
0.5 mM DTT and 0.2 mM CaCl2 
 
F Buffer 2 mM Tris–Cl (pH 8.0), 0.2 mM ATP, 
0.5 mM DTT and 0.2 mM CaCl2, 50 mM 
KCl, 2 mM MgCl2 and 0.1 mM EGTA 
 
 
2.6.2 F-actin preparation  
G-actin was purified from rabbit muscle as described previously (Spudich & 
Watt, 1971). G-actin was maintained in G-buffer: (2 mM Tris–Cl (pH 8.0), 0.2 mM 
ATP, 0.5 mM DTT and 0.2 mM CaCl2). Polymerisation of the actin was achieved 
by addition of 50 mM KCl, 2 mM MgCl2 and 0.1 mM EGTA, the resulting buffer 
being F-buffer. Concentrations given for F-actin refer to the initial concentration 
of G-actin prior to polymerisation. 
2.6.3 Pyrene labelling 
1mg/ml G-actin was labelled with pyrene (5mg/ml - approx. 15M excess) in DMF 
(dimethylformamide) for 15 hours and dialysed in G-buffer. The G-actin was 
then polymerised and ultracentrifuged to pellet the F-actin. The F-actin pellet 
resuspended in G-buffer and concentration determined. 
2.6.4 F-actin Severing 
For the severing assay, G-actin (95% unlabelled: 5% pyrene labelled) was 
polymerised at 2.5µM (G-actin final concentration) over night. 50 µl of Labelled 
F-actin (at 2.5µM) was added to a PTI glass cuvette (with or without the addition 
of 10µM PTD FLAG WT Cofilin) and steady state fluorescence (Ex = 339 nm; Em = 
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384nm) measured on a spectrofluorimeter for 1000 seconds. Data was 
normalised to allow comparison between data sets, and reported as percentage 
fluorescence over time. 
2.7 Zymography 
Zymography was used to assess the levels of active matrix metaloproteases 
(MMPs) being excreted by MDAMB231 cells into the surrounding media, 
specifically MMP2 and MMP9 (gelatinases). 
2.7.1 Buffers and Reagents 
Zymogram precast gels and buffers were purchased from Invitrogen; 
10% Zymogram Gelatin Gel  Invitrogen 
Zymogram Renaturing Buffer  Invitrogen 
Zymogram Developing Buffer  Invitrogen 
Tris-Glycine SDS Running Buffer  Invitrogen 
Tris-Glycine Non-reducing sample buffer  Invitrogen 
2.7.2 Zymography – Gelatinase activity. 
In brief, the enzyme sample was prepared in SDS buffer (non reducing 
conditions) and electrophoresed on a 10% Tris-Glycine gel with 0.1% gelatine 
incorporated as a substrate, without heating, using Tris-Glycine SDS running 
buffer at 125V for ~90 minutes. After the run was complete, the enzyme was re-
natured by incubating the gel in Zymogram Renaturing Buffer (contains a non-
ionic detergent). The gels were equilibrated in Zymogram Developing Buffer (to 
add the divalent metal cation required for enzymatic activity) and then the gel 
stained and destained using Invitrogen Safestain (coomassie blue). The protease 
bands should appear as clear bands against a dark background where the 
protease has digested the substrate within the gel. 
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2.8 Immunofluorescent microscopy 
2.8.1 Reagents 
Calcein AM, ProLong Gold antifade reagent (mount) Invitrogen 
Clear Nail Varnish MaxFactor 
Sterile PBS (Phosphate Buffered Saline) Beatson Institute Central Services 
Vectashield mounting medium, Vectashield with 
DAPI (4',6-diamidino-2-phenylindole) 
Vector Laboratories, Inc 
 
2.8.2  Fixing and staining cells on glass for microscopy 
Cells were set up at appropriate concentration on glass cover slips in 12 or 24 
well plates. After treatment, cells were washed 3x in PBS and fixed either in 4% 
paraformaldehyde for 15 minutes. Cover slips were then washed 3x in PBS, 
permeabilised for 15 minutes in 0.1% Triton X-100 in PBS, washed 3x PBS and 
blocked for 30 minutes in 1%-5% BSA in PBS. The blocking solution was then 
replaced with a 1/1000 dilution of primary antibody/antibodies  in blocking 
buffer. After 1-24hours of incubation at room temperature (depending on the 
antibody) the cells were washed 3x 5 minutes in blocking buffer. Then the 
secondary antibody/antibodies added in a 1/500 dilution in blocking buffer (plus 
a suitable phalloidin at this stage if f-actin staining) for 1 hour and the whole 
dish being stained placed in a black box or wrapped in foil. Cover slips were then 
washed twice in blocking buffer and once in PBS before being mounted on a glass 
slide with Vectashield (clear or with Dapi) or ProLong Gold antifade reagent and 
sealed with clear nail varnish. The slides were then visualised using an 
appropriate microscope such as a Leica confocal microscope and windows based 
LCS software. 
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2.8.3 Fixing and staining cells for 3D Confocal imaging 
Stained nuclei or whole cells were visualised by confocal microscope using a 20X 
objective. Optical sections (Z-sections) were scanned at 15 m intervals (Z-
steps) moving up from the underside of the filter into the matrigel, producing a 
series of images. To quantify these “Image J” software was used. This 
programme gives each on-screen pixel an intensity value from 0 through to 255. 
The background pixel value is then operator-defined as the point (pixel value) on 
the 0-255 scale at which only cells from that individual section are visible with 
no bleed-through from bordering sections. Only pixels with an intensity value 
greater than background are then counted by “Image J”. 
2.8.4  Time-lapse microscopy 
Time-lapse microscopy was performed using an inverted Zeiss microscope system 
with temperature humidity 37°C and CO2 control. Pictures were taken using a 
10x objective and bright field channels at 15 minute intervals over up to 24 
hours. Analysis of experimental data was performed using ImageJ, or AndorIQ 
software. 
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3 Requirement of LIMK in cancer cell motility and 
invasion 
3.1 Chapter Summary 
LIM Kinases act as convergence points for many upstream signals that influence 
the architecture of the actin cytoskeleton. Not only has LIMK1 been implicated 
in cancer (as it is found to be over expressed in melanoma cells(Okamoto et al, 
2005), breast cancer tumours(Bagheri-Yarmand et al, 2006) and tumour cell 
lines(Yoshioka et al, 2003), prostate tumours and cell lines(Davila et al, 2003; 
Yoshioka et al, 2003), but perturbing the balance between active Cofilin (LIM 
Kinases primary substrate) and inactive Cofilin appears sufficient to affect cell 
motility(Hotulainen et al, 2005) . 
LIMK1 has been shown recently to increase human breast cancer cell 
metastasis(Bagheri-Yarmand et al, 2006), but it was not known whether both LIM 
Kinase 1 and 2 were requirements of cancer cell motility and invasion when this 
project commenced, nor whether there were differing roles for the LIM Kinases 
in cancer cells. This chapter describes studies investigating the requirement for 
LIMK1 and LIMK2 by cancer cells during motility and invasion in both 2D and 3D 
environments. 
3.2 Results 
3.2.1 LIMK knock down by siRNA in MDAMB231 cells 
In order to address the requirement of LIMK in cell motility or invasion an 
approach needed to be taken to reduce LIMK levels in cells. The principal 
technique used throughout this chapter to knockdown LIMK levels in cells was 
short interfering RNA. 
Since its identification in plants (Hamilton & Baulcombe, 1999) short interfering 
RNA (siRNA) has become an invaluable tool for reducing expression of specific 
proteins in mammalian cell culture(Elbashir et al, 2001). It is not, however, 
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without its caveats, and genes with partially complimentary sequences may 
sometimes be inadvertently down regulated by an siRNA in an ‘off-target’ 
effect. Off target effects can lead to problems in data interpretation or even 
toxicity, but can be partly addressed by using multiple independent siRNAs side 
by side to confirm a genuine effect. Along with non-targeting negative controls, 
positive controls can be used using validated siRNAs that target an unrelated 
mRNA, for example Lamin A/C. These controls help to validate that 
transfections have worked and help with the identification of any potential off 
target effects. 
To increase confidence in data gathered from reducing LIMK levels by siRNA, 
four different siRNAs for each kinase were tested. Twenty four hours following 
transfection, MDAMB231 were lysed with RIPA buffer and the lysates analysed by 
western blot, Figure 3.3.1 part A.  LIMK1 was successfully knocked down by 
siRNAs numbered 1,3,4 and 5, without an effect on LIMK2 levels or Lamin A/C 
protein levels. LIMK2 was successfully knocked down by siRNAs 6,7,8 and 9 with 
no effect on LIMK1 or Lamin A/C protein levels. Lamin A/C positive control 
indicated that siRNA transfection worked and neither of the non-targeting siRNA 
controls reduced LIMK1, LIMK2 or LAMIN A/C levels. 
To assess if the siRNA treatment had any toxic effect on cells, cell numbers were 
determined over time. Cells were pre-treated with two different siRNAs for each 
kinase (#1 and #3 for LIMK1 and #6 and #7 for LIMK2) and also in combination for 
both kinases (#1&#6, #3&#7) for 24 hours, counted and seeded in 12 well dishes 
and after 5 days trypsinised and counted again to determine any difference in 
cell numbers between conditions (Figure 3.3.1part B). No significant differences 
were observed between conditions, as determined by ANOVA. 
Since LIMK is successfully knocked down by the above chosen siRNAs, and this 
process does not appear to affect cell viability, effects of LIMK siRNA on 
MDAMB231 cells could be confidently interpreted as specific to the loss of LIMK. 
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Figure 3.3.1-siRNA of LIMK1 and LIMK2 in MDAMB231 and effect on proliferation.  
A. Western blot of MDAMB231 cell lysates following siRNA against LIMK1 (oligonucleotides 
numbered 1, 3, 4 and 5) and LIMK2 (oligonucleotides numbered 6,7,8 and 9) were tested for 
efficacy along with negative control non targeting siRNA (NT1 and NT2) and positive control Lamin 
A/C (L A/C). B. MDAMB231 cell number following treatment with siRNA; cells were counted 5 days 
after treatment, Error bars represent Standard Error, n=3. No significant differences were observed 
between conditions (Determined by ANOVA).  
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3.2.2 Knockdown of LIMK induces changes in the actin 
cytoskeleton  
LIM Kinases inactivate Cofilin by phosphorylating Serine 3, it would therefore be 
expected that reducing cellular LIMK levels would result in increased active 
Cofilin, and thus a decrease in F-actin cytoskeletal structures within cells.  
In order to establish if this were the case, MDAMB231 cells were subject to 
transfection with LIMK siRNA, distributed onto coverslips, fixed and stained for 
F-actin and tubulin, and imaged using a Zeiss Axioplan 200 microscope to 
identify any changes to the cytoskeleton following knockdown of either LIM 
Kinase. Non-targeting siRNA treated cells showed cytoplasmic actin staining and 
strong peripheral staining with ‘microspikes’, seen in Figure 3.3.2. Whilst 
knockdown of LIMK1 caused a slight decrease in cytoplasmic F-actin staining and 
micro-spikes, these cells maintained some peripheral actin staining but with a 
slightly rounder, smoother cell shape in comparison to non-targeting (NT) siRNA 
treated control cells (first panel of Figure 3.3.2). Knockdown of LIMK2 caused a 
more dramatic loss of F-actin staining, both cytoplasmic and peripheral. Cells 
were rounded in comparison to controls, a morphology also seen in the double 
knockdown cells. Tubulin staining in the second panel shows little change 
following loss of LIMK; staining serves to outline the rounder, less spiky shape of 
the cells following treatment with siRNAs against the LIM Kinases. The third 
panel shows the loss of peripheral actin staining and microspikes by LIMK 
knockdowns in an overlay of F-actin (red) and tubulin (green) staining, the red 
edges of the cells were reduced following LIMK1 or LIMK2 knockdown and more 
so following double knockdown.  
In a similar experiment BT549 cells were subject to siRNAs against LIM Kinases, 
and fixed and stained as described above. Knockdown of both LIM Kinases in 
these cells reduced peripheral actin staining as was seen in MDAMB231. This is 
particularly clear in the merged images where F-actin staining (red) is seen at 
the periphery of only the control cells (Figure 3.3.3). 
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Figure 3.3.2-MDAMB231 morphology on glass. 
Following siRNA treatment against LIMK1, LIMK2, both in combination or with a non-targeting 
oligonucleotide; The first column shows staining of the actin cytoskeleton for F-actin using Texas 
Red phalloidin, column number two shows staining of the microtubule network with an anti-alpha 
tubulin antibody and FITC secondary antibody, the third column shows an overlay of the two; 
where red corresponds to F-actin staining and green to microtubules. Images captured on the 
Zeiss Axioplan 200 at x40 using Imaging Associates Isis software. Scale bar equals 20µm. 
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Figure 3.3.3-BT549 morphology on glass. 
Following siRNA treatment against LIMK1, LIMK2, both in combination or with a non-targeting 
oligonucleotide; The first Column shows weak staining of the actin cytoskeleton for F-actin using 
Texas Red phalloidin, the second shows staining of the microtubule network with an anti-alpha 
tubulin antibody and FITC secondary antibody, and the third column an overlay of the two. Images 
captured on the Zeiss Axioplan 200 at x40 using Imaging Associates Isis software. Scale bar 
equals 20µm. 
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Figure 3.3.4-BE morphology on glass. 
A. Following siRNA treatment against LIMK1, LIMK2, both in combination or with a non-targeting 
oligonucleotide; Staining of the actin cytoskeleton for F-actin using Texas Red phalloidin is shown 
in red, staining of the nucleus with DAPI in blue shown as an overlay of the two. Images captured 
on the Zeiss Axioplan 200 at x20 using Imaging Associates Isis software. Scale bar equals 40µm. 
B. Quantification of the shift in cell morphology from mixed (in this case described as with a large 
flat cytoplasm, a partially contracted cytoplasm or a contracted cytoplasm, illustrated by examples 
under the graphs legend) to more contracted following knockdown of both LIM Kinases by siRNA. 
Examples of wider fields of cells following transfection with non-targeting control siRNAs or LIMK1& 
siRNAs are shown below the legend. All images captured on the taken Zeiss Axioplan 200 at x20. 
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Knockdown of LIMK caused a decrease in F-actin staining in MDAMB231, BT549 
and BE cells, and a loss of peripheral micro-spikes in MDAMB231. This fits in with 
our current understanding of LIMK function as a regulator of Cofilin activity. Loss 
of LIMK by knockdown leads to a reduction in Cofilin phosphorylation which 
equates with more active Cofilin being present within the cell, in turn leading to 
a decrease in polymerised actin. Loss of F-actin staining in the three cell lines 
examined following knockdown of LIMK additionally validated that the LIMK 
siRNA oligonucleotides have direct and targeted effects. 
BE cells respond in a similar manner to knockdown of LIM Kinases (Figure 3.3.4 
part A), displaying a reduction in F-actin staining following loss of either LIMK or 
both LIMK1 and LIMK2 in combination. When stained for alpha tubulin to visualise 
the whole cell it became apparent that the morphology of BE cells as a 
population was changing. In culture they can be described as split into roughly 3 
morphologies; A) a large, flat, spread cytoplasm, B) a partially contracted 
cytoplasm, and C) a contracted cytoplasm. Following transfection with siRNA 
against LIMK1, 2 or both in combination there was a shift from equal 
distributions of these morphologies to an increase in the contracted population 
of cells (Figure 3.3.4 part B). 
3.2.3 Initial observations suggest LIM Kinases are important in 
cell motility. 
Most published LIMK literature describes effects of either LIMK1 or LIMK2, but a 
systematic comparison of the roles both kinases could be playing in cell motility 
or invasion had not been undertaken. Wound healing assays are a simple method 
used to measure cell migration in vitro and are based upon the observation that 
cells on the edge of an artificially created scratch or ‘wound’ will move toward 
the opening in the monolayer until new cell-cell contacts are made(Liang et al, 
2007). This method aims to mimic the migration of cells in vivo, similar to the 
effect seen in rat studies where endothelial cells migrate into wounded areas of 
blood vessels to close up deliberately damaged areas(Haudenschild CC, 1979). 
With the aid of time-lapse microscopy and imaging software it is possible not 
just to image wound size at the start and end of an experiment, but also the 
migratory paths of individual cells. These tracks can then be compared between 
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experimental conditions and controls to determine the role of a protein (in this 
case LIMK1 or LIMK2) in directional cell migration. 
In order to address whether LIMK1, LIMK2 or both LIMK1 and LIMK2 were required 
for cell migration, wound healing assays (also referred to in some literature as 
scratch assays) were performed. MDAMB231 cells were subject to siRNA against 
either LIMK1 (siRNA #1), LIMK2 (siRNA#2) or both kinases in combination in 6well 
dishes. 48hrs after siRNA transfection, a scratch was made across the confluent 
monolayer using a micro pipette tip and the media gently changed to reduce the 
likelihood of free floating cells moving into the field of view during imaging. The 
wounds were then imaged using a Zeiss time-lapse microscope for 24 hours at 
15minute intervals, creating image timelines for each wound. Images of each 
wound at T=0 and T=24 hours are compared in Figure 3.3.5 part A. After 24 
hours, control cells transfected with non-targeting siRNA (NT) closed the wound, 
as did cells subjected to siRNA against LIMK1 (siLIMK1). Cells with reduced levels 
of LIMK2 (siLIMK2) did not close the breach in the monolayer, and cells siRNA 
treated for both LIMK1 and 2 (siLIMK1&2) managed to cross the wound but did 
not close it fully. Individual cells along the leading edge of the ‘wounds’ were 
tracked using imaging software (ImageJ) to visualise the directionality of cells 
under each knockdown condition, as illustrated in Figure 3.3.5 part B. The tracks 
mapped for control cells and those with knocked down LIMK1 appear longer and 
smoother than the twisting tracks taken by cells with knocked down LIMK2 or 
those with LIMK1 and 2 knocked down. The distance over which these tracks 
spread was also reduced in the LIMK2 and LIMK1&2 knock downs, cells rarely 
travelled further than the 200 unit point, compared to siLIMK1 where some 
reach 250 or the NT control cells that travelled up to around the 300 limit. In 
the cells with reduced LIMK fewer cells were seen to move up and down the 
leading edge of the wound in comparison to NT control, the tracks were 
predominantly directional, closing the wound. 
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Figure 3.3.5-MDAMB231 wound healing assay.  
Following siRNA treatment LIMK1 (#1&#3), LIMK2 (#6&#7)or both LIMK1 and LIMK2 (#1&#6 or 
#3&#7) in combination or with a non-targeting oligonucleotide; A.i. Time equals zero, confluent 
MDAMB231 were denuded to create a ‘wound’. A.ii. Time equals 24 hours. Cells subject to 
knockdown of LIMK1 appear to have unaffected wound healing, knockdown of LIMK2 or both in 
combination show slightly reduced capacity for wound healing. Scale bar for A equals 100µm B. 
Tracks of individual cells during wound healing. Cells with reduced LIMK have shorter, more 
compact tracks than control cells. Images captured on a Zeiss Timelapse Microscope at x20 using 
Andor IQ software. Cells were followed manually using ImageJ software to visualise cell tracks 
during wound healing, arbitrary units displayed. 
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These early observations indicated that loss of LIMK1 had little effect on 
directional motility but that reducing LIMK2 reduced wound healing capability, 
and that loss of both kinases had an intermediate effect. The intermediate 
effect seen when both LIMK1 and LIMK2 were knocked down could have been due 
to the design of the experiment. siRNA treatment against both LIMK1 and LIMK2 
used the same total concentration of RNA as the knockdowns targeting LIMK1 or 
LIMK2, but this was achieved by using half the amount used against each 
individual LIMK to make a mixture targeting both. This could have made the 
LIMK2 knockdown less efficient and cause an intermediate reduction in motility.  
 
3.2.4 Knockdown of LIMK has little effect on cell motility in 2D on 
plastic. 
Having confirmed that LIMK levels can be successfully knocked down by siRNA in 
MDAMB231, cell motility assays were used to examine if a reduction in LIMK 
affected cell motility. Initial observations were obtained from a traditional 
wound healing assay, a scratch made across a monolayer of cells using a micro 
pipette tip, and suggested that reducing LIMK2 levels had a greater effect 
(Figure 3.3.5). The wounds in these assays can vary between conditions, as can 
the force generated to denude the area of the dish. In order to perform a more 
reproducible and quantifiable motility assay, one that generates a regular wound 
size between all conditions, the Oris cell migration assay was employed. 
Oris migration assays were performed in a 96well dish format. Rubber plugs are 
placed within each well of the dish and cells seeded around the plug, after a 
suitable time for cells to settle has passed the plugs are removed and the centre 
of each well is clear of cells, leaving a regular and repeatable ‘wound’. This 
technique was used to compare the motility of cells over plastic following 
knockdown of LIMK1, LIMK2 or both in comparison to those treated with non 
targeting control oligonucleotides. Twenty four hours following siRNA knockdown 
MDAMB231, BT549 and BE cells were seeded into individual Oris migration plates 
in quadruplicate for each condition, with one row of 4 wells retaining their plugs 
to act as a control (i.e.‘no motility’). All other wells were given 24 hours to 
move into the wound following removal of the plug. Subsequent staining with 
the live cell dye Calcein AM was performed and the plates were then imaged on 
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an upright fluorescent microscope. A ‘mask’ was added to the bottom of each 
plate to allow visualisation of only the ‘wound’ and then the plate was either 
read on a Tecan Safire plate reader to quantify the fluorescence (cells) in the 
wound, or the images taken used to quantify the area of cells in the wound by 
ImageJ Software. Despite confirmation of LIMK knockdown by western blot there 
did not appear to be any difference in motility between cells that had lost 
LIMK1, LIMK2 or both by siRNA in comparison with control MDAMB231 cells 
(Figure 3.3.6). There was a reduction in pCofilin (phospho-Cofilin) levels 
following LIMK knockdown, further confirming a reduction in LIMK activity. This 
would have predicted a change in cell motility as Cofilin has been found to 
determine the migration behaviour of metastatic cancer cells(Sidani et al, 2007). 
In contrast to the results observed in MDAMB231 cells, there was a significant 
reduction in motility of BT549 cells following knockdown of LIMK1, LIMK2 or both 
in comparison with control cells (Figure 3.3.7), and a similar trend was seen in 
BE cells. Knockdown of LIMK2 in BE cells caused a consistently significant 
reduction of motility (Figure 3.3.8). The trend for BE cells suggest a loss of 
motility following LIMK1 knockdown or when both LIMK1 and LIMK2 are knocked 
down, but only one of each set of oligonucleotides per condition could be 
considered statistically significant. Results from Oris migration assays suggest 
that LIM Kinases are important for the motility of some cells across plastic, but 
not all. MDAMB231 cells are known to be a motile cell line, capable of 
interacting with their environment to facilitate invasion. There appeared to be 
no requirement for LIMK in MDAMB231 motility on plastic following wound 
healing experiments, despite initial indications from traditional ‘scratch’ assays. 
The original scratch assays were somewhat flawed. Cells were plated, siRNA 
treated and then the monolayer disrupted, without counting cells before the 
wounds were generated. The later experiments using Oris migration assays 
counted cells before generating a wound, so any subtle change in cell number 
could be accounted for and not suggest a false effect on cell migration via 
proliferation. Although there was not a statistical difference between cells with 
knockdown LIMK compared to controls, there was a subtle change in number.   A 
malleable substrate more reflective of physiological conditions could present 
changes in motility following knockdown of LIMK compared to the rigid plastic 
substrate. 
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Figure 3.3.6-Motility of MDAMB231 using the Oris cell migration assay 
MDAMB231 cells subject to loss of LIMK1, LIMK2 or both LIMK1 and LIMK2 in combination by 
siRNA oligonucleotides closed the ‘wound’ in a comparable way to cells subject to non-targeting 
control oligonucleotides. A. Brightfield images of wounds after 24hours, imaged on an Olympus 
tissue culture microscope at x2.5. B. Quantification of cells in centre of wound using Imaging 
software (ImageJ), no significant differences were observed between conditions (as determined by 
ANOVA). C. Western blot confirmation of LIMK knockdown, and reduction in phospho-Cofilin 
levels.  
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Figure 3.3.7-Motility of BT549 using the Oris cell migration assay 
Following siRNA treatment against LIMK1, LIMK2, both in combination or with a non-targeting 
oligonucleotide; A shows images of wounds after 24hours, cells stained in all conditions using 
Calcein AM. B. Quantification of cells in centre of wound using Tecan Safire plate reader. Double 
asterisk indicates P < 0.01 as determined by a Student T test. Images captured on Olympus 
Fluorescent Tissue Culture Microscope at x2.5 Scale bar equal to 750µm. 
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Figure 3.3.8- BE wound healing and motility on plastic.  
Following siRNA treatment against LIMK1, LIMK2, both in combination or with a non-targeting 
oligonucleotide; A shows images of wounds after 24hours, cells stained in all conditions using 
Calcein AM. B. Quantification of cells in centre of wound using Tecan Safire plate reader. Double 
asterisk indicates P < 0.01 as determined by a Student T test. Images captured on Olympus 
Fluorescent Tissue Culture Microscope at x2.5 Scale bar equal to 750µm. 
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3.2.5 Knockdown of LIMK has no effect on cell motility on CDM. 
Cell derived matrix (CDM) in the following experiments refers to the oriented 3D 
fibrillar extracellular matrix generated by primary cultured human dermal 
fibroblasts (Cukierman et al, 2001) and secreted into their environment, in this 
case onto tissue culture plastic-ware. After the removal of the transformed 
fibroblast cells, the remaining structured matrix can be used to study motility of 
chosen cell types. The CDM provides a substrate that moving cells can adhere to, 
distort and degrade but it does not require the generation of low-resistance 
paths by ECM remodeling. Cell movement is guided by the meshwork of long 
fibronectin fibrils secreted by the fibroblasts which promotes polarity and results 
in efficient directional protrusion, making this model ideal for measuring the 
persistence of cells (ratio between vectorial and accumulated distance 
travelled).  
Following knockdown for LIMK1, LIMK2, LIMK1&2 or non targeting siRNA, 
MDAMB231 cells were plated sub-confluently onto CDM and imaged every 15 
minutes for 12 hours using phase contrast microscopy on a time-lapse 
microscope. Individual cells were then tracked using ImageJ software. 
MDAMB231 placed on CDM predominantly moved along the ‘tracks’ left by the 
removed TIF cells (telomerase-immortalised human fibroblasts), occasionally 
moving between these ‘tracks’ that outline the previous cell positions (Figure 
3.3.9). Quantification of accumulated distance (total distance travelled by 
cells), vectorial distance (direct distance between start point and end point of 
cell track) saw no difference between the knockdown conditions (Figure 3.3.10) 
and the level of persistence shown by cells (the most persistent being considered 
‘1’, with no difference between vectorial and accumulative distances) was also 
statistically insignificant between conditions. There was, however a visible 
difference in cell morphology between control cells and those subjected to 
LIMK1&2 knockdown, as can be seen in Figure 3.3.11, knockdown cells were 
more refractile and maintained a more ‘raised’ morphology as they moved (like 
snails with larger shells but a similar sized footprint to their control 
counterparts). The morphological differences between control cells and those 
with reduced LIMK did not translate into a difference in motility by invasive 
MDAMB231 cells in the conditions used, but all of these experiments were 
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essentially performed in 2D. Where CDM, a more interactive substrate than 
tissue culture plastic, was used to examine the effects of blocking LIMK activity 
on cell motility a morphological change was observed using phase contrast 
microscopy.  
3.2.6 LIMK is a requirement of cell invasion into 3D matrix 
Over expression of LIMK1 can increase motility and invasiveness of human breast 
cancer cells(Yoshioka et al, 2003) and can promote the acquisition of an invasive 
phenotype in benign prostate epithelial cells(Davila et al, 2003), it was therefore 
concluded that loss of LIMK1 or loss of LIMK2 could reduce the capability of 
invasive cancer cells to invade. In 2D motility there is no requirement for 
degradation or the use of force in path generation, cells are free to move in any 
direction across a 2D field. In 3D cells require both the ability to move but also 
the ability to generate a path along which to move, this may be achieved by 
proteolytic activity or in combination with the cells ability to physically deform 
its environment. In order to understand the potential role LIM Kinases play in 
cancer cell invasion, a physiologically relevant assay was employed; one in which 
the cells could both interact with their substrate but also have the opportunity 
to move in a 3-dimensional manner, allowing for degradation and deformation. 
Inverse invasion assays(Hennigan RF, 1994) provide a 3D environment through 
which cells can invade and interact and the assay is outlined in Figure 3.3.12. 
The matrix used as a 3D interactive substrate is produced by BD Biosciences and 
mimics the complex extracellular matrix secreted by cells in tissue. It is 
extracted from Engelbreth-Holm-Swarm (EHS) mouse sarcoma, and although its 
exact composition has not been determined it is known to contain, (along with 
other growth factors from the EHS tumour), laminin, collagen IV, TGF-β, EGF, 
insulin-like growth factor and FGF(BD Biosciences 
http://www.bdbiosciences.com/nvCategory.jsp?modeCategory=FULL). 
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Figure 3.3.9-MDAMB231 Motility on Cell Derived Matrix mapped. 
Representative data from tracks of cells moving on cell derived matrix following knockdown of 
LIMK1, 2 or both in combination by siRNA. A. shows the tracks of MDAMB231 cells following 
transfection with a non-targeting control siRNA. The direction of growth of Tiffs used to generate 
the CDM is reflected in the routes taken by the MDAMB231. B. Tracks of MDAMB231following 
siRNA against LIMK1, 2 (C.) or both in combination (D.) no significant differences were observed 
between conditions (determined by ANOVA on the quantitative data used to plot these graphs).  
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Figure 3.3.10-MDAMB231 Motility on Cell Derived Matrix quantified. 
A. Mean accumulated distance travelled by cells following siRNA treatment against LIMK1, LIMK2, 
both in combination or with a non-targeting siRNA. B. Mean Vectorial distance travelled by cells 
following siRNA treatment. C. Persistence of cells travelling over CDM following siRNA treatment. 
Error bars refer to Standard Error, n=3 throughout, no significant differences were observed 
between conditions (determined by ANOVA).  
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Figure 3.3.11-Timeline of MDAMB231 motility on CDM, LIMK knockdown cells refract more 
than controls. 
MDAMB231 cells moving across Cell Derived Matrix (CDM). Following knockdown of both LIMK1 
and LIMK2 by siRNA cells refract more in comparison with control cells subject to non-targeting 
siRNA, appearing to maintain a more ‘raised’ morphology as they move across the substrate. 
Images captured on a Zeiss Timelapse Microscope at x20 using Andor IQ software. 
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To assess the role LIM Kinases play in 3D invasion MDAMB231 cells, which have 
previously been shown to be an invasive cell line(Munoz-Najar et al, 2005; 
Nizamutdinova et al, 2008), were subject to knockdown of LIMK1, LIMK2 
LIMK1&2 or non targeting (NT) siRNA and placed into inverse invasion assays (as 
described in Figure 3.3.12). Following a 5 day period to allow for cell invasion, 
cells were stained with Calcein AM and Z-stacks imaged of each matrigel 
invasion ‘plug’ using a Leica Confocal microscope at x10 magnification; examples 
of which can be seen for MDAMB231 cells in part A of Figure 3.3.13. Before 
quantification, a clear reduction in invasion by MDAMB231 following knockdown 
of both LIMK1&2 can be seen. Image stacks such as these were then quantified 
using ImageJ software. The cumulative invasion of MDAMB231 is illustrated in 
part A of Figure 3.3.14. Although many cells in all conditions crossed the initial 
filter barrier at the bottom of the transwell invasion assay, NT control cells 
achieved a greater overall level of invasion. This can be seen by the initially 
steeper curves of the lines representing control cells in this cumulative graph, 
and the larger values 135µm into the matrigel (total invasion). One way to 
standardise the quantification of invasion is to score cells that have moved over 
45µm into the matrigel(Spence et al, 2006). This method of quantification 
similarly illustrates the importance of both LIMK1 and LIMK2 in the invasiveness 
of MDAMB231 (Figure 3.3.14). Loss of either kinase reduced invasion beyond 
45µm, loss of both LIMK1 and LIMK2 caused an equally large reduction in 
invasiveness. This contrasts with the lack of requirement for LIMK for MDAMB231 
2D motility. The cells that required LIMK for 2D motility (BT549 and BE) showed 
no clear requirement for LIMK in invasion (Figure 3.3.15 and Figure 3.3.16). 
However, this data cannot be interpreted fully as even in control conditions 
these cells failed to invade the matrigel fully, most not reaching the 45µm cut 
off often referenced in publications investigating invasion. Considering this, 
further investigations into 3D invasion were then conducted using the invasive 
cell line MDAMB231. 
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Figure 3.3.12-Inverse invasion assay. 
The inverse invasion technique uses 8µm filter transwells filled with matrigel to provide a 3D 
environment for cells to invade into (A. and B.). Cells are stained in the matrigel plug with Calcein 
(C) and imaged by confocal microscopy in 15µm sections (D. and E.). E. shows the invasion of 
MDAMB231 cells into matrigel in 15µm sections. 
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Figure 3.3.13-Loss of LIMK reduces MDAMB231 3D Invasion 
A. 15µm Z sections of MDAMB231 cells invading through matrigel following knockdown of LIMK1, 
LIMK2 or both in comparison with control cells transfected with a non-targeting siRNA. Images 
obtained using a Leica Confocal microscope at x10. B. Western Blot of LIMK levels following 
siRNA treatment for siLIMK1, siLIMK2, a combination of both siLIMK1 & siLIMK2 and non-targeting 
siRNA controls. Lamin A/C siRNA functions as a loading control, as well as a positive control for 
siRNA activity. 
 
104 
100
120
140
160
180
200
220
0 15 30 45 60 75 90 105 120 135
Depth into Matrigel
 R
el
at
iv
e 
In
va
si
on
 (A
cu
m
ul
at
iv
e)
siLIMK1 (1)
siLIMK1 (3)
siLIMK2 (6)
siLIMK2 (7)
siLIMK1&2 (1&6)
siLIMK1&2 (3&7)
NT1
NT2
n=3
A.
B.
0
2
4
6
8
10
12
14
16
18
NT
1
NT
2
siL
IM
K1
.1
siL
IM
K1
.3
siL
IM
K2
.6
siL
IM
K2
.7
siL
IM
K1
.1 
&2
.6
siL
IM
K1
.3 
& 2
.7
siRNA
%
 In
va
si
on
 >
45
uM
 
Figure 3.3.14-Quantification of MDAMB231 loss of Invasion following knockdown of LIM 
Kinases 
A. Cumulative invasiveness of MDAMB231 cells invading into Matrigel; Cells that have been siRNA 
treated against LIMK1, LIMK2 or LIMK1 and LIMK2 invade less into the Matrigel, and those that 
have invaded following loss of LIMK do not go as far into the matrigel in comparison with controls. 
B. Percentage invasion of MDAMB231 cells over 45µm following LIMK1, 2 or both knock-down by 
siRNA in comparison with cells treated with non targeting control siRNA. 
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Figure 3.3.15-Quantification of BT549 loss of Invasion following knockdown of LIM Kinases 
A. Western Blot of LIMK levels following siRNA treatment for siLIMK1, siLIMK2, a combination of 
both siLIMK1 & siLIMK2 and non-targeting siRNA controls. Lamin A/C siRNA functions as a 
loading control, as well as a positive control for siRNA activity. A. Cumulative invasiveness of 
BT549 cells invading into Matrigel; There is no clear pattern of effect on invasion into the matrigel 
by cells that have been siRNA treated against LIMK1, LIMK2 or LIMK1 and LIMK2 in comparison 
with controls. 
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Figure 3.3.16 Quantification of BE loss of Invasion following knockdown of LIM Kinases 
A. Western Blot of LIMK levels following siRNA treatment for siLIMK1, siLIMK2, a combination of 
both siLIMK1 & siLIMK2 and non-targeting siRNA controls. Lamin A/C siRNA functions as a 
loading control, as well as a positive control for siRNA activity. A. Cumulative invasiveness of BE 
cells invading into Matrigel; There is no clear pattern of effect on invasion into the matrigel by cells 
that have been siRNA treated against LIMK1, LIMK2 or LIMK1 and LIMK2 in comparison with 
controls. 
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3.2.7 Cell morphology in 3D following loss of LIMK 
MDAMB231 cells showed subtle morphological changes following knockdown of 
LIMK when cultured on cell derived matrix, an interactive 2D substrate. Previous 
work has shown environmental cues can also alter the morphology of cells in 
culture(Kenny et al, 2007). Whether this was the case in 3D, and correlated with 
loss of invasion following knockdown of LIMK, was then investigated. MDAMB231 
cells were pre-treated with siRNA against LIMK1, LIMK2, LIMK1&2 or a non 
targeting oligonucleotide and transferred to the inverse invasion assay to provide 
a 3D substrate for invasion. The cells in the matrigel plug were then fixed and 
stained with a whole cell dye (in this case Calcein AM) for visualisation on a 
FV100 Olympus confocal microscope. Using a water lens, 2µm sections were 
taken up through the matrigel ‘plug’ until the point where no cells were 
detected. These image stacks were then processed using Volocity 6.0 imaging 
software to construct a 3D model of the MDAMB231 cell invasion (Figure 3.3.17 A 
and B – movie on supplementary CD). As expected from the images in Figure 
3.3.13 cells with knockdown of LIMK1, LIMK2 or both LIMK1&2 invaded less than 
control cells transfected with non targeting siRNAs. In all conditions cells moved 
through the 8µm filter and were sitting on top of the filter, just beneath the 
matrigel. From this ‘base’ layer of cells on the filter, control cells were seen as 
elongated globular chains; suggesting that cells may have tracked after each 
other into the matrix as well as invading the matrix individually. Of the cells 
with reduced levels of LIMK1, the small number of cells that managed to invade 
a short distance into the matrix did so in a singular manner, there were no 
visible ‘tracks’ of cells. This was also the case for cells subject to LIMK2 
knockdown, in the image for oligonucleotide number ‘7’ against LIMK2, it is 
interesting to see some cells that were captured moving up through the filter to 
sit beneath the matrigel. Knockdown of both LIMK1 and LIMK2 appeared to 
reduce cell size/shape in 3D, the few cells that invaded were smaller and more 
rounded in appearance than control cells. In all the knockdown conditions 
tested, cells were still able to cross the 8µm filter and position themselves 
beneath the matrigel. 
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Figure 3.3.17-3D morphology of MDAMB231 cells invading into matrigel. 
3D reconstruction of MDAMB231 invasion into matrigel and staining with Calcein AM. Following 
siRNA treatment against LIMK1 (oligonucleotides 1 and 3), LIMK2 (oligonucleotides 6 and 7), both 
in combination (oligonucleotides 1 and 6 or 3 and 7), or with a non-targeting oligonucleotide (NT1 
or NT2). Control cells invade into matrigel, tracking after each other, loss of LIMK1, 2 or both 
respectively causes a loss of invasion and tracking phenotype. B. Movie of 3D reconstructed 
invasion following knockdown of LIMK in MDAMB231. Invasion was imaged on an FV1000 
Olympus Confocal at x40 (water lens) using FV10-ASW.1.7b software and reconstructed using 
Volocity 6.0. Invasion sections are approximately 140µm wide. 
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Figure 3.3.18-MDAMB231 cells lose the ability to invade in tracks following LIMK 
knockdown. 
Optical slices of 3D reconstructions of MDAMB231 invasion into matrigel (staining with Calcein 
AM). Following siRNA treatment against LIMK1, LIMK2, both in combination or with a non-targeting 
oligonucleotide A. Control cells invade into matrigel, tracking after each other. B, C and D. show 
loss of LIMK1, 2 or both respectively causes a loss of invasion and tracking phenotype. Invasion 
was imaged on an FV1000 Olympus Confocal at x40 (water lens) using FV10-ASW.1.7b software 
and reconstructed using Volocity 6.0. Invasion sections are approximately 140µm wide. 
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3.2.7.1 MDAMB231 cells invade into Matrigel in tracks 
MDAMB231 cells appeared to invade into matrigel collectively, following each 
other up through the matrix in a strand (previously described by (Wolf et al, 
2007)), and knockdown of either LIMK both reduced invasion and this morphology 
in 3D. In order to further assess whether this was the case optical slices were 
made through reconstructed invasion plugs, such as those seen in Figure 3.3.17. 
These slices more clearly show cells following each other up into the matrigel, 
but not in the event of LIMK knockdown (Figure 3.3.18).These are not long cells 
stretched out through the matrix, they are individual cells as was confirmed by 
PI staining of nuclear DNA. This can be seen in parts A and B of Figure 3.3.19 
where a 3D reconstruction of MDAMB231 invading into matrigel (stained with 
Phalloidin (green) to visualise F-actin, and PI (red) for nuclei) demonstrates that 
multiple cells track together through the matrix. part A. shows a Z-section of 
the 3D reconstruction of MDAMB231 3D invasion in part B, illustrating how 
MDAMB231 cross the filter  of the transwell but only a proportion of the 
population of cells then invades in tracks into the matrigel. 
3.2.7.2 Loss of F-actin structures in 3D corresponds with loss of 
invasiveness following reduction in LIMK levels 
In 2D cells were seen to lose F-actin staining following knockdown of LIMK, 
knockdown of both kinases was achieved using two different combinations of 
oligonucleotides. In the later stages of these investigations a potent LIMK 
inhibitor became available to use within our lab, the structure of which is 
presented in Figure 3.3.19 part C (Ross-Macdonald et al, 2008). This inhibitor 
was used to investigate whether changes observed in 2D F-actin structures were 
also seen in 3D, in turn to determine whether this did in fact correlate with loss 
of invasion. Cells treated with 3µM inhibitor have reduced F-actin staining (and 
invasion) in comparison with control cells treated only with an equivalent 
volume of DMSO vehicle. 10µM LIMKi further reduced cell invasion and F-actin 
staining in 3D as can be seen in Figure 3.3.19 where invasion plugs are viewed 
from the side and have been stained with Phalloidin (green) to visualise F-actin, 
and PI (red) for nuclei. This was also the case for cells that had LIMK knocked 
down and was thus a specific effect (Figure 3.3.20), Z slices visualise the cells 
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just above the filter in the inverse invasion assay set up. Reduction of LIMK by 
either drug or siRNA dramatically reduced F-actin staining in 3D, correlating with 
a loss of invasiveness (Figure 3.3.20). In all of these assays, under all conditions 
(including controls) there was also a non invasive and non motile (did not cross 
the filter) population of cells. These too lost F-actin structures following 
reduction of LIMK levels by siRNA or Drug (Figure 3.3.21).  
LIM Kinases have been shown here to be a requirement of 3D cancer cell 
invasion, but not necessarily a requirement of 2D cell motility. As a requirement 
of invasion it could be hypothesised that increasing cellular levels of LIMK in 
these cells would increase invasiveness, as previous work with benign epithelial 
cells suggests (Davila et al, 2003).  
3.2.8 Is LIMK a driver of cell motility or invasion? 
LIMK has thus far been shown to be a requirement for 3D invasion by cells by the 
data presented in this chapter, but it is not known whether LIMK is also a driver 
of invasion. It has previously been reported that LIMK1 is elevated in cancer cell 
lines (Davila et al, 2003; Okamoto et al, 2005; Yoshioka et al, 2003)and 
tumours(Bagheri-Yarmand et al, 2006; Davila et al, 2003), and following 
commencement of this project, that LIMK1 over expression increases the 
invasiveness of human breast cancer cells(Bagheri-Yarmand et al, 2006). In order 
to address if LIMK is a driver of invasion, a conditionally activated LIMK fusion 
protein was generated.  
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 Figure 3.3.19-3D F-actin staining and invasion of MDAMB231 is reduced by LIMK inhibitor. 
A. Z section of ‘B.’, MDAMB231 cells invading matrigel in columns, cells ‘following’ each other. B. 
3D reconstruction of MDAMB231 invasion into matrigel and staining with Phalloidin (green) to 
visualise F-actin, and PI to visualise nuclei demonstrating that multiple cells track together. C. LIMK 
inhibitor. D. Cells treated with LIMK inhibitor at 3µM and 10µM show both a reduction in F-actin 
staining and invasion in comparison with control cells treated with DMSO. Invasion was imaged on 
an FV1000 Olympus Confocal at x40 (water lens) using FV10-ASW.1.7b software and 
reconstructed using Volocity 6.0. Invasion sections are 100µm wide. 
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NT1 NT2 DMSO
siLIMK1 #1 siLIMK1 #3
siLIMK2 #6 siLIMK2 #7 10µM LIMKi
siLIMK1&2 #1&#6 siLIMK1&2 #3&#7
3µM LIMKi
 
Figure 3.3.20- F-actin staining of MDAMB231 in 3D is reduced by siRNA knockdown of LIM 
Kinases in the invasive population of cells. 
Cells on top of the filter at the end of a 5 day invasion assay display a loss of F-actin staining 
following knockdown of LIMK1, 2 or both in combination by siRNA or inhibition by LIMK inhibitor. F-
actin was stained with Texas Red phalloidin and imaged on an FV1000 Olympus Confocal at x40 
(water lens) using FV10-ASW. 
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siLIMK1 #1 siLIMK1 #3
siLIMK2 #6 siLIMK2 #7 10µM LIMKi
siLIMK1&2 #1&#6 siLIMK1&2 #3&#7
3µM LIMKi
 
Figure 3.3.21-F-actin staining in 3D is reduced by siRNA knockdown of LIM Kinases in the 
non invasive population of cells. 
Cells under the filter at the end of a 5 day invasion assay (the non invasive population of cells) also 
display a loss of F-actin staining following knockdown of LIMK1, 2 or both in combination by siRNA 
or inhibition by LIMK inhibitor. F-actin was stained with Texas Red phalloidin and imaged on an 
FV1000 Olympus Confocal at x40 (water lens) using FV10-ASW. 
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3.2.8.1 Generation of LIMK:ER inducible cell lines 
To produce a conditionally regulated system to study the consequences of LIMK 
activation, a conditionally activated form of LIMK1 was created, made 
conditionally activate by fusion with the hormone binding region of estrogen 
receptor (ER).Activated only in cells only in the presence of estrogen analogs, 
the structure of the LIMK:ER fusion protein is illustrated in Figure 3.3.22 part A. 
This kind of fusion protein has been used extensively with a variety of proteins 
such as transcription factors and kinases, and within our lab a fusion protein to 
ROCK has been used to analyse its role in regulation of the actin cytoskeleton 
(Croft et al, 2006; Croft et al, 2004).   
Retroviral vectors encoding LIMK:ER were subject to site directed mutagenesis to 
generate two ‘active’ phospho-mimetic mutants; Thr508Glu referred to as 
LIMK:ER (E), and Thr508GluGlu referred to as LIMK:ER (EE) (illustrated as a red 
band in the kinase domain in Figure 3.3.22 part A), and the estrogen receptor 
hormone-binding domain expressed at the C terminus. The LIMK:ER, LIMK:ER (E) 
and LIMK:ER (EE) retroviral vectors were each packaged as ecotropic virus and 
then introduced into mouse (NIH3T3) cells or stably transfected ecotropic 
receptor  expressing  cells (SAOS). The estrogen receptor hormone-binding 
domain was stimulated with estrogen analogs tamoxifen or 4-HT, but this did not 
lead to a 4HT dependent increase in pCofilin as hoped, illustrated for NIH3T3 
cells in Figure 3.3.22 part B. The addition of 4-HT led to a slight increase in 
LIMK:ER (WT), LIMK:ER (E) and LIMK:ER (EE)levels; potentially an indicator of the 
stability of the protein following 4-HT activation. GFP and LIMK antibodies were 
overlaid using different species and wavelength LiCor secondary antibodies to 
identify the fusion protein. Although there was not an increase in pofilin levels 
following 4-HT activation, it was hoped that there may still have been a 
phenotypic effect on the actin cytoskeleton of the cells. 
Effects of an increase in active LIMK:ER on the actin cytoskeleton was difficult to 
discern. The selection process for generating stable LIMK:ER expressing cell lines 
appears to have selected for a different phenotype to the parental cells, as can 
be seen in the first panel of Figure 3.3.23. LIMK:ER  expressing cells are less 
ruffled at the edges and have slightly stronger cortical F-actin staining and more 
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stress fibres. Sixteen hours following 4-HT addition in the absence of serum the 
control cells show no difference in morphology, LIMK:ER (E) expressing cells look 
more like Control NIH3T3 cells, slightly more ruffled, and LIMK:ER (EE) cells also 
have slightly more ruffled edges and appear flatter, more spread out (Figure 
3.3.23). The subtle changes in morphology in this cell line following 4-HT 
induction led to the generation of SAOS LIMK:ER cells, in the attempt to make a 
cell line with more easily identifiable LIMK dependent morphological changes. 
SAOS cells were retrovirally transduced with LIMK:ER constructs and drug 
selected before being subject to induction with 4-HT as the NIH3T3 before them, 
Figure 3.3.24. As with the NIH3T3 LIMK:ER cells, the construct expressed at low 
levels without induction and drug selection led to the un-stimulated cells having 
a markedly different morphology to the parental Control cells as can be seen in 
the first panel of images in Figure 3.3.24. LIMK:ER (E) expressing cells had a 
smaller, more compacted and less polarised morphology in comparison with 
control cells when un-stimulated. Following 4-HT stimulation the LIMK:ER (E) 
SAOS cells displayed reduced F-actin staining in comparison with un-stimulated 
cells (Figure 3.3.23, middle row). LIMK:ER (WT) cells were considerable larger 
than the parental Control cells when unstimulated, less polarised and with 
stronger cortical F-actin staining and stress fibres. However, following 4-HT 
stimulation, they were smaller than control cells and had greatly reduced F-
actin staining, more resembling LIMK:ER (E) un-stimulated cells(Figure 3.3.24). 
Stimulation in the presence of serum had no discernable effect upon the 
morphology of LIMK:ER WT cells, and under these unstressed conditions there 
was only a subtle difference in cell size between the un-stimulated control cells 
and un-stimulated LIMK:ER WT cells (Figure 3.3.25).  
LIMK:ER activation in cells resulted in very subtle phenotypic changes in the 
actin cytoskeleton, raising doubt over the activity of LIMK:ER. In order to 
determine the activity of LIMK:ER in cells immunoprecipitation (IP) kinase assays 
were performed. 
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 CGCTACGAAGAAGTGGTG, Thr508GluGlu (EE mutant) 
 CGCTACGAAGTGGTG, Thr508Glu (E  mutant) 
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pcofilin
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LIMK:ER (overlay)
LIMK1
- +            - +           - +          - +              4-HT  
NIH3T3 LIMK:ER (WT)LIMK:ER (E) LIMK:ER (EE)
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B.
 
Figure 3.3.22-Conditional activation of LIMK:ER by 4-Hydroxytamoxifen 
A. Illustration of LIMK:ER structure and component domains. Red band intonates point of point 
mutation for E and insertion for EE mutants. B. Western blot illustrating the conditional activation of 
LIMK:ER, LIMK:ER (E) and LIMK:ER (EE) following addition of 4-HT. Blots were imaged using 
LiCor software to allow visualisation of the colocalisation of  EGFP and LIMK, confirming LIMK:ER 
construct expression. 
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Figure 3.3.23-NIH3T3 Express LIMK:ER, exhibiting a very subtle phenotype following 
induction with 4HT.  
NIH3T3 expressing LIMK:ER constructs and stained to visualise F-actin. Un-stimulated cells across 
conditions do not show the same cell shape or actin staining, selection for stable LIMK:ER 
expression has led to selection of a cell line which is phenotypically different from the parental cell 
line used (Control). Following stimulation with 4-HT LIMK:ER expressing cells display a subtle 
change in F-actin staining; both LIMK:ER (WT) and LIMK:ER (E) become slightly more spread out 
than un-stimulated cells, and have a slightly more ruffled cell edge.  Cells stained with Texas Red 
Phalloidin to visualise F-actin and treated with 4-HT in the absence of serum for 16 hours. Images 
captured on the Zeiss Axioplan 200 at x20 using Imaging Associates Isis software. Scale bar 
equals 40µm. 
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Figure 3.3.24-SAOS express LIMK:ER but do not exhibit a consistent phenotype following 
induction with 4HT.  
SAOS expressing LIMK:ER constructs and stained to visualise F-actin. Un-stimulated cells across 
conditions do not show the same cell shape or actin staining, selection for stable LIMK:ER 
expression has led to selection of a cell line which is phenotypically different from the parental cell 
line used (Control). Following stimulation with 4-HT LIMK:ER expressing cells display a subtle 
change in F-actin staining; LIMK:ER (WT) cells become smaller, with less F-actin staining and 
stress fibres following 4-HT stimulation, LIMK:ER (E) show less F-actin staining, with a reduction in 
stress fibres and cortical actin.  Cells were stained with Texas Red Phalloidin to visualise F-actin 
and treated with 4-HT in the absence of serum for 16 hours. Images captured on the Zeiss 
Axioplan 200 at x20 using Imaging Associates Isis software. Scale bar equals 40µm. 
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Figure 3.3.25-SAOS express LIMK:ER but do not exhibit a consistent phenotype following 
induction with 4HT.  
SAOS expressing LIMK:ER constructs and stained to visualise F-actin. Un-stimulated cells across 
conditions do not show the same cell shape or actin staining, selection for stable LIMK:ER 
expression has led to selection of a cell line which is phenotypically different from the parental cell 
line used (Control). Following stimulation with 4-HT LIMK:ER expressing cells displayed a subtle 
change in morphology; LIMK:ER (WT) cells appear slightly more spread than un-stimulated, there 
was no obvious difference in the actin cytoskeleton following 4-HT stimulation.  Cells were stained 
with Texas Red Phalloidin to visualise F-actin and treated with 4-HT in the presence of serum for 
16 hours. Images captured on the Zeiss Axioplan 200 at x20 using Imaging Associates Isis 
software. Scale bar equals 40µm. 
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3.2.8.2 LIMK:ER Activity 
Immunoprecipitation (IP) Kinase assays give a direct measurement in vivo kinase 
activity and can be used to assess fusion protein activity (Croft et al, 2004). 
Using Cofilin as a substrate, pCofilin levels would indicate in vitro activity and 
therefore reflect the activity status of LIMK:ER in cells. 
The kinase assay conditions were optimised to increase the chance of seeing 
LIMK:ER activity, as can be seen in Figure 3.3.26. The optimised kinase assay 
conditions were then employed in the following experiments. The dose of 4-HT 
and treatment time was also optimised.   
LIMK:ER is up-regulated in a 4-HT dose dependent manner in both NIH3T3 and 
SAOS, part A and B of Figure 3.3.27 respectively. The slight increase in pCofilin 
levels seen in NIH3T3 whole cell lysates suggested that the fusion protein was 
active, but Cofilin phosphorylation did not increase with dose, it had reached its 
maximum level. Although LIMK:ER was expressed in cells, the protein levels do 
not give a gauge of its activity and so using the optimal kinase assay conditions 
determined in Figure 3.3.26 the activity of LIMK:ER was re-examined, with 
further optimisation of 4-HT dose and timing. The optimal dose of 4-HT for 
LIMK:ER induction was confirmed as 100nM from the experiments in part B of 
Figure 3.3.27, and the optimal time for induction was then ascertained by a time 
course experiment as reported in part C of Figure 3.3.27.  
Under the assay conditions tested, immunoprecipitated LIMK:ER exhibits no in 
vitro activity. This may be an insight into the requirements of full length LIMK 
activity in vivo, perhaps the added domains inhibit the activation of LIMK. The 
LIMK:ER may also have been activated but could then have been unable to 
phosphorylate Cofilin due to the additional EGFP and ER structures, interfering 
with substrate interaction. Since the activity of LIMK:ER could not be confirmed 
in vitro, and the ‘phenotypes’ of stably transfected cells were so subtle, the use 
of LIMK:ER to address the role of LIMK as a driver of cell invasion was 
abandoned.  
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Figure 3.3.26-LIMK:ER activity in vitro, optimisation of kinase assays  
Kinase assay buffer optimisation (as described in the methods); Phospho-imager imaged gels 
showing kinase assays performed to assess the ability of recombinant LIM Kinase to 
phosphorylated Cofilin in vitro using kinase buffer A. or the superior kinase buffer B which was 
optimised for kinase assays. Black bands indicate Cofilin phosphorylation, increased at lower 
concentrations of Cofilin following optimisation.   
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Figure 3.3.27- Identification of optimal dose and timeframe in which to assess LIMK:ER 
activity in cells. 
A. Western Blot of dose response to 4HT after 16hrs.30nM 4HT appears to be sufficient to 
increase pCofilin levels from background levels. B. IP Kinase assay corresponding to A. None of 
the doses tested increased LIMK:ER activity in the described IP kinase assay conditions. Lanes 1, 
2 and 3 correspond to kinase assay controls  A : LIMK1, B : LIMK1 +Cofilin1, C : Reaction mix 
(containing cofilin1). C. IP kinase assay at 100nM 4HT following different  exposures to 4HT. None 
of the lysates from the time-points tested at 100nM yielded a LIMK:ER capable of phosphorylating 
cofilin1 under these conditions. Controls in lanes 1-3 as with B., control D contains antibody and 
beads. N denotes lysates from cells containing no construct, L denotes LIMK:ER expressing cells.  
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3.2.8.3 Increased levels of cellular LIMK reduces cell invasion 
The generation of a LIMK:ER cell line was initially undertaken to address whether 
LIMK could also be a driver of invasion, but failed to yield a useful tool. Instead, 
LIMK was transiently transfected into cells to deduce whether either LIMK1 or 
LIMK2 (or both kinases) were drivers of invasion, and the inverse invasion (Figure 
3.3.12) was used to provide a 3D environment for cell invasion.  
Cells were co-transfected by nucleofection with GFP and a combination of empty 
vectors (control nucleofection), LIMK1 & empty vector, LIMK2 & empty vector, 
or both LIMK1 & LIMK2 cDNA. Transfection efficiency was deemed high by 
fluorescent microscopy of cells (>90% of cells were GFP positive) and the cells 
transferred to invasion assays. In comparison with control cells there was a 
decrease in invasion following up regulation of LIMK, LIMK2 or both kinases as 
seen when graphed in an accumulative manner in Figure 3.28 part A. This was 
consistent with a decrease in the percentage of cells invading over 45µm with 
increased LIMK1, LIMK2 or both LIMK1 and LIMK2 (Figure 3.28 part B). Cells were 
also more rounded in morphology following the increase in cellular LIMK1 or 
LIMK2 (Figure 3.28) which was similar to the morphology of cells following 
reduction of LIMK (Figure 3.3.17).  
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Figure 3.28-Increased levels of LIMK reduces 3D invasion of MDAMB231 cells. 
A. Cells Transfected with LIMK1, LIMK2 or both LIMK1&2 all displayed reduced invasion in 
comparison with cells transfected with a vector control. All plasmids were co-transfected with GFP 
as a transfection efficiency control by the method of ‘nucleofection’. B. % Invasion of cells over 
45um following nucleofection of LIMK is reduced by LIMK1 and LIMK2, as well as both in 
combination. C. Movie Showing 3D reconstruction of invading MDAMB231 cells following 
nucleofection.   
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3.3 Conclusions  
Both LIMK1 and LIMK1 have been shown in this chapter to be required for BE and 
BT549 cell motility in 2D. Neither LIMK1 nor LIMK2 was found to be required for 
2D motility of MDAMB231 cells. It could not be concluded from the assays used 
whether LIMK1 or LIMK is required for the 3D invasion in BE or BT549 cell lines as 
they did not successfully invade in the conditions tested. MDAMB231 cells, which 
invaded well into the trans-well inverse invasion assays, both LIMK1 and LIMK2 
were shown to be requirements of invasion. This effect was not found to be 
additive upon the reduction of both kinases protein levels by siRNA, but this may 
be because the effectiveness of the LIMK double knockdown by siRNA is at its 
maximum, perhaps only complete inhibition of LIMK activity by LIMK inhibitors 
would show a greater effect. It could also be that the double knockdown has 
reached the threshold of the effect of reducing LIMK levels, and that this is the 
maximal effect that will be seen by interfering with LIMK protein levels or 
activity.  
Reduction of either LIMK1 or LIMK2 levels lowered F-actin staining in BE, BT549 
and MDAMB231 in 2D, loss of both kinases caused a greater reduction of F-actin 
staining in all cell lines examined. In a 3D setting, the inhibition of LIMK by LIMKi 
reduced F-actin staining in a dose dependent manner. Reduced F-actin levels 
correlated with reduced invasive capacity in 3D for MDAMB231 which had lost 
peripheral spike-like actin structures in initial 2D formats, structures that may 
play a role in 3D invasion but, it would seem, not 2D motility. One possible 
explanation for the lack of effect of LIMK inhibition in 2D was that the two 
dimensional migration across a rigid substrate is principally propelled by actin 
polymerization and forward protrusion (DesMarais et al, 2002). Since Cofilin 
activation could result in F-actin severing and an increased number of barbed 
ends available to provide sites for monomer addition and filament extension, it 
is possible to hypothesise how this form of 2D motility could be insensitive to 
LIMK knockdown as the potential for leading edge protrusion would not be 
impaired. 
In the 3D invasion assays the majority of cells, control and knockdown, were 
able to move through the filter to the bottom of the matrigel through the 
127 
predefined ‘tracks’ (pores). The pores may have allowed MDAMB231 movement 
as the form of motility did not require proteolytic activity or force generation 
(Vignjevic & Montagnac, 2008). In contrast invasion, which requires both 
deformation and degradation of a substrate, was reduced by LIMK knockdown  
(the level of invasion from the filter up was dependent on LIMK status). Cells 
subject to LIMK knockdown lost ‘invasiveness’ but also lost the ability to make 
tracks through matrigel. Those cells that did manage to migrate a short distance 
into the matrix following LIMK knockdown displayed a more amoeboid 
morphology than the usual MDAMB231 mesenchymal invasive form.  
Given that LIMK is a requirement of invasion, it was hypothesised to be a driver 
of invasion. However, increasing levels of LIMK in MDAMB231 cells by transient 
transfection reduced invasion of cell into a 3D matrix. The work in this chapter 
suggests that perturbing the balance between active Cofilin (LIM Kinases primary 
substrate) and inactive Cofilin by increasing or decreasing LIMK levels is 
sufficient to interfere with cell motility. This compliments previous work 
describing motility defects upon Cofilin knockdown (Hotulainen et al, 2005; 
Sidani et al, 2007) and observations where over expression of Cofilin inhibited 
the invasion of human lung cancer cells (Lee et al, 2005) and the motility of 
glioblastoma cell lines(Yap et al, 2005). 
In conclusion, the data presented in this chapter suggests that LIMK is not 
necessarily a requirement for cell motility, but that it is a requirement for 
successful 3D cell invasion.  
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4 LIM Kinase regulation of invasion  
4.1 Chapter summary 
LIM kinases have previously been shown to be important in cancer cell motility 
and invasion (Yoshioka et al, 2003) and are implicated in increasing the invasive 
phenotype of cells(Bagheri-Yarmand et al, 2006; Davila et al, 2003). Results from 
Chapter 2 suggest that both LIM Kinase 1 and LIM Kinase 2 are important for 
invasion, and this correlates with a loss of F-actin staining following LIMK 
inhibition. The actin cytoskeleton is a crucial element in maintaining the 
invasive capability of cancer cells(Daisuke et al, 2005), and structures such as 
invadopodia have emerged as potential facilitators of invasion(Liu et al, 
2009).This chapter describes studies investigating the mechanism by which LIM 
Kinases influence 3D invasion via; invadopodia formation, extracellular matrix 
degradation and regulating the invasiveness of leading cells in collective forms 
of invasion. 
4.2 Results 
4.2.1 Knock down of LIM Kinase reduces functional invadopodia 
formation and gelatin degrading activity in MDAMB231 cells 
It was observed in Chapter 2 that the invasive cancer cell line MDAMB231 
exhibited a more rounded morphology in 2D following LIM Kinase knockdown, 
and similarly that BT549 cells showed a reduction in peripheral F-actin staining. 
Knocking down either LIM Kinase 1 or LIM Kinase 2 by siRNA also reduced F-actin 
staining in 3D invading cells, and this effect was enhanced by lowering activity 
of both kinases (either by siRNA or CRT101106 LIMK inhibitor). Invadopodia are 
actin rich peripheral structures associated with localised proteolytic activity that 
contribute to invasiveness in vitro (Coopman et al, 1998).To invade and 
metastasise through tissue, cancer cells must produce and secrete proteolytic 
enzymes to degrade extracellular matrix. The studies in this section try to 
address whether the cytoskeletal changes observed following LIM Kinase 
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knockdown during 3D invasion in the previous chapter affect the formation of 
invasive structures such as invadopodia, or reduction in proteolytic activity. 
To ascertain whether LIM Kinases play a role in invadopodia formation, gelatin 
degradation assays were performed. FITC-labelled gelatin was gluteraldehyde 
cross-linked on glass cover-slips to provide a malleable substrate for MDAMB231 
cells. Following a four hour time period to allow degradation, the cells were 
fixed and F-actin stained with Texas Red phalloidin to visualise F-actin. The 
assay measures the formation of invadopodia by visualising focalised degradation 
of matrix; confirmation that actin structures are involved can be seen in Figure 
4.4.1. In these two examples of MDAMB231 cells making invadopodia, red F-actin 
staining can be seen to protrude into the layer of green gelatin, both when 
viewed from below in the XY plane, or from the side in the XZ or YZ panels that 
cut through the cells. The outlines of the cells are seen as yellow when viewed 
from below due to the co-localisation of FITC gelatin and F-actin staining with 
Texas Red phalloidin. The invadopodia are visible in red where localised 
degradation of the gelatin matrix has occurred and there is, therefore, no co-
localisation with FITC gelatin. Not all cells plated had degraded matrix by the 
four hour end-point, only a proportion of the population appears to be making 
invadopodia at any given time (Figure 4.4.4). The previously observed effects 
that reducing LIM Kinase levels had on the actin cytoskeleton could have 
affected the ability of MDAMB231 to settle on to the gelatin substrate. Taking 
this into consideration, MDAMB231 cells were transfected with siRNA (against 
LIMK1, LIMK2, both LIMK1 and LIMK2 or non-targeting controls) 24 hours before 
being seeded on to gelatin cover-slips in the presence of GM6001 (matrix 
metalloproteinase inhibitor). The MMP inhibitor allowed the cells to settle onto 
the gelatin overnight so that when it was washed out of the media, matrix 
degradation was a reflection of invadopodia activity, not the cells ability to 
settle following loss of LIMK. The cells were left for four hours after GM6001 
washout before being fixed, stained for F-actin, and imaged using OpenLab 
software. Examples are shown in Figure 4.4.2; less degradation of the gelatin 
substrate appears to have taken place under cells subjected to either LIMK1 or 
LIMK2 siRNA in comparison with those treated with non-targeting siRNA. 
Knocking down both LIMK1 and LIMK2 by siRNA reduced the level of gelatin 
degradation but this did not appear to have an additive effect. Reducing levels 
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of either LIMK1 or LIMK2 was sufficient to reduce gelatin degradation by 
MDAMB231 cells. Similarly, when CRT101106 was used to inhibit LIMK activity in 
MDAMB231, reduced gelatin degradation was observed at all doses (3 µM, 10 µM 
and 20 µM). 3µM was sufficient to reduce invadopodia formation and gelatin 
degradation, increasing the dose of inhibitor did not seem to increase the 
inhibitory effect (Figure 4.4.3). The observed effects of knocking down or 
inhibiting LIM Kinases were quantified using images of gelatin degradation such 
as the examples in Figure 4.4.2 and Figure 4.4.3. Images were analysed using 
ImageJ software to calculate the area of degradation per cell. The program 
firstly uploads F-actin images of cells, to determine each cells area, and then 
the corresponding images of gelatin degradation to work out the area of 
degradation under each cell (Figure 4.4.5). Knockdown of LIMK1, LIMK2 or both 
LIMK1&2 by siRNA reduced the area degraded per cell in comparison with cells 
transfected with non-targeting control siRNA (Figure 4.4.6 A), as does inhibition 
of LIMK by CRT101106 (LIMKi) at 3µM, 10µM or 20µM in comparison with DMSO 
control treated cells (Figure 4.4.6 B.). 
These results suggest that the changes in F-actin staining observed following LIM 
Kinase knockdown in the previous chapter led to a corresponding loss of F-actin 
rich invadopodia structures, which are important for invasion and proteolysis of 
extracellular matrix during invasion. The matrix metalloproteinases responsible 
for gelatin (denatured collagen) degradation are the collagenases MMP2, MMP9 
and membrane bound MT1-MMP (Stylli et al, 2008). It was hypothesised that the 
loss of gelatin degradation observed in this chapter following a reduction in LIM 
Kinase protein levels could relate to either a reduction in MMP2, MMP9 or MT1-
MMP activation and/or MMP2 and MMP9 secretion by cells. 
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Figure 4.4.1-F-actin rich invadopodia of MDAMB231 degrade FITC labelled gelatin matrices. 
MDAMB231 cells stained with Texas Red Phalloidin for F-actin degrading FITC gelatin matrices. 
MDAMB231 cells form F-actin rich invadopodia (stained with Texas red phalloidin) that protrude 
into the fluorescent gelatin (FITC) substrate (dissected here by the yellow gridlines). A dark cavity 
of degraded gelatin surrounds each F-actin rich invadopodia, (visualised by a lack of yellow co-
localisation) in the red regions protruding into the FITC gelatin. Images taken in 2µm Z sections on 
an Olympus FV1000 confocal microscope using a x60 oil objective and reconstructed in 3D using 
Volocity imaging software. 
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Figure 4.4.2-Knock-down of LIM Kinase 1 and 2 by siRNA reduces invadopodia formation.  
Gelatin degradation assay showing MDAMB231 degradation of FITC gelatin following knockdown 
of LIMK1, LIMK2 or both LIMK1 & LIMK2 in combination by siRNA. Left panel shows Texas-Red 
phalloidin staining of F-actin in each condition, punctate F-actin staining in control cells (treated 
with Non-Targeting control siRNA (NT)) correlates with gelatin degradation, imaged here as dark 
cavities in the gelatin surface. Actin staining after siLIMK1 or siLIMK2 still shows punctate staining 
but does not correspond with gelatin degradation (right panel).F-actin staining following siLIMK1&2 
is weaker and less defined than control cells and corresponds with a lack of gelatin degradation. 
Images were taken using OpenLab software on a Zeiss Axioskop2 microscope fitted with a 
Hamamatsu black and white camera. 
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Figure 4.4.3-Inhibition of LIMK1 and 2 by CRT101106 reduces invadopodia formation. 
Gelatin degradation assay showing MDAMB231 degradation of FITC gelatin following inhibition of 
LIM Kinases by CRT101106 at 3µM and 10µM. Invadopodia formation is reduced in cells exposed 
to all doses of CRT101106 but not in control cells exposed only to DMSO. The cells exposed to 
CRT101106 have reduced overall F-actin staining and fine punctate staining associated with 
invadopodia, but an increase in larger punctate structures. Images were taken using OpenLab 
software on a Zeiss Axioskop2 microscope fitted with a Hamamatsu black and white camera.  
134 
0
5
10
15
20
25
30
35
40
45
50
NT
 C
on
tro
l
siL
IM
K1
 #1
siL
IM
K1
 #3
siL
IM
K2
 #6
siL
IM
K2
 #7
siL
IM
K1
&2
 #1
&6
siL
IM
K1
&2
 #3
&7
%
 C
el
ls
 D
eg
ra
di
ng
 F
IT
C
 G
el
at
in
 M
at
rix
A.
B.
0
5
10
15
20
25
30
35
40
45
50
DMSO
Control
3µM 10µM 20µM
%
 C
el
ls
 D
eg
ra
di
ng
 F
IT
C
 G
el
at
in
 M
at
rix
 
Figure 4.4.4-Inhibition of LIMK reduces the percentage of cells making invadopodia. 
A. Graph of the percentage of cells degrading FITC gelatin in degradation assays following 
knockdown of LIMK1, LIMK2 or both LIM Kinases. Knockdown reduces the proportion of cells 
making invadopodia in a 4 hour time frame. B. Graph of the percentage of cells degrading FITC 
gelatin in degradation assays following CRT101106 LIMK inhibition at 3µM, 10 µM and 20µM. 
Inhibition of LIMK reduces the proportion of cells making invadopodia in a 4 hour time frame at all 
doses, and to a greater degree than siRNA against LIMK. 
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Figure 4.4.5-ImageJ method for analysis of invadopodia. 
F-actin Images of cells plated on FITC Gelatin (A.) and the corresponding images of FITC Gelatin 
(B.) where the arrow indicates thearea of degredation. The area of each cells is calculated using 
the peripheral F-actin staining (C.) and this area overlaid with the gelatin image (D.) to determine 
the area in which to convert the image to binary and quantify pixels corresponding to gelatin 
degradation (E.). . Images were taken using OpenLab software on a Zeiss Axioskop2 microscope 
fitted with a Hamamatsu black and white camera. The area degraded under this example 
MDAMB231 cell was 151 pixels, as calculated using ImageJ software and a software ‘plug in’ 
kindly provided by L.Machesky.  
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Figure 4.4.6-Quantification of gelatin degradation following LIM Kinase inhibition by 
CRT101106 or knockdown by siRNA. 
A. Graph of the area of gelatin degraded per cell following FITC gelatin degradation assays is 
reduced by knockdown of LIMK1, LIMK2 or both LIM Kinases. B. The area of gelatin degraded per 
cell following FITC gelatin degradation assays is reduced by CRT101106 LIMK inhibition at 3µM, 
10 µM and 20µM. 
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4.2.2 Knockdown of LIMK reduces levels of secreted active MMP9 
Invadopodia are organised actin rich membrane protrusions with localised 
proteolytic enzyme activity, the formation of which have recently shown to be 
regulated by Cortactin (Amanda Gatesman & Scott, 2008). Cortactin has been 
shown to regulate invadopodia assembly by binding and inhibiting Cofilin actin 
severing. Phosphorylation of Cortactin releases Cofilin from this inhibition and 
this cycle of Cofilin inhibition and release is proposed to regulate invadopodia 
formation by exerting control over rates of actin severing (Oser et al, 2009). 
LIMK is also a negative regulator of Cofilin, and as such could play a similar role 
in the development of invadopodia by influencing the level of barbed ends 
available for polymerisation. Recent work using live cell imaging has identified 4 
phases of invadopodia formation: (i) localisation of cortactin to ventral puncta, 
(ii) recruitment of membrane bound MMPs to these sites (such as MT1-MMP), (iii) 
the appearance of degraded foci in matrix, and (iv) the dissociation of cortactin 
from the site of degradation (Artym et al, 2006; Stylli et al, 2008). Cortactin 
binds Cofilin and stops it from severing F-actin, stabilising invadopodia. 
Therefore, if LIMK regulates invadopodia formation in the same manner, by 
regulating Cofilin activity, LIMK inhibition would destabilise invadopodia and 
prevent the recruitment of MMPs. Studies have shown that MT1-MMP is the key 
metalloprotease for matrix degradation in MDAMB231 (Kelly et al, 1998) and that 
the ability of MDAMB31 cells to invade matrigel was impaired by MMP inhibitor 
Ilomastat (Canning et al, 2001). Gelatin degradation assays give an indication of 
the activity of the collagenases MMP2, MMP9 and the membrane bound MT1-
MMP, but perhaps the loss of punctate gelatin degradation observed following 
LIMK inhibition is due to a reduction in cortical actin structures required to 
deliver membrane bound MMPs such as MT1-MMP to the site of invadopodia 
formation. MMP activity across the whole cell may not be reduced following LIMK 
siRNA, perhaps it reduced the focalisation of proteolytic activity. 
To ascertain if the loss of invadopodia activity seen in MDAMB231 cells following 
LIMK inhibition related to a loss of total MMP2 or MMP9 activity, a zymography 
approach was taken. Zymogram gels were used to analyse MMP activity in 
concentrated conditioned media following LIMK knockdown or inhibition. 24 
hours following transfection of MDAMB231 with siRNA against the LIM Kinases, 
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fresh media (DMEM 10% FCS) was added to each well of cells and ‘conditioned’ 
for 24 hours (allowing cells to secrete MMPs into the media). The media was then 
collected, concentrated by centrifugation and denatured in SDS buffer using a 
non-reducing buffer. Samples were electrophoresed on gelatin zymogram gels 
(10% Tris-Glycine gel with 0.1% gelatin incorporated as a substrate), the gels re-
natured in a zymogram renaturing buffer (containing a non-ionic detergent) and 
equilibrated in a developing buffer (to add Zn2+ required for enzymatic activity). 
Zymogram gels were stained (as described) to reveal protease activity as clear 
bands against a dark blue background. Knock-down of LIMK1 or LIMK2 reduced 
extracellular MMP9 activity and thus the intensity of the corresponding white 
bands seen in Figure 4.4.7. Knock-down of both Lim Kinases in combination 
enhanced this effect on MMP9 activity in an additive manner. No detectable 
MMP2 activity was observed in the conditioned media of MDAMB231, nor were 
there any discernable pro-MMP bands visible on the zymogram. Previous work 
using MDAMB231 cells to look at metalloprotease activity have found that MMP2 
activity was higher than MMP9 (Kim et al, 2008), however other earlier work 
with this cell line was unable to detect  MMP2 activity in comparison with MMP9 
(Antonietta et al, 1998). This suggests that MMP2 levels vary between clones, 
and could explain the absence of MMP2 activity on these zymograms.  
 
4.2.3 Knockdown of LIMK has no effect on MMP9 transcription 
QPCR was performed to determine the whether knockdown of LIMK was causing 
a reduction in MMP activity by reducing transcription. Cellular levels of RNA 
following knockdown of LIMK1, LIMK2 or both in combination were compared to 
control transfections in MDAMB231, (using the housekeeping gene 18S as a 
reference). LIMK1 RNA levels were reduced following knockdown of LIMK1 or in 
combination with LIMK2 as a double knockdown (Figure 4.4.8part A.). LIMK2 RNA 
levels were reduced following knockdown of LIMK2 or in combination with LIMK1 
in a double knockdown (Figure 4.4.8part B.). There was a slight trend towards a 
reduction in MMP14 RNA levels following LIMK1, LIMK2 or LIMK1&2 knockdown 
(Figure 4.4.8 part C.) but there was no discernible effect on MMP9 RNA levels 
(Figure 4.4.8 part D.). 
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Figure 4.4.7-Knockdown of LIM Kinases reduces MMP9 activity in MDAMB231 
A. Gelatin Zymogram gel, white bands indicate areas of matrix metalloproteinase activity. Control 
cells (treated with Non-targeting siRNA) degrade the gelatin laced gel in a band the correct size to 
indicate MMP9 activity. LIMK1 or 2 knock-down by siRNA results in reduced MMP9 activity, further 
reduced by knockdown of both LIMK1 and LIMK2 in combination. Media alone (DMEM 10% FCS) 
has very low levels of MMP9 activity, this activity can be accounted for by the serum supplementing 
the media. Gel was imaged using a Syngene imaging system. B. Western Blot of whole cell lysates 
confirming knockdown of LIMK1, LIMK2 and both LIMK1&2. Knockdown of LIMK1 or LIMK2  
reduces both total cofilin and pcofilin levels but has no effect on MMP14 or MMP9 protein levels. 
Knockdown of both LIMK1 and LIMK2 further reduces pcofilin levels, does not effect MMP14 levels 
but may have a slight effect on total MMP9 levels. Irrelevant bands have been excised for 
illustrative purposes.  
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Figure 4.4.8-Effects of LIM Kinase Knockdown on MMP RNA levels 
QPCR to determine cellular levels of RNA following knockdown of LIMK1, LIMK2 or both in 
combination compared to control transfections in MDAMB231, (referencing gene 18S). A. LIMK1 
RNA levels are reduced following knockdown with siLIMK1 number 3 (1.3) or when siLIMK1 
number 3 (1.3)  is used in combination with siLIMK2 number 7 (1.3&3.7). B. LIMK2 RNA levels are 
reduced following knockdown with siLIMK2 number 7 (2.7) or when siLIMK2 number 7 (2.7) is used 
in combination with siLIMK1 number 3 (1.3&3.7). C. There is a slight trend towards a reduction in 
MMP14 RNA levels following LIMK1, LIMK2 or LIMK1&2 knockdown. D. Knockdown of LIMK1, 
LIMK2 or both incombination has no discernible effect on MMP9 RNA levels. 
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4.2.4 LIMK is required for optimal collagenase activity in 3D 
Having seen a reduction of MMP9 activity in the conditioned media of cells with 
reduced LIMK levels cultured in 2D, the next step was to identify if this 2D effect 
was also relevant to 3D invasion. To visualise collagenase activity in 3D, matrigel 
plugs (set up in invasion assay trans-wells as previously described) were spiked 
with DQ collagen. DQ collagen fluoresces upon degradation, and can be used to 
qualitatively identify areas of activity or degradation by cells. Supplied by 
Invitrogen, it is described as ‘analogs of the natural substrate that have an 
excessive number of fluorescent dyes attatched’. Their close proximity on the 
intact substrate causes the signal to be quenched and fluorescence to be 
reduced to almost nothing, hydrolysis by MMPs causes separation of the dye 
molecules and thus an increase in fluorescence 
(http://products.invitrogen.com/ivgn/en/US/adirect/invitrogen?cmd=catProduc
tDetail&entryPoint=adirect&productID=D12060&messageType=catProductDetail). 
By adding it to the matrigel matrix, MMP activity can be visualised in 3D. 
Following LIMK1&2 knockdown or transfection with non targeting controls, 
MDAMB231 RFP cells (stably transfected with membrane bound RFP) were 
allowed to invade DQ collagen spiked matrigel for 5 days (Figure 4.4.9) Control 
cells invaded into the matrix, tracking after each other and displaying ‘halos’ of 
green fluorescence, reflecting collagenase activity (Figure 4.4.9 part A.). Cells 
that invaded following knockdown of both LIMK1&2 were more rounded in 
morphology, as described in the previous chapter, and displayed reduced 
collagenases activity (Figure 4.4.9 B.). MMP activity was not completely ablated, 
consistent with the low level invasion that was observed following LIMK 
knockdown and the reduced levels of MMP9 activity observed by zymography.  
This data is consistent with previous studies on MMP activity and invasion. It has 
previously been shown that siRNA treatment of MDAMB231 for MT1-MMP reduces 
hypoxia induced invasion (Munoz-Najar et al, 2005), and MT1-MMP (also known as 
MMP14) has been shown to be important in cell invasion through marix (Sabeh et 
al, 2004) and the pathway leading to activation of MMP9 in chondrocytes (Dreier 
et al, 2004). A link could be hypothesised between LIMK activity and MMP14 
activation of MMP9.  
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Figure 4.4.9-Knockdown of LIMK reduces Collagenase activity in 3D 
MDAMB231 cells invading into a matrigel and collagen matrix, DQ collagen fluoresces (green) 
upon degradation. A. MDAMB231 cells stably transfected with membrane bound RFP invading into 
a DQ collagen/matrigel matrix following transfection with a non targeting siRNA. The green halo 
around each red cell indicates collagenase activity (MMP2 or MMP9). B. MDAMB231 cells stably 
transfected with membrane bound RFP invading into a DQ collagen/matrigel matrix following 
knockdown of LIMK1&2 by siRNA. The faint green halo around each red cell indicates less 
collagenase activity than control cells in B.  
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4.2.5 LIMK is important in cells ‘leading’ invasion 
MMP activity has been reported to be important in the collective invasion of cells 
(Friedl & Wolf, 2008; Wolf et al, 2007) and the invasion of MDA MB 231 cells into 
3-D matrigel appeared to be via collective tube-like strands, as could be seen in 
the previous chapter and as reported by Wolf et al (Wolf et al, 2007). Since 
MDAMB231 cells are capable of providing the path generating activity required in 
leading cells during collective invasion, MDAMB231 cell lines stably expressing 
either membrane bound either green or red fluorescent proteins (GFP or RFP) 
were generated by drug selection, and further mechanically sorted for the 
greatest RFP and GFP expression. While GFP expressing cells were untreated, 
RFP expressing cells were transfected either with NT or LIMK1&2 siRNA. 
Consistent with earlier results presented in this thesis, NT siRNA did not affect 
matrigel invasion and RFP and GFP cells invaded in strands together(Figure 
4.4.10 part A and Figure 4.4.11 part A) and the occurrence of RFP-expressing 
cells leading the collective strands was approximately 50% (Figure 4.4.11 part 
C). As could be predicted from the previous chapter LIMK1&2 siRNA treatment of 
only the RFP expressing cells slightly reduced over all invasion (Figure 4.4.10 
part B), and there were fewer RFP cells invading into the matrigel, and the RFP-
expressing cells observed were largely restricted to following GFP-positive cells 
(Figure 4.4.11 part B). The occurrence of RFP-expressers as leading cells of 
invasion dropped significantly to 18%. These results indicate that LIMK activity is 
required for path generation by the leading cells in collective invasion. 
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Figure 4.4.10-Cells leading collective invasion require LIMK 
A.MDAMB231 cells stably expressing either RFP or GFP when mixed together in a 1:1 ratio 
invade matrigel collectively. Both red and green cells lead this invasion. B. RFP cells 
following siRNA against LIMK1 and 2 do not invade as successfully as controls, and appear 
to ‘lead’ invasion less. Images were acquired on an Olympus FV1000 using a x40 water lens, 
z-stacks were used to reconstruct 3D invasion on Volocity imaging software.  
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Figure 4.4.11-Loss of leading ‘tip’ position during invasion by cells following LIMK 
knockdown. 
Optical slices through z stacks show MDAMB231 cells stably expressing either RFP or GFP mixed 
together in a 1:1 ratio invading matrigel collectively. A.Both red and green cells lead this invasion 
when red cells are transfected with non targeting siRNA oligonucleotides. B. RFP cells following 
siRNA against LIMK1 and 2 shows although some red cells still invade following knockdown of 
LIMK1 and 2 they tend to ‘follow’ more invasive green cells. C.Quantification of the proportion of 
RFP MDAMB231 cells to GFP MDAMB231 cells leading invasion as a ‘tip’ cell following invasion 
into matrigel (cells were mixed 1:1). Following knockdown of LIMK in RFP MDAMB231 the 
proportion of GFP MDAMB231leading ‘tip’ cells increases. Images were acquired on an Olympus 
FV1000 using a x40 water lens, z-stacks were used to reconstruct 3D invasion on Volocity imaging 
software. 
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4.3 Conclusion 
Both LIMK1 and LIMK2 have been shown to play a role in the formation of 
functional invadopodia in gelatin degradation assays. Loss of LIMK by siRNA was 
shown in Chapter 2 to reduce F-actin staining, correlating with a loss of 
invadopodia in this chapter and a reduction of MMP activity. Gelatin zymography 
confirmed that reducing LIMK levels reduced levels of active MMP9 being 
secreted by cells, which could in turn play a role in the loss of 3D invasion 
observed in Chapter 2. Collagenase activity in 3D invasion was reduced following 
knockdown of both LIM Kinases and this could be important in the role LIMK plays 
in cells leading invasion. The proportion of RFP MDAMB231 cells to GFP 
MDAMB231 cells leading invasion as a ‘tip’ cell is relatively equal when mixed 1:1 
and allowed to invade into matrigel. Following knockdown of both LIM Kinase 1 
and LIM Kinase 2 in RFP MDAMB231 cells this changes and the majority of leading 
‘tip’ cells are GFP MDAMB231. However, the RFP cells that have been subject to 
knockdown of both LIMK1&2 still follow GFP cells into the matrigel, the cells 
that have full proteolytic activity. The ‘following’ cells are still motile, and 
could have adapted to a more amoeboid form of motility to follow the leading 
cells that degrade the substrate to facilitate motility (Friedl & Wolf, 2003; 
Wyckoff et al, 2006). This is somewhat similar to previous observations in the 
preceding chapter where MDAMB231 invasion into matrigel was reduced by siRNA 
knockdown of LIMK, but that the cells could still move through the filter with its 
preformed holes.    
In conclusion, the data presented in this chapter suggests a role for LIMK 
regulated matrix degradation in cells leading collective forms of invasion, but 
that LIMK does not play a role in the capability of cells to follow ‘leading’ cells 
with a more invasive phenotype.  
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5 Cofilin phosphorylation and invasion 
5.1 Chapter Summary 
Cofilin is the most well documented and characterised LIMK substrate. Its 
activity is believed to relate inversely to that of LIMK as it is the primary 
substrate and downstream effector of LIM Kinase; Cofilin is rendered inactive by 
LIMK phosphorylation on Serine 3. It can bind to both F-actin filaments and G-
actin monomers, severing F-actin filaments as part of a cycle of polymerisation 
and depolymerisation(Hawkins et al, 1993). Previous work has implicated Cofilin 
as an important regulator of migratory behaviour in metastatic cancer cells 
(Sidani et al, 2007), and work presented in previous chapters of this thesis has 
outlined the link between a loss of filamentous actin levels and a loss of 
invasiveness in cancer cells. As these previous observations were made to 
identify the role LIMK plays in invasion, the work completed in this chapter 
aimed to elucidate if the phosphorylation status of the LIM Kinase substrate was 
enough to affect cell invasion. 
An optimised protein transduction domain (PTD) derived from HIV TAT 
(transactivator of transcription) protein amino acids 47–57 was used in the 
generation of a membrane permeable PTD Cofilin, a phosphomimetic mutant 
Cofilin and a non-phosphorylatable Cofilin mutant. These were then used to 
examine the effects of cofilin phosphorylation on cancer cell motility and 
invasion. 
5.1.1 PTD Flag Cofilin1 
TAT fusion proteins have been used previously to give quick high efficiency 
transduction of proteins and peptides into cells without need for transfection 
(Ho et al, 2001; Sahai et al, 2006). An optimized protein transduction domain 
based on the HIV TAT protein (Ho et al, 2001) was fused to Cofilin1 to promote 
cellular uptake. The version of optimised TAT protein used was PTD4 
(YARAAARQARA , optimised Protein Transduction Domain 4, as described in 
reference(Ho et al, 2001)), found to be 33 times more effective at cell 
transduction than wild type TAT due to additional strengthening of the putative 
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α-helix with Alanine residues and limiting the Arginine content to three residues 
down one face of the helix (Figure 5.5.1 part A and B.). The fusion constructs 
made included a PTD wild type Cofilin, a phospho-mimetic mutant 
(constitutively inactive S3E mutant), and a non phosphorylatable mutant 
(constitutively active S3A mutant) as well as PTD GST as a control for protein 
transduction (Figure 5.5.1part C.). 
5.1.1.1 Generation of PTD Flag Cofilin 
PTD FLAG Cofilin1 was generated by the annealing of double standed 
oligonucleotides coding for the PTD peptide (YARAAARQARA) and FLAG epitope, 
and subsequent ligation into pGEX KG Cofilin plasmid. The mutants were 
subsequently produced by site directed mutagenisis. The Cofilin proteins were 
expressed in E.coli and purified as described, cleaving fused GST in all but the 
control protein for final products as outlined in Figure 5.5.1 part C. The PTD 
cofilin proteins routinely expressed and purified well, as can be seen by an 
example gel run during protein production in Figure 5.5.2 part A. At high 
concentrations PTD Cofilin had fewer contaminants than commercially sourced 
BSA. The PTD proteins were added directly to media on cells and entered cells in 
a dose dependent manner; as can be seen in the example western blot of Figure 
5.5.2 part B. showing PTD Cofilin1 WT entering NIH3T3 cells at doses ranging 
from 0-800µg per ml media. Endogenous cofilin levels were unchanged by the 
addition of PTD Cofilin. The PTD proteins enable direct entry of Cofilin into the 
cell, without the need for transfection or the constraints of expressing an 
already abundant protein.  
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Figure 5.5.1-PTD, an optimised TAT protein. 
A. Predicted α-helical wheels of TAT and the optimised PTD number 4 (single-letter amino acid 
code) (Ho et al, 2001). Note the reduction of Arginine residues in PTD4, the optimised TAT protein. 
Numbering refers to sequential amino acid position; the values in parentheses refer to the fold 
change of FITC emission normalized to TAT peptide (1x) (as expanded in part B.). B. 
Characterization of PTD-FITC peptides in vitro (Ho et al, 2001). Flow cytometry comparison of 
untreated and treated Jurkat T cells with equal molar amounts of control FITC and TAT, and PTD-
3, PTD-4, and PTD-5 peptides. Normalized fluorescent values are to that of TAT peptide (1x; right). 
C. Diagramatic illustration of the PTD fused proteins generated. From top to bottom; PTD FLAG 
Cofilin1 WT, PTD FLAG Cofilin1 S3A (non-phosphorylatable), PTD FLAG Cofilin1 S3E phospho-
mimetic and GST construct control. A. and B. Adapted from Ho, A. et al. Cancer Res 2001;61:474-
477, Copyright ©2001 American Association for Cancer Research. 
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Figure 5.5.2-PTD Cofilin purification and cell permeability. 
PTD proteins were expressed in bacteria and purified before tbeing added to cells in media. A. An 
example of a SafeStain stained acrylamide gel showing high purity during the production of PTD 
Cofilin proteins. Left hand lanes show BSA protein and right hand lanes show PTD Cofilin1 at 
comparable concentrations. B. Western Blot of whole cell lystates following 24 hour treatment with 
PTD Cofilin1 WT. PTD Cofilin1 WT entered NIH3T3 cells in a dose dependent manner, with no 
discernable effect on endogenous Cofilin levels. 
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5.1.1.2 2D localisation of PTD cofilin in cells 
Loading cells with PTD FLAG Cofilin should counteract the effect of LIM Kinase 
by shifting the Cofilin:pCofilin balance with the active non phosphorylated form 
of Cofilin. By flooding cells with WT Cofilin1 we would expect to see a reduction 
in F-actin staining for structures such as stress fibres. MDAMB231 cells were 
seeded onto coverslips and cutured in media containing PTD Cofilin proteins at 
800µg per ml. 24 hours later the MDAMB231 cells were fixed and stained for F-
actin; to establish if any cytoskeletal changes had occurred following an excess 
of unphosphorylated cellular Cofilin, and FLAG antibody; to identify cells 
successfully transduced with PTD FLAG Cofilin protein or PTD FLAG GST control 
(Figure 5.5.3). All PTD Cofilin proteins and GST control were successfully 
delivered into cells, and were distributed in a diffuse manner as determined by 
immunofluorescence using a FLAG antibody. PTD FLAG Cofilin also showed some 
localisation with cortical F-actin staining. Cells exposed to the S3E Cofilin 
mutant appeared slightly more spread than control cells, S3A Cofilin and WT 
Cofilin treated cells appeared fractionally more rounded or ruffled than 
controls. To validate if the subtle morphological changes observed in cell shape 
were due to the activity of these PTD Cofilin fusion proteins an in vitro line of 
investigation was used. 
 
5.1.2 In Vitro activity of PTD Cofilins 
Pyrene fluorescence increases 10-20 fold when G-actin is incorporated into 
filaments and the converse of this can be utilised to quantify F-actin 
depolymerisation by steady state fluorescence (Cooper JA, 1983). The F-actin 
severing activities (Hawkins et al, 1993) of PTD Cofilin WT, S3E, S3A and PTD 
GST were validated in vitro using this pyrene labelled F-actin severing assay. 
Pyrene labelled F-actin was added to a cuvette (with or without the PTD FLAG 
WT Cofilin) and steady state fluorescence measured on a spectrofluorimeter as 
described in the methods chapter. Data gathered was normalised and reported 
as a percentage of fluorescence over time (Figure 5.5.4). F-actin 
depolymerisation, described here as the reduction in Pyrene fluorescence was 
reduced by less than 10% after 900 seconds for polymerisised Pyrene F-actin 
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alone and after the addition of PTD GST control, PTD FLAG S3E Cofilin or PTD 
FLAG S3A Cofilin. PTD WT Cofilin (WT) depolymerised Pyrene F-actin by almost 
75% over the 900 second time-course. Despite the subtle morphological changes 
seen, although the PTD FLAG Cofilin WT had actin severing activity and the 
controls reassuringly had no activity, PTD FLAG Cofilin S3A also did not have 
actin severing activity. This makes it difficult to interpret whether the 
phosphomimetic mutant, PTD FLAG Cofilin S3E, which was not expected to show 
activity in vitro (the glutamate (E) negative charge mimics the negative charge 
of phosphate to render the protein inactive) did not have activity because the 
mutation makes the protein misfold rather than altering the serine 3 
phosphorylation site. With this in mind, knowing that only the activity of the WT 
protein can be validated in vitro, the influence of Cofilin levels on motility in 2D 
was assessed simply using the WT protein.  
5.1.3 Increased levels of Wild Type Cofilin do not affect cell 
motility in 2D 
In order to assess if perturbing the ratio of phosphorylated to non-
phosphorylated Cofilin had an effect on cell motility MDAMB231 cells were 
plated onto CDM (generated as previously described) and dosed with either PTD 
GST control protein, or equivalent levels of PTD FLAG Cofilin WT. Since PTD 
FLAG Cofilin S3E could not be validated it was not used in investigations into 
motility. Cells were then imaged every 15 minutes by timelapse microscopy for a 
period of 12 hours, and the images analysed using ImageJ software to trace 
individual cell tracks. Following the introduction of equivalent amounts of PTD 
GST or PTD FLAG Cofilin to MDAMB231 initial observations suggested a subtle 
difference in cell motility between conditions (Figure 5.5.5); cells appeared to 
turn less frequently following an increase of cellular Cofilin, but the 3% increase 
in persistence from 0.18 to 0.21 was not statistically significant.  
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Figure 5.5.3-Localisation of PTD FLAG Cofilin in MDAMB231 cells. 
All PTD FLAG Cofilin proteins and control PTD FLAG GST successfully entered MDAMB231 cells, 
with 100% efficiency. The localisation of the PTD proteins was determined using an anti-FLAG 
antibody, and the cells stained with Texas Red phalloidin to visualise F-actin. All PTD proteins were 
distributed diffusely through out the cells, except PTD FLAG Cofilin WT which also had strong 
peripheral staining, colocalising with cortical actin. Images were captured. Images captured on the 
Zeiss Axioplan 200 at x40 using Imaging Associates Isis software. Scale bar equals 40µm. 
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Figure 5.5.4-In Vitro F-actin severing activity of PTD Cofilin 
The F-actin severing activity of PTD Cofilin was validated in vitro. F-actin severing is quantified as 
percentage reduction in Pyrene Fluorescence over time. F-actin depolymerisation (fluorescence 
reduction) was <10% after 900 seconds for control PTD GST (PTD), PTD S3E Cofilin (S3E), PTD 
S3A Cofilin (S3A) and Polymerisised Pyrene Actin alone (Actin) conditions. PTD WT Cofilin (WT) 
depolymerised Pyrene F-actin by up to 75% over time. Data shown from a representative 
experiment. 
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Figure 5.5.5-Motility in 2D following an increase in cellular levels of Cofilin. 
Following the introduction of equivalent amounts of PTD GST or PTD FLAG Cofilin to MDAMB231 
individual tracks were traced. A. Individual cell tracks of cells moving across CDM following 
exposure to PTD GST. B. Individual cell tracks of cells moving across CDM following exposure to 
PTD FLAG Cofilin WT. A subtle increase in persistence was noted between the twoconditions, this 
trend may reflect a reduction in turning frequency by cells. Example tracks shown are 
representative of replicate experiments and were analysed using ImageJ imaging software. 
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Figure 5.5.6- Quantification of motility in 2D following an increase in cellular levels of Cofilin 
Following the introduction of equivalent amounts of PTD GST or PTD FLAG Cofilin to MDAMB231 
the effects on cell motility across CDM was quantified. A. The Accumulative distance (Vectorial 
distance) travelled by cells was slightly reduced following an increase in cellular Cofilin, but this 
was not deemed statistically significant (as determined by ANOVA). B.The Euclidean distance 
travelled by cells following a cellular increase in Cofilin levels was not altered in a statistically 
significant manner (as determined by ANOVA). C. The mean velocity of cells was reduced slightly 
following exposure to high levels of cellular Cofilin, but this was also deemed statistically 
insignificant by ANOVA.  
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5.1.4 3D Invasiveness is altered by disruption of the Cofilin 
phosphorylation balance 
In Chapter 3 it was shown that LIMK knockdown reduced the relative proportion 
of phosphorylated to unphosphorylated Cofilin and reduced cell invasion. To 
determine if introducing an excess of unphosphorylated Cofilin into cells would 
affect invasion, a return was made to 3D inverse invasion assays. 
Following the introduction of equivalent amounts of PTD GST or PTD FLAG Cofilin 
WT, a statistically significant effect of PTD FLAG Cofilin WT on inhibiting 
matrigel invasion was observed. There was a significant reduction of invasion in 
cells treated with wild type PTD Cofilin compared to the PTD GST control 
treated cells (Figure 5.5.4).  
These results demonstrate that disruption of the active to inactive balance of 
Cofilin is enough to perturb actin regulation, and thus invasion. 
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Figure 5.5.7-Disruption of the Cofilin balance reduces cell invasion. 
Following the introduction of equivalent amounts of PTD GST or PTD FLAG WT Cofilin, to 
MDAMB231 cells and the corresponding matrigel invasion plugs, cells were given 5 days for 
invasion, then fixed and stained for imaging, (part A). B.Quantification of invasion images is 
graphed showing a significant reduction in invasion of cells subject to increased levels of PTD 
FLAG Cofilin WT compared to PTD GST control treated cells. Invasion was imaged on an FV1000 
Olympus Confocal at x40 water lens using FV10-ASW.1.7b software. P <0.001 as determined by 
Students t-test. 
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5.2 Conclusions  
Data from the previous chapters suggested that the phosphorylation status of 
Cofilin was important in invasion as inhibiting LIMK reduced MDAMB231 invasion 
of matrigel. This inhibition also led to a reduction in phospho-Cofilin levels, as 
demonstrated previously by western blot following knockdown of LIMK by siRNA. 
It was also found in those chapters that knockdown of LIM Kinases did not have a 
significant effect on 2D cell motility. This chapter aimed to determine if these 
effects were mediated by Cofilin, and if Cofilin phosphorylation status was 
important for cell motility or invasion. 2D motility was not significantly affected 
by increasing levels of unphosphorylated (active) Cofilin into cells; 3D invasion 
was, however, significantly reduced by increasing the levels of unphosphorylated 
cellular Cofilin. Data from WT PTD Cofilin indicates that Cofilin phosphorylation 
status is important in invasion, but no conclusions could be drawn from the 
generated mutants. Although specific amino acid substitution should allow 
correct protein folding, and provide the desired change to mimic or prevent 
phosphorylation, it is not a foolproof system. The mutant Cofilin proteins may 
have been misfolded and therefore not had the expected activity.  
Although the transduction method of PTD proteins is advantageous as it reduces 
the time taken to ‘transfect’ cells, allowing rapid analysis of the effect of 
increasing Cofilin levels the system still relies upon a tagged protein. Tagged 
proteins are ‘carrying’ extra protein and are not the same as endogenous, 
potentially interfering with the activity of the tagged protein. In many studies 
PTD-based delivery of fusion proteins results in nuclear targeting but the use of 
PTD4 in my studies results in cytoplasmic localisation {Chauhan, 2007 #217}. It 
would be good to do this work with an untagged protein to compare the cellular 
effects of Cofilin on F-actin structures aswell as the in vitro F-actin severing 
activity incase the tags also influenced the activity of the mutants.  
Perturbing the ratio of phosphorylated to non-phosphorylated Cofilin had similar 
consequences to LIMK inhibition. Increasing the levels of active to inactive 
Cofilin resulted in inhibition of three dimensional collective invasion, inferring 
that the requirement of LIMK in cell invasion is mediated by the phosphorylation 
status of its primary substrate, Cofilin. 
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Invasion requires cell motility and remodelling of the extracellular matrix, 
through proteolysis and force-mediated deformation.  2D cell motility was 
unaffected by increased Cofilin levels, but in 3D cells became less invasive. The 
two aspects of invasion, cell motility and ECM remodelling, can be tested in the 
inverse invasion assay. Cells that are motile can move through the filter, and if 
they are also able to remodel ECM they can also invade the matrigel. Following 
reduction in LIMK activity or an increase in unphosphorylated Cofilin levels cells 
were able to cross the filter at the bottom of the transwell, but were unable to 
invade the matrigel. This, in conjunction with the results showing both LIMK and 
Cofilin levels having no effect on 2D motility, suggests that through Cofilin LIMK 
is influencing ECM remodelling, not cell motility.    
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6 Identification of Novel LIMK1 substrates 
6.1 Chapter Summary 
As described in the previous chapter, Cofilin is the most well characterised LIMK 
substrate. LIMK inactivates Cofilin by phosphorylation on serine 3 and is a useful 
readout of LIMK activity. In addition to Cofilin proteins, recent research has 
identified the nuclear transcription factors CREB and Nurr1 (Sacchetti et al, 
2006; Yang et al, 2004a)as putative LIMK substrates in neurons, and the 
microtubule assembly protein p25/TPPP was shown to be inactivated by LIMK 
phosphorylation (Acevedo et al, 2007).  
These recent discoveries suggest that there may be other undiscovered 
substrates of LIMK within cells. This chapter outlines attempts made to identify 
and validate putative substrates of LIMK using glass mounted peptide arrays and 
the Kestrel approach to substrate identification. 
6.2 LIMK1 phosphorylates Cofilin1 on Serine 3 and 
potentially Serine 8 
Wild type Cofilin1 is known to be phosphorylated on residue Serine 3 (Nebl et al, 
1996). To confirm this as the only site of phosphorylation by LIMK1, Cofilin1 was 
mutated by site directed mutagenesis (SDM) on residue 3 from serine to alanine 
(S3A) to make a non-phosphorylatable mutant protein. This S3A Cofilin was then 
subjected to in vitro phosphorylation by recombinant LIMK1 in parallel with WT 
Cofilin in a γ32p kinase assay, stopped and fixed on Whatman P81 
phosphocellulose cation exchanger paper, as detailed in the methods section. 
Mutation of Serine 3 almost completely ablates phosphorylation by LIMK1 in vitro 
(Figure 6.6.1 part A), indicating that Serine 3 is the primary site of 
phosphorylation by LIMK1. However, the first 10 amino acids of Cofilin1 are 
‘MASGVAVSDG’; it contains a further Serine (S8) potentially accessible for 
phosphorylation as the initial ‘arm’ of Cofilin is not buried within the protein 
structure (Agnew et al, 1995; Pope et al, 2004). To identify whether residual 
phosphorylation of the S3A Cofilin is due to S8 phosphorylation a truncated 
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Cofilin was generated, phosphorylated in an in vitro γ32p kinase assay and run 
out on SDS PAGE gel in parallel with both WT and S3A Cofilin (Figure 6.6.1 part 
B).  LIMK strongly phosphorylates WT Cofilin, weakly phosphorylates S3A Cofilin 
but does not phosphorylate truncated Cofilin. This would suggest that LIMK can 
also weakly phosphorylate Serine 8 of Cofilin1. This second Serine is not 
conserved in the other Cofilin family members ADF or Cofilin 2, it is specific to 
Cofilin1.  
6.3 Peptide Array 
Having confirmed the in vitro activity of recombinant LIMK1 in Figure 6.6.1 a 
Pepscan glass mounted peptide array was employed to identify potential novel 
substrates of LIMK1.  
The Pepscan peptide array produced 148 possible substrates for LIMK1, some of 
these were overlapping peptide sequences from the same protein, many of those 
with serine repeats. Twenty two spots were considered to have greater 
phosphate incorporation than the rest, and were also repeated well on both 
peptide arrays on either side of the slide. Once ranked the ‘hottest’ spots 
corresponded to:  
 Kros (p08941) Proto-oncogene tyrosine kinase c- ROS 
 FIBA (p02671) Fibrinogen alpha chain 
 Lyc (p00698) Lysozyme C 
 Glr2 (p19491) Glutamate Receptor 2 
Peptides corresponding to the overlapping sequences for each of the proteins 
above were generated to be tested in in vitro kinase assays to confirm if they 
were substrates of LIMK1. 
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Figure 6.6.1- LIMK1 phosphorylates Cofilin 1 predominantly on Serine 3. 
A. Incorporation of phosphate over time following an in vitro kinase assay in the presence of 32p to 
test LIMK phosphorylation of WT Cofilin and S3A Cofilin in parallel. Mutation of this Serine 3 to 
Alanine almost completely ablates phosphorylation of Cofilin by LIMK1. B. Western blot and 
phosphoimaging of In vitro 32p kinase assay following SDS page demonstrating that truncation of 
Cofilin completely ablates phosphorylation by LIMK1. S3A mutant Cofilin is phosphorylated at a low 
level in comparison with WT Cofilin.  
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Figure 6.6.2- Pepscan Peptide Array. 
Merged image of peptide orientation grid and the phosphoimage of array following an in vitro γ32p 
kinase assay . The replicate arrays are outlined in red, and an example of a phosphorylated 
peptide that is repeated in both arrays is outlined in green. The peptide array produced 148 
possible substrates for LIMK1, some of these were overlapping sequences from the same peptide 
and many of these contained serine repeats. 22 were ‘hotter’ than the rest and well repeated on 
both sides of the slide. The hottest spots included; Kros (p08941), FIBA (p02671), Lyc (p00698), 
Glr2 (p19491). 
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6.3.1 Proto-oncogene tyrosine kinase c- ROS (Kros) 
Proto-oncogene tyrosine-protein kinase c-ROS (KROS) is one of the last orphan 
receptors, as of yet its ligand has not been identified. As a potential substrate of 
LIMK it is interesting, LIMK has been shown to be upregulated in a variety of 
cancers and c-ROS has been found ectopically expressed in malignant gliomas, 
suggesting that over expression of c-ROS may be tumorogenic (Jun et al, 2009). 
Chromosomal  rearrangements that result in c-ROS fusion kinases have also been 
identified in sarcomas, glioblastoma multiforme (GBM), and non-small cell lung 
cancers (Acquaviva et al, 2009). 
An in vitro kinase assay was performed to establish whether LIMK1 could 
phosphorylate a peptide corresponding to the region of c-ROS identified as a 
putative site of phosphorylation by LIMK1. The generated c-ROS peptide was not 
found to be phosphorylated by LIMK1 in vitro, despite being a target when 
mounted on glass, and was therefore eliminated as a potential new substrate of 
LIMK1 (Figure 6.6.3).    
6.3.2 Fibrinogen alpha chain (FIBA) 
Fibrinogen alpha chain is a blood-borne glycoprotein composed of three pairs of 
non identical polypeptide chains. Fibrinogen is cleaved by thrombin to form 
fibrin which is the most abundant component of blood clots (Farrell et al, 1992). 
The various cleavage products of fibrinogen and fibrin are also believed to 
regulate cell adhesion and spreading, display vasoconstrictor and chemotactic 
activities, and are mitogens for several cell types (Entrez Gene 
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&Ter
mToSearch=2243). 
An in vitro kinase assay was performed to establish whether LIMK1 could 
phosphorylate a peptide corresponding to the region of Fibrinogen identified as a 
putative site of phosphorylation by LIMK1. The generated Fibrinogen peptide was 
not found to be phosphorylated by LIMK1 in vitro, despite being a target when 
mounted on glass, and so was also eliminated as a potential new substrate of 
LIMK1 (Figure 6.6.4). 
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Figure 6.6.3- c-ROS peptide is not phosphorylated by LIMK1 in vitro. 
Under these in vitro kinase conditions c-ROS peptide ARDIYKNDYYRKR is not a substrate of 
LIMK1. 
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Figure 6.6.4- Fibrinogen alpha chain peptide is not phosphorylated by LIMK1 in vitro. 
Under these conditions FIBA peptide SRGKSSSYSKK is not a substrate of LIMK1. 
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6.3.3 Lysozyme C  
Lysozymes have a bacteriolytic function in the body and Lysozyme C is capable 
of both hydrolysis and transglycosylation (Masschalck & Michiels, 2003). It is 
found in tissues and body fluids, such as in ocular secretions, and is associated 
with the monocyte-macrophage system and enhancement of the activity of 
immunoagents in the body (Uniprot http://www.uniprot.org/uniprot/P00698).  
An in vitro kinase assay was performed to establish whether LIMK1 could 
phosphorylate a peptide corresponding to the region of Lysozyme C identified as 
a putative site of phosphorylation by LIMK1. The generated Lysozyme C peptide 
was not found to be phosphorylated by LIMK1 in vitro, despite being a target 
when mounted on glass, and was therefore eliminated as a potential new 
substrate of LIMK1 Figure 6.6.5. 
6.3.4 Glutamate Receptor 2 (GLR2) 
Glutamate receptors are transmembrane receptors located on the membranes of 
neuronal cells, these receptors bind the neurotransmitter glutamate, the most 
prominent neurotransmitter in the body. GLR2 is a metabotropic glutamate 
receptor, part of a family of G protein-coupled receptors Entrez Gene 
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&Ter
mToSearch=2912). 
An in vitro kinase assay was performed to establish whether LIMK1 could 
phosphorylate a peptide corresponding to the region of Glutamate receptor 2 
identified as a putative site of phosphorylation by LIMK1. The generated GLR2 
peptide was not found to be phosphorylated by LIMK1 in vitro, despite being a 
target when mounted on glass, and was therefore eliminated as a potential new 
substrate of LIMK1 (Figure 6.6.). 
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Figure 6.6.5- LYC does not appear to be phosphorylated by LIMK1. 
Under these conditions LYC peptide YRGYSLGNWKK is not a substrate of LIMK1. 
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Figure 6.6.6- GLR2 does not appear to be phosphorylated by LIMK1.  
Under these conditions GLR2 SRGKSSSYSKK is not a substrate of LIMK1. 
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6.3.5 LIMK1 does not phosphorylate peptides in vitro 
LIMK does not appear to phosphorylate any of the previously identified peptide 
substrates in in vitro kinase assays. To establish whether the technique of 
identifying novel LIMK substrates using peptides was a valid approach 
experiments to phosphorylate peptides in vitro from the known LIMK1 substrate 
were performed, peptides were also phosphorylated in the presence of 
truncated Cofilin.  It was hypothesised that peptides were unable to interact 
with LIMK1 sufficiently to facilitate phosphorylation, the proposed mechanism by 
which truncated Cofilin might enable peptides to be phosphorylated by LIMK is 
outlined in Figure 6.6.7 and the results of these experiment combined in Figure 
6.6.8. Cofilin peptide containing the known site of phosphorylation by LIMK1 was 
not phosphorylated in vitro by LIMK (lanes 11 and 16 of Figure 6.6.8). Cofilin 
peptide was not phosphorylated in the presence of truncated Cofilin either, thus 
disproving the hypothesis outlined in Figure 6.6.7.  
LIMK did not phosphorylate peptides in vitro in the conditions used, and thus this 
was not a suitable approach for the identification of novel substrates. The glass 
mounted peptide arrays may have returned many false positive results due to 
the orientation or charge of the peptides on glass, and it has now been 
suggested that cellulose mounted peptide arrays are more suitable. 
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Figure 6.6.7- Hypothesised mechanism by which peptides may be phosphorylated by 
LIMK1. 
Truncated Cofilin could facilitate phosphorylation of peptide substrates, if the peptides are unable 
to interact appropriately with LIMK1 to facilitate phosphorylation. 
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Figure 6.6.8- LIMK does not phosphorylate Cofilin Peptides in vitro. 
Under the described conditions LIMK does not phosphorylate Cofilin peptides. Part A. shows the 
kinase assay gel following Safestain staining to visualise protein. Part B. shows the developed 
‘phospho-image taken from the same gel, imaged on a phosphoImager. Full length WT Cofilin is 
phosphorylated, short cofilin peptides are not phosphorylated, even in the presence of truncated 
Cofilin.  
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6.4 Kestrel approach to novel substrate identification. 
In order to identify novel substrates of LIMK a collaboration with Axel Knebel 
was formed to perform a Kestrel screen (Kinase substrate tracking and 
elucidation) with the aim of validating any potential  substrates in vitro at the 
Beatson. Kestrel screening takes large quantities of active purified kinase (in this 
case LIM Kinase1) and incubates them with cell extracts in the presence of ATP 
of a high specificity. This approach is different to previous ones as the extracts 
are first been depleted of ATP and other nucleotides by gel filtration, and 
subject to ion-exchange chromatography to separate endogenous substrates 
from their kinases before the reaction takes place(Cohen & Knebel, 2006).  
For this collaboration with Kinasource, rat brain and skeletal muscle extracts 
were prepared, desalted and chromatographed on heparin sepharose. 30 column 
fractions were diluted in kinase buffer with LIMK and the fractions run out on 
gels, an example gel showing the potential LIMK substrates is shown in Figure 
6.6.9. EF1a2, Creatine kinase M chain, GAPDH, Phosphoglycerate mutase 2 
(PGM2) and Cofilin were all identified in this screen. 
Work to validate these novel substrates was limited to Ef1α2. 
6.4.1 Ef1α2 
EF1α proteins bind guanine nucleotides and in the GTP-liganded form can 
interact with amino acyl-tRNA to direct its association with mRNA codons and 
ribosomes (Gareth & Christopher, 2002). Elongation Factor 1α2 is the second of 
two isoforms of the eukaryotic elongation factor 1 alpha protein (eEF1α). The 
two isoforms share greater than 90% identity but although Ef1α1 is ubiquitously 
expressed, Ef1α2 is only expressed in the heart, brain and skeletal muscle 
(Sanne et al, 1993).  
An in vitro kinase assay was performed to establish whether LIMK1 could 
phosphorylate recombinant Ef1α2, identified as a putative substrate of LIMK1 by 
Ketsrel analysis performed by Axel Knebel. The γ32p kinase assay was performed 
as described in the Methods section, BSA added to a duplicate set of reactions to 
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reduce the likelihood of Ef1α2 sticking to the reaction tubes, and all reactions 
stopped with 6x loading buffer. The reactions were run out by SDS PAGE and the 
gel stained for protein with ‘Safestain’. The gel was exposed and imaged using a 
phosphoimager. Control reactions were successfully phosphorylated but Ef1α2 
was not found to be phosphorylated by LIMK1 in vitro under these conditions, 
and so Ef1α2 could not be confirmed as a new substrate of LIMK1 (Figure 6.6.10). 
6.5 Conclusions and Discussion 
Identification of novel substrates of LIMK by peptide array proved fruitless as 
LIMK did not phosphorylate peptides in vitro, not even peptides of validated 
substrates and phosphorylation sites. 
Kestrel screening for potential novel substrates of LIMK identified EF1a2, 
Creatine kinase M chain, GAPDH, and Phosphoglycerate mutase 2 (PGM2), 
although only EF1a2 was subject to further insvestigation. Although it was not 
phosphorylated as a recombinant protein in vitro, EF1a2 appeared to be 
phosphorylated by LIMK in cell extracts, perhaps the recombinant protein was 
incorrectly folded and did not provide the appropriate site for phosphorylation. 
It is also a possibility that the bands extracted from gels to identify EF1a2 as a 
substrate of LIMK harboured a less abundant protein substrate that was masked 
by the more abundant Ef1α 2. However, EF1a2 is a good potential candidate as a 
LIMK substrate as Ef1α has been found to co-localise with F-actin, and its 
cellular localisation has been found to correlate with changes in the actin 
cytoskeleton during chemotaxis.  Ef1α1 and Ef1α2 have both been implicated in 
cell transformation (Tatsuka M, 1992 ) and linked to ovarian cancer (Lee, 2003), 
and it is also over-expressed at the mRNA level in metastatic rat mammary 
adenocarcinoma (Edmonds et al, 1996). Before Ef1α2 can be confirmed to be a 
substrate of LIMK further work to confirm phosphorylation in cells needs to be 
performed. Since in the conditions tested LIMK did not phosphorylate in vitro 
perhaps there were cofactors missing for the facilitation of phosphorylation. If 
Ef1α2 could be immunoprecipitated from cells, perhaps it would co-IP other 
proteins it is complexed with in the cell, potentially leading to successful in 
vitro phosphorylation of the protein and identification of a novel substrate.  
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Figure 6.6.9- Kestrel screening for novel substrates. 
Four possible new LIMK1 substrates were identified through kestrel screening, outlined in colour 
are; EF1a2, Creatine kinase M chain, GAPDH, and Phosphoglycerate mutase 2 (PGM2). Cofilin, 
the only confirmed substrate of LIMK, was also identified during the screening process. 
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Figure 6.6.10-Ef1a2 kinase assay.  
A. Safestained gel of kinase assay. Control lanes contain kinase reaction mix and LIMK alone, 
Cofilin, S3A Cofilin and trCofilin, with or without BSA. Lanes 8-11,13 and 14 have added BSA. B. 
Phosphoimager analysis of  gel shown in part A. Ef1a2 was not phosphorylated by LIMK1 under 
these conditions, with or without BSA. Control reactions using Cofilin as a substrate were 
successfully phosphorylated. 
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7 Discussion 
7.1 Chapter Summary 
This thesis details experiments undertaken with the aim of understanding the 
role LIM Kinases play in cell motility and invasion. In Chapter 3 I provide 
evidence that LIMK1 and LIMK2 are requirements for cancer cell invasion, and 
that altering the actin cytoskeleton by up or down regulation of LIMK is 
sufficient to reduce invasion.  The results in Chapter 4 describe a role for LIMK in 
invadopodia formation and matrix degradation, and a novel role for LIMK in the 
leading cells of collective invasion. Chapter 5 outlines the role of Cofilin in 
disseminating LIMK signalling in invasion and the results in Chapter 6 outline 
attempts made to identify novel substrates of LIMK. The data presented in this 
thesis and their relevance to previous literature and future work are discussed in 
this chapter. 
7.2 Requirement for LIMK in cell motility and Invasion 
Individual cell invasion has been classified into two forms, either mesenchymal 
or amoeboid. Mesenchymal invasion is characterised by the proteolytic 
degradation of ECM by morphologically elongated cells, followed by force 
generation by actin polymerisation to push the cell through the remodelled 
matrix (Croft & Olson, 2008). During amoeboid invasion, cells adopt a rounded 
morphology and use the force of actin-myosin contraction to physically deform 
the ECM and push through the 3D environment (Croft & Olson, 2008). The mode 
of motility used by a cell probably depends on environmental factors, cells may 
respond to cues from the micro-environment in order to use the most 
appropriate mode of motility suitable for the environment challenges they are 
subjected to. Both of these forms of motility have been observed in vivo in 
invading tumour cells (Wyckoff et al, 2006), and tumour cells can switch 
between rounded and elongated modes of movement (Sidani et al, 2007), 
indicating that they retain all the activities necessary for either mode of 
invasion(Croft & Olson, 2008). However, how the activity of LIMK1 or LIMK2 
regulates the mechanisms that contribute to cell invasion had not been 
previously characterized prior to this investigation. 
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7.3 Role for LIMK in motility and invasion 
As investigations into LIMK in cancer cell motility and invasion commenced it was 
not known whether both LIM Kinase 1 and 2 were requirements of cancer cell 
motility, or whether there were any compensation between the two kinases. As 
detailed in the introduction, LIMK1 has been found to be overexpressed in 
malignant melanoma cells (Okamoto et al, 2005), breast cancer tumours and 
tumour cell lines (Bagheri-Yarmand et al, 2006) (Yoshioka et al, 2003), in 
prostate tumours and tumour cell lines (Davila et al, 2003; Yoshioka et al, 2003) 
and up-regulated in invasive carcinoma cells in comparison with non-invasive 
cells within primary mammary tumours (Wang et al, 2004). Data presented in 
Chapter 3 shows that both LIMK1 and LIMK2 were necessary for 2D cell motility 
in wound healing assays for BE and BT549 cell lines, but not for the invasive cell 
line MDAMB231. The lack of effect seen on 2D motility following LIMK knockdown 
could have been because this form of migration relies on actin polymerization 
and leading edge protrusions to propel the cell forward (DesMarais et al, 2002). 
Reducing cellular levels of LIMK would have led to more active Cofilin, resulting 
in F-actin severing and an increase in the number of barbed ends available for 
filament extension and leading edge propulsion, which would not negatively 
affect motility that was the result of actin polymerisation.  
When active, LIM kinases phosphorylate and inactivate Cofilin proteins, thereby 
reducing filamentous-actin (F-actin) severing leading to F-actin stabilization. 
Although a reduction in cytoskeletal F-actin was observed in both 2D and 3D 
following LIMK inhibition, cell morphology in 2D was more affected by LIMK1&2 
knockdown when cells were plated on the fibroblast-derived matrix than they 
had been on plastic. Cells were more rounded and refractile in appearance in 
general with shortening of polarized extensions, however tracks of individual cell 
movement did not appear to greatly differ from non-targeting siRNA transfected 
cells. Analysis of multiple experiments revealed that the vectorial and 
accumulated distances were no different between NT or LIMK1&2 siRNA 
transfected cells. Persistence of movement, which is a directional ratio of 
vectorial over accumulated distances, also did not differ between treatments.  
These results indicate that the directionality and velocity of cell motility was 
driven by intrinsic properties of the cell that were as unaffected on fibroblast-
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derived oriented matrices (CDM) by LIMK inhibition as the wound-healing induced 
MDAMB231 motility on plastic.  
LIMK1 and LIMK2 were both found to be requirements for MDAMB231 invasion in 
3D. Consistent with these findings, interfering with LIMK function by anti-sense 
mediated knockdown of LIMK1 in metastatic prostate cancer cells (Davila et al, 
2003) or metastatic mammary carcinoma cells (Mouneimne et al, 2006), by 
overexpression of a dominant negative form of LIMK1 in metastatic breast cancer 
cells (Yoshioka et al, 2003) or by ribozyme-mediated knockdown of LIMK2 in 
metastatic fibrosarcoma cells (Suyama et al, 2004) inhibited chemotaxis and 
invasiveness/metastasis.  Reduction of both LIMK1 and LIMK2 by siRNA did not 
have an additive effect on the reduction of MDMB231 cell invasion in the data 
presented in Chapter 3, as might have been expected. This may have been 
because the effectiveness of the double knockdown by siRNA was reduced 
compared to the individual knockdowns because there was half the siRNA used 
against each individual LIMK in the double knockdown compared to individual 
conditions to retain consistent levels of siRNA between conditions. The data 
presented show that both LIMK1 and 2 are important for invasion, and are 
consistent with the hypothesis that LIMK inhibition would effectively reduce 
cancer metastasis and support LIMK as a potential anti-metastatic drug target.  
7.3.1 LIMK levels important for invasion 
It was hypothesised that LIMK could be a driver of cell motility and invasion. 
Results presented in chapter 3 reveal LIMK as a requirement of cell invasion, and 
it has been found over expressed in a variety of cancer cell lines and tumours 
detailed above (Bagheri-Yarmand et al, 2006; Davila et al, 2003; Okamoto et al, 
2005; Yoshioka et al, 2003). Over expression of LIMK1, LIMK2 or both LIMK was 
expected to increase invasion of MDAMB231 cells in 3D in line with observations 
in metastatic models (Bagheri-Yarmand et al, 2006). However, increased levels 
of either or both kinases reduced invasion to a similar degree as observed upon 
knockdown of LIMK. This is consistent with a report that over expression of 
LIMK1 kinase domain reduced cell motility (Zebda et al, 2000), and suggests that 
the “correct” level of LIMK activity is required for cells to move and invade 
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effectively. This likely reflects the activity status of the principle substrate of 
LIMK, Cofilin. 
7.3.2 Cofilin regulation 
Spatially and temporally-regulated cycles of Cofilin inactivation and activation, 
regulated principally by phosphorylation mediated by LIMK and 
dephosphorylation mediated by phosphatases such as SSH1-3 and cronophin, 
initiate dynamic alterations to the actin cytoskeleton (Van Troys et al, 2008). 
Cofilin activity is related inversely to LIMK activity, Cofilin is phosphorylated by 
LIMK and rendered inactive. LIMK inhibition lead to a reduction in F-actin 
structures and a corresponding reduction in invasion in chapters 3 and 4, and 
disruption of the Cofilin:phosphoCofilin balance was shown in chapter 5 to be 
sufficient to affect cell invasion. Increasing the levels of active to inactive 
Cofilin inhibited three dimensional collective invasion, suggesting that the role 
of LIMK in cell invasion is mediated by Cofilin phosphorylation status. This fits in 
well with the current understanding of the role Cofilin plays in invasion, that 
LIMK-mediated increases and decreases in Cofilin activity relate directly to 
invasiveness (Sidani et al, 2007; Wang et al, 2006). Although LIMK plays an 
important role in regulating Cofilin activity, additional factors have been found 
to influence Cofilin activity such as; pH (Frantz et al, 2008), PIP2 release 
(Leyman et al, 2009; van Rheenen et al, 2007) and oxidation (Klemke et al, 
2008). Therefore, although LIMK is the primary regulator of Cofilin activity, 
these additional factors may modulate the effects on invasion.  
7.3.3 LIMK inhibition impairs matrix degradation 
Since LIMK inhibition significantly reduced invasion into a three-dimensional 
matrix without affecting cell motility in chapter 3, one possible explanation was 
that the processes required for 3D path generation were affected. Collective 
invasion requires proteolytic remodelling of ECM for leading cells to initiate path 
generation. In Chapter 4, 3D invasion assays of RFP-labelled MDA MB 231 cells 
through DQ collagen cells were used to visualise proteolytic activity in 3D. Cells 
transfected with non-targeting siRNA were associated with fluorescence 
(collagenase activity) both directly adjacent and further afield from the cells, 
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possibly activity left by motile cells or cells outside of the focal plane. In 
contrast, cells transfected with both LIMK1&2 siRNA had lower levels of 
fluorescence, both distal and proximal to the cells, indicating reduced 
proteolytic activity. Similarly, in the quantifiable 2D gelatin degradation system, 
and consistent with previous reports (Lizarraga et al, 2009), MDA MB 231 cells 
had large numbers of actin-rich projections into the gelatin matrix. These were 
identified as discrete dark foci, and are dependent on the membrane-associated 
MT1-MMP (Stylli et al, 2008). Knockdown of LIMK1&2 resulted in significantly 
reduced area of gelatin degradation per cell, similarly, LIMKi treatment at 3 or 
10 µM significantly lowered the area of gelatin degradation. The requirement for 
MT1-MMP in invadopodia (Artym et al, 2006; Poincloux et al, 2009) likely reflects 
direct proteolytic actions on the ECM, but also the secretion and/or activation of 
soluble proteases such as MMP 9 (Dreier et al, 2004; Itoh & Seiki, 2004). 
Knockdown of LIMK1&2 decreased cofilin phosphorylation without affecting MT1-
MMP expression. However, LIMK1&2 knockdown reduced the secreted gelatin-
degradation activity almost to the background levels observed in concentrated 
cell-free serum-containing media. The molecular weight of the gelatin-degrading 
activity was 86 KDa, consistent with the mobility of activated MMP 9 (Curran & 
Murray, 2000; Lindenmeyer et al, 1997). Despite the lower activity of this MMP 
9-like protein, RT-PCR analysis revealed that LIMK1&2 knockdown did not 
significantly reduce MMP 9 expression.  
MT1-MMP was shown to be the membrane bound protease necessary for invasion 
through matrix (Sabeh et al, 2004) and actin skeleton integrity has been found to 
be important for MMP2 and MT1-MMP activity in fibroblasts (Tomasek et al, 
1997). Actin skeleton disruption has been shown to reduce  MMP activity in 
trabecular meshwork (TM) cells (Sanka et al, 2007) and micotubules play a role 
in MMP2/MMP9 secretion during human melanoma cell invasion (Schnaeker et al, 
2004), highlighting the relationship between MMP activity and the cytoskeleton. 
The results of Chapter 4 reveal that LIMK inhibition significantly affected ECM 
degradation in 3-D and 2-D contexts, this could be by inhibiting the formation of 
stable F-actin structures required to focalize MT1-MMP activity to areas of 
matrix degradation and MMP secretion. The link between MMP secretion and 
both actin cytoskeletal and tubulin structures could be mediated through LIMK, 
as LIMK is also now known to regulate p25/TPPP tubulin polymerisation 
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activity(Acevedo et al, 2007). LIMK activity could be important in regulation of 
the cytoskeleton during the processes to recruit MT1-MMP to sites of 
degradation, and future work could be performed to examine the role LIMK plays 
in the dynamic actin structures at points of matrix degradation (Baldassarre et 
al, 2006).  
It has been recently suggested that LIMK1 increases expression levels of the 
serine protease urokinase type plasminogen activator (uPA) and its receptor, 
thought to be involved in metastasis (Bagheri-Yarmand et al, 2006). LIMK1 
overexpression was found to increase tumor growth in female athymic nude 
mice, tumor angiogenesis and metastasis to livers and lungs, and this was 
associated with increasing uPA expression in the tumors (Bagheri-Yarmand et al, 
2006). MMPs are also thought to interact with the urokinase-type plasminogen 
activator (uPA)–plasmin system, MT1-MMP is proteolytically activated by plasmin 
by means of cleavage between its pro- and catalytic domains, the region 
associated with pro-MMP-2 activation (Curran & Murray, 2000; Okumura et al, 
1997). These findings suggest a regulatory connection between LIMK1 and the 
uPA system and MMP acivity during invasion, a second line of potential future 
investigation. 
7.4 LIMK is required in leading path-generating cells for 
collective invasion 
The inability of cells to remodel ECM by proteolysis, without affecting 2-D 
motility, following LIMK inhibition suggests that down regulation of LIMK affects 
path generation in collective invasion to a greater extent than path following. 
The invasion of MDA MB 231 cells into 3-D matrigel appeared to be via collective 
strands in chapter 3 and 4, as previously reported (Wolf et al, 2007). Since MDA 
MB 231 cells are capable of providing the path generating activity required in 
leading cells during collective invasion, in chapter 4 cells were labeled with 
either green or red fluorescent proteins and one colour pool subject to 
knockdown of LIMK1&2 or treatment with NT siRNA.  Knockdown of LIMK in red 
cells reduced the number of cells leading invasion from roughly 50% to < 20%, 
but these cells were still able to follow green invasive cells into the matrix. LIMK 
inhibition was shown in Chapter 4 to reduce extracellular MMP activity, an 
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important cellular function for cells leading collective invasion (Friedl & Wolf, 
2008; Wolf et al, 2007). These results indicate that LIMK activity is required for 
path generation by leading cells in collective invasion, but not for ‘following’. 
This would agree with previous work presented in this thesis suggesting LIMK was 
not required for 2D cell motility, or motility through a preformed path such as 
the holes in a transwell filter used in invasion assays. 
7.5 Investigations into novel substrates of LIMK 
Recent investigations have identified novel substrates of LIMK in the form of 
nuclear transcription factors CREB (Yang et al, 2004a) and Nurr1 (Sacchetti et al, 
2006) and the microtubule bundling protein p25/TPPP (Acevedo et al, 2007). 
Peptide arrays mounted on glass in a microarray format were used in chapter 6 
when trying to identify further novel substrates of LIMK. It was found that LIMK 
did not phosphorylate peptides in vitro, from which it could be concluded that 
the potential substrates identified in such screens were false positives. Shortly 
after this line of investigation was underway a Nature Protocols paper cast doubt 
over the use of glass mounted peptide arrays in the identification of novel 
substrates of kinases known to have few dedicated substrates (Turk et al, 2006). 
The technique required LIM kinase to be very efficient in substrate 
phosphorylation, and assumed that it did not require interaction with parts of 
the protein outside of the active site to facilitate phosphorylation. Data 
presented in chapter 6 would suggest that LIMK requires interaction with other 
parts of its substrates to facilitate phosphorylation (as is the case for eIF-2α 
kinases and MAP kinase kinases (Turk et al, 2006)), and since in vitro 
phosphorylation of full length Cofilin, but not a peptide of the Cofilin 
phosphorylation site, was possible.   
Kestrel (Kinase substrate tracking and elucidation) screening for novel LIMK 
substrates did not rely on the use of peptides, this technique screened for LIMK 
phosphorylation of endogenous proteins in cell extract fractions. Only one 
substrate from this screen was investigated further, and there is still the 
possibility that within the potential substrates identified in chapter 6 there are 
genuine cellular substrates. Although Ef1α2 was not confirmed as a substrate by 
further in vitro testing, it could still be a substrate but the conditions for 
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phosphorylation were not optimal for that particular protein. Identifying novel 
substrates of LIMK using full length proteins extracted from cells could yield 
success in the future if further investigation of the putative substrates identified 
by Kestrel is carried out. It is also possible that low abundance substrates were 
masked by similarly sized high abundance proteins in the gel. Potential solutions 
to which could be the use of 2-D gels to separate out similarly sized proteins, or 
further purification or fractionation before phosphorylation.   
7.6 Final conclusions  
When this project was first undertaken it had been suggested that LIMK was 
important in cancer invasion and thought that either LIMK1 or LIMK2 might make 
a suitable anti-metastatic drug target (Davila 2008, Suyama 2004, Davila 2003, 
Yoshioka 2003). However, that either LIMK1 or LIMK2 played a role in invasion 
had not been studied in a comparative manner to elucidate how LIMK regulates 
invasion, nor whether pharmacological inhibition of LIMK was a valid anti-
metastatic approach. This thesis presents data to suggest that targeting either 
LIM kinase, or both in combination, would be a suitable anti-invasive therapy.  
Previous work considered invasion as one activity, but in this body of work cell 
invasion was considered as two separate functions, cell motility or proteolysis 
and deformation, and investigated as separate cell activities and leading to the 
elucidation of how LIMK regulates invasion. LIMK is not required in 2D cell 
motility but is a requirement for both proteolysis and deformation, leading to a 
novel understanding of the role LIMK plays in collective invasion. LIMK is 
required in leading, path generating cells of collective invasion, and not cells 
‘following’ in collective invasion (see Figure 7.1). The path generating cells need 
not necessarily be cancer cells and as such we now understand that LIMK 
inhibitors would not be targeting the cancer cells in a tumour but would be anti-
invasive by targeting cells leading invasion, whether they be tumour or stromal.   
There is currently debate over the usefulness of developing anti-metastatic 
therapeutics, some would argue that using such drugs would often be like 
“shutting the door after the horse has bolted”. This attitude has left industry 
reluctant to invest in such areas of drug development. However, there are 
obvious avenues for anti-metastatic drug use. Cancers that are well screened 
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and often caught at early stages, such as cervical or prostate cancers, could 
benefit from the use of adjuvant anti-metastatic drug use alongside current 
treatments. In instances where cancers are caught early following metastatic 
events, anti-metastatic drugs could be used to limit cell invasion and motility at 
sites of micro-metastasis, preventing cancer cells from spreading out with the 
immediate metastatic microenvironment. Anti-metastatics are also no doubt of 
great interest to those researching glioma, the prognosis for which is currently 
very poor and is characterised by localised invasion which does significant 
damage to the brain, also often breaking down the blood brain barrier. The 
potential benefits of anti-metastatic therapies should not be dismissed at this 
early stage in understanding the mechanisms of metastasis.     
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Figure 7.1 Novel understanding of LIMK Role in cell invasion  
A.Cell invasion requires 2 activities, Cell motility – LIMK not required, and matrix remodelling – 
LIMK required for both proteolysis and deformation. B. LIMK is required for path generation by 
leading cells in collective invasion (illustrated in the model above as the cell outlined in red), the red 
cell requires LIMK to degrade and deform its environment in order to lead collective invasion of the 
other cells (green). 
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